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Summary  
Fetuin-A is a hepatic serum protein playing a major role in mineralized matrix 
metabolism. It acts as a mineral chaperone mediating the stabilization of protein-
mineral complexes and their clearance from circulation. Fetuin-A deficient mice on 
the genetic background DBA/2 develop severe soft tissue calcification particularly in 
highly capillarized and metabolically active tissues. Additional deletion of fetuin-A in a 
mouse model of atherosclerosis, the Apoe-/- C57BL/6 mouse, results in a model 
organism for calcifying atherosclerosis. 
Different therapeutic strategies were tested regarding their ability to inhibit 
development of calcified lesions in DBA/2,Ahsg-/- mice. These strategies included 
sodium thiosulfate as a potential therapeutic agent in the treatment of calciphylaxis, 
fetuin-A as a systemic inhibitor of calcification, and magnesium as an inhibitor of 
calcification in vascular smooth muscle cells. Furthermore, the influence of 
phosphate was analyzed. Rivaroxaban®, an anticoagulant inhibiting blood clotting 
factor Xa, was used to test the involvement of blood coagulation in calcification. This 
was studied, because calcified lesions first develop in the lumen of microvessels, and 
lesions contain blood coagulation factors. Soft tissue calcification was scored in vivo 
by CT and fluorescence molecular tomography (FMT) employing labeled fetuin-A as 
a molecular probe for calcified matrix. Post mortem analysis included chemical 
calcium quantification and histochemistry of tissue sections. While sodium thiosulfate 
and Rivaroxaban® treatment did not affect calcification, magnesium, low phosphate 
diet and fetuin-A reduced the calcification burden significantly.  
C57BL/6,Apoe-/-/Ahsg-/- mice were used to investigate the influence of 
anticoagulants and fetuin-A in atherosclerosis. Previous publications reported that 
high serum fetuin-A levels are associated with insulin resistance and metabolic 
syndrome. A recent study comparing Apoe-/- and Apoe-/-/Ahsg-/- mice showed that 
fetuin-A is involved in lipid metabolism in that Apoe-/-/Ahsg-/- mice had increased 
serum cholesterol levels suggesting impaired reverse cholesterol transport. In this 
current study Apoe-/-/Ahsg-/- mice had serum cholesterol levels similar to those of 
single knockout mice. Instead, the presence of fetuin-A seemed to exacerbate 
atherosclerosis. I hypothesize that fetuin-A by exerting its role as a lipidic mineral 
debris carrier may inadvertently enhance lipidic mineral debris uptake into plaque 
macrophages leading to increased plaque size and increased calcification. 
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Zusammenfassung  
Fetuin-A ist ein hepatisches Serumprotein, dessen Hauptfunktion im Metabolismus 
mineralisierter Matrix liegt. Es vermittelt als Mineralchaperon die Stabilisierung und 
Clearance von Protein-Mineral Komplexen. Fetuin-A defiziente Mäuse auf dem 
genetischen Hintergrund DBA/2 entwickeln Weichgewebsverkalkungen 
hauptsächlich in stark kapillarisierten und metabolisch aktiven Geweben. Die 
zusätzliche Deletion von Fetuin-A in einem Mausmodell der Atherosklerose, der 
Apoe-/- C57BL/6 Maus, resultiert in einem Modellorganismus für kalzifizierende 
Atherosklerose. 
Verschiedene therapeutische Strategien wurden hinsichtlich ihrer Fähigkeit, die 
Entwicklung kalzifizierter Läsionen in DBA/2,Ahsg-/- Mäusen zu inhibieren, getestet. 
Diese Strategien umfassten Natriumthiosulfat als potentes Mittel in der Behandlung 
der Kalziphylaxie, Fetuin-A als systemischer Kalzifizierungsinhibitor und Magnesium 
als Inhibitor der Kalzifizierung von glatten Gefäßmuskelzellen. Darüber hinaus wurde 
der Einfluss von Phosphat untersucht. Rivaroxaban®, ein Antikoagulanz welches den 
Gerinnungsfaktor Xa inhibiert, wurde eingesetzt, um den Einfluss der Blutgerinnung 
in der Kalzifizierung zu untersuchen. Dies wurde analysiert, weil kalzifizierte Läsionen 
im Lumen von Mikrogefäßen entstehen und Gerinnungsfaktoren enthalten. 
Weichgewebskalzifizierung wurde in vivo mit CT und FMT evaluiert, wobei Fetuin-A 
als molekulare Probe für kalzifizierte Matrix diente. Post mortem Analysen umfassten 
Kalziumquantifizierung und histologische Analysen von Gewebsschnitten. 
Natriumthiosulfat und Rivaroxaban® zeigten keinen Einfluss auf die Kalzifizierung; 
Magnesium, Niedrigphosphatdiät und Fetuin-A hingegen reduzierten die 
Weichgewebskalzifizierung signifikant.  
C57BL/6,Apoe-/-/Ahsg-/- Mäuse wurden eingesetzt, um den Einfluss von 
Antikoagulanzien und Fetuin-A in der Atherosklerose zu untersuchen. Vorherige 
Publikationen zeigten, dass hohe Fetuin-A Serumspiegel mit Insulinresistenz und 
metabolischem Syndrom assoziiert sind. Der frühere Vergleich von Apoe-/- und 
Apoe-/-/Ahsg-/- Mäusen zeigte, dass Fetuin-A im Lipidmetabolismus involviert ist; 
Apoe-/-/Ahsg-/- Mäuse hatten erhöhte Cholesterinwerte, vermutlich verursacht durch 
Störungen im reversen Cholesterintransport. In der vorliegenden Studie waren die 
Cholesterinwerte von Apoe-/-/Ahsg-/- und Apoe-/- Mäusen vergleichbar, allerdings 
schien Fetuin-A die Atherosklerose zu verschlimmern. Fetuin-A könnte durch seine 
Rolle als Carrier die Aufnahme von lipidischem Mineraldebris in Plaque-residente 
Makrophagen fördern, was zu größeren und stärker verkalkten atherosklerotischen 
Plaques führen könnte.  
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1. Introduction 
 
1.1 Fetuin-A  
Fetuin-A was first described by Pedersen in 1944 as a globin in fetal calf serum 1. In 
1961, the human homolog protein was isolated from the α2 fraction of serum by 
Heremans, Schmid and Bürgi and was consequently called α2-Heremans-Schmid-
glycoprotein (Ahsg) 2, 3. Further homologues were identified in different vertebrates 
including mice, rat 4 and snake 5.  
Fetuin-A is most strongly expressed during the fetal period of development 6. Directly 
after birth expression is downregulated. Expression is almost exclusively restricted to 
the liver. The physiologic concentration in humans is 0.58 ± 0.12 mg/ml 7.  
Fetuin-A together with fetuin-B (FETUB), kininogen (KNG) and histidine-rich 
glycoprotein (HRG) form a small subfamily of the cystatin superfamily 8, 9. Members 
of this family comprise two cystatin-like protein domains (D1 and D2), and a third 
(D3) domain specific for each protein. Domain D1 in fetuin-A is strongly negatively 
charged and has a high affinity for calcium phosphate 10. Fetuin-A is post-
translationally modified, including glycosylation 11, sulfation 12 and phosphorylation 13. 
In humans, a single chain precursor is cleaved into the circulating two-chain form, 
which is connected by a disulfide bond. In contrast, bovine and murine fetuin-A 
mostly circulate uncleaved, in a single chain form 14. Human mature fetuin-A has 350 
amino acids and an apparent molecular weight of 56 kDa 14. 
 
1.2 Functions of Fetuin-A 
Fetuin-A is a protein with multiple functions. It has been described in the context of 
mineralization biology, inflammation and metabolic syndrome. In addition, chemical 
interactions like proteinase interaction 15-23, lipid binding 24-26, and lectin binding 27-30 
have been reported. Other suggested functions include a role in opsonization 31, 
endocytosis 31 and serine protease inhibition 32. Sequence homology to the TGF-β 
receptor indicated antagonistic properties for TGF-β and bone morphogenetic protein 
(BMP) signaling 33-35. Accordingly studies of fetuin-A deficient mice showed altered 
bone growth as a result of impaired TGF-β/BMP signaling in osteoblasts 35, 36. An 
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additional finding related to the TGF-β antagonizing property of fetuin-A is its action in 
tumorigenesis. Swallow et al. reported that fetuin-A inhibits intestinal tumor 
progression 37. In contrast Ochieng et al. determined that fetuin-A facilitates tumor 
growth 38-40. In addition fetuin-A plays a role in modulation of the immune system. 
Fetuin-A is a negative acute phase protein, meaning that expression of fetuin-A is 
downregulated during inflammation 41. In the late 1990ies, the group of Tracey found 
that fetuin-A is an important co-factor in the inhibition of excretion of the 
proinflammatory cytokines tumor necrosis factor alpha (TNF-α) and interleukin-1 beta 
(IL-1β) mediated by spermine 42-44. The anti-inflammatory properties of fetuin-A could 
be confirmed in animal models. Dziegielewska and colleagues reported that fetuin-A 
was protective in lipopolysaccharide-induced abortion in rats 45. In 2010 and 2011 
Wang et al. have shown that fetuin-A attenuates early cerebral ischemic injury in rats 
46 and has a protective role in lethal systemic inflammation in mice 47. Furthermore, 
fetuin-A was described to be associated with rheumatoid arthritis 48, intrauterine 
growth restriction 49 and Alzheimer’s disease 50. Elevated fetuin-A levels were shown 
to be associated with preeclampsia 51 and non-alcoholic steatohepatitis 52, whereas 
fetuin-A levels are reduced in chronic obstructive pulmonary disease 53. In addition, 
fetuin-A was reported to serve as a biomarker in multiple sclerosis 54. The group of 
Le Cam showed that a protein, initially called pp63 (rat phosphoprotein of 63 kDa) 
and later identified as rat fetuin-A, was an inhibitor of the insulin receptor tyrosine 
kinase 55, 56. These results indicated a role for fetuin-A in insulin signaling and finally 
in metabolic syndrome which was studied in great detail in the past years (for details 
see chapter 1.6.4). Most recently, fetuin-A was described as a missing link in fat 
inflammation 57. In addition, several clinical studies implicate a role of fetuin-A in 
diabetes and metabolic syndrome 58-61.  
Against all putative roles and functions of fetuin-A, its role in mineralized matrix 
metabolism stands out. The best documented function of fetuin-A is the inhibition of 
ectopic calcification described in detail in chapter 1.4.1. 
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1.3 Calcification 
1.3.1 Regulation of Calcification  
Maintenance of mineral homeostasis is of critical importance involving complex 
regulation. The blood of vertebrates contains calcium and phosphate concentrations 
high to sustain mineralization once a mineral nucleus has formed. This requires the 
inhibition of crystal growth by serum components 62, 63. William Neuman declared that 
we all suffer “Lot’s wife’s problem”, the imminent danger of turning into a pillar of salt 
64. 
Total calcium in human serum ranges from 2.1 to 2.6 mM, roughly half of which is 
ionized calcium available for mineralization reactions. Dietary uptake as well as 
excretion and bone turnover lead to the necessity of compensatory mechanisms. Key 
player in this regulation is the parathyroid hormone (PTH). When sensing low serum 
calcium levels, PTH is secreted by the parathyroid gland 65. It promotes calcium 
reabsorption by the kidney and mobilization of calcium and phosphate by bone 
resorption. Additionally, PTH leads to increased phosphate secretion via the kidneys 
to guarantee homeostasis of calcium x phosphate product. As a secondary effect 
after long-term hypocalcaemia PTH stimulates calcitriol synthesis, the physiologically 
active form of vitamin D3. Calcitriol in turn induces calcium and phosphate 
reabsorption in the gut and also has been shown to activate bone resorption 66. The 
normalization of calcium levels induces a negative feedback loop which 
downregulates PTH and calcitriol synthesis. Serum phosphate regulation has been 
shown to be mediated by fibroblast growth factor 23 (FGF23) 67-69. FGF23 is 
predominantly expressed by osteocytes and osteoblasts, its synthesis is regulated by 
phosphate levels and calcitriol 70. The main action site of FGF23 is the kidney. Here, 
it inhibits phosphate re-uptake and calcitriol synthesis by binding to its receptor 
complex composed of FGFR and klotho 71. Binding of klotho induces transformation 
of FGFR into a specific receptor for FGF23 72.Mice lacking FGF23 or klotho suffer 
from hyperphosphataemia, elevated calcitriol and soft tissue calcification 73. 
1.3.2 Physiological Calcification  
Physiological mineralization in vertebrates mainly concerns the deposition of 
hydroxyapatite (HAP) in bones and teeth. HAP is a stable product of calcium and 
phosphate ions which may form in the circulation when nucleation inhibitors are 
missing 63.  
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Under physiological conditions, the deposition of HAP is restricted to bone and teeth 
as mentioned above. This is a highly regulated process. Proteins synthesized and 
excreted by osteoblasts and ameloblasts/odontoblasts, respectively, and enriched 
from plasma form a matrix which is subsequently mineralized by HAP deposition 74. 
Osteoblastic proteins include collagen type I as most abundant protein, osteonectin, 
osteopontin (OPN), bone sialo protein, osteocalcin, and matrix-GLA-protein (MGP). 
Fetuin-A is a serum-derived major protein representing about 25% of the non-
collagenous protein in bone mineralized matrix. 9. 
1.3.3 Ectopic Calcification  
When the regulatory mechanisms of physiological calcification are disrupted in 
diseases like calcific uraemic arteriolopathy (CUA) in CKD or atherosclerosis, HAP is 
deposited in vasculature and soft tissue 75-77.  
The tight regulation of calcium and phosphate serum concentrations is disturbed and 
nucleation and deposition of HAP can no longer be inhibited. Additionally, ectopic 
calcification is prevented by low molecular compounds like pyrophosphate 78, 
bisphosphonates 79 and magnesium 80, 81 which inhibit formation of HAP through 
competitive crystallization inhibition. Furthermore, several proteins like OPN, MGP 
and fetuin-A act as regulators of ectopic calcification (details in chapter 1.4).  
If prevention of unwanted HAP formation fails, deposition of crystals can occur in all 
soft tissues although some organs e.g. kidneys and cardiovascular tissue seem to be 
more calcification-prone than others. Diseases described to be associated with 
calcified lesions can be either genetically induced like fibrodysplasia ossificans 
progressiva 82, 83 or pseudoxanthoma elasticum (PXE) 81, 84, 85. Furthermore, systemic 
lupus erythematosus, an autoimmune disease has been reported to be associated 
with calcified lesions 86. In addition, infectious diseases like tuberculosis can lead to 
ectopic calcification 87. Further diseases described to be associated with ectopic 
calcification are cancer – different kinds of tumors and metastasis have been found 
to develop calcified lesions – 88-90, CKD 91 and cardiovascular diseases like 
atherosclerosis 92.  
Moreover, calcification occurs after implantation of prostheses. In particular biologic 
heart valve implants have been described to bear the risk of calcification 93. Here, 
inflammation as well as mechanical stress and additional treatment with 
anticoagulants have been shown to be the main reasons for the development of 
calcified lesions 94. 
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1.3.3.1 Ectopic Calcification in CKD and Atherosclerosis 
Calcification associated with CKD is primarily found in the cardiovascular system 95 
or in the skin 96. Skin lesions are characteristic for a rare disease called calcific 
uraemic arteriolopathy (CUA), also known as calciphylaxis. CUA has been described 
to have various causes including inflammation, endovascular fibrosis and vascular 
smooth muscle cell apoptosis leading to calcification of small blood vessels 97. Low 
serum calcitriol levels as a consequence of kidney damage induce increased PTH 
secretion. PTH promotes bone turnover as well as calcium and phosphate release 
from bone tissue 98. At the same time, calcification inhibitors like fetuin-A are 
decreased in CKD patients. Thus, spontaneous HAP nucleation cannot be prevented 
and crystals are deposited in vascular walls of small arterioles of the skin and 
subcutaneous fat tissue 99. In addition, myocard and heart valves can be affected by 
HAP deposition in CKD as well as preexisting atherosclerotic plaques being a major 
risk factor for cardiovascular mortality in CKD patients 100. Vascular calcification 
occurs in two distinct forms 101. One is media calcification, also known as 
Mönckeberg sclerosis which is mainly found in CUA 102. Here, vascular smooth 
muscle cells (VSMC) undergo a phenotypic change into the osteochondrocytic 
lineage contributing to HAP deposition 103, 104. The more common form of vascular 
calcification in CKD patients is intimal calcification. In 2003 Ketteler et al. reported 
that elevated phosphate and calcium concentrations but also decreased levels of 
calcification inhibitors contributed to this mechanism 105. Additionally an active 
component of intimal calcification, the osteochondrogenic differentiation of VSMC 
was described and is regarded as important factor 106. Until now it remains unclear 
whether this reprogramming is cause or consequence of vascular calcification. It was 
demonstrated that under different cell stressing conditions occurring in 
atherosclerosis and CKD including oxidative stress, elevated inflammation markers, 
hyperphosphataemia and elastin degradation Cbfa-1 expression is induced 107. 
Cbfa-1, also known as Runx2, is described to be major osteoblastic transcription 
factor and thus the main factor in osteochondrogenic transdifferentiation of VSMC 108. 
These reprogrammed VSMC then release vesicles comparable to matrix vesicles in 
bone formation and thus contribute to ectopic calcification in atherosclerosis 106.  
In addition to the mechanisms described above, the lack of inhibitory proteins plays a 
crucial role and leads to formation and deposition of HAP crystals. Namely the most 
important proteins are OPN, MGP and fetuin-A. OPN is member of the non-
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collageneous bone proteins and was found to possess various functions in immune 
system and bone biology 109. OPN is expressed in bone and kidneys but also by 
macrophages and VSMC and many other cell types 110. Mohler et al. demonstrated 
an accumulation of OPN in calcified lesions in heart valves suggesting a role in HAP 
binding and calcification inhibition 111. OPN acts on several levels to prevent and 
resolve calcification. OPN can block the growth of HAP crystals. In addition, it 
induces the expression of carboanhydrase II by monocytes. Carboanhydrase II 
expression leads to acidification of the surrounding milieu and finally to dissolution of 
existing HAP crystals 112. Furthermore opsonization of HAP by OPN was described 
resulting in uptake by macrophages 113.  
A second calcification inhibitory protein, MGP, is crucial in atherosclerosis. The role 
of MGP was demonstrated in a knockout mouse model generated by Luo et al. 114. 
These mice developed lethal calcifications at sites of highest MGP expressions in 
their wildtype littermates, namely the aortic wall where MGP is expressed by VSMC. 
MGP is a γ-carboxylated protein requiring activation by vitamin-K-dependent gamma-
carboxylase. In agreement with this, studies in rats and on cultured human VSMC 
have showed that inhibition of MGP function by warfarin can accelerate spontaneous 
calcification 115. High dietary vitamin K intake inhibits the progression of vascular 
mineralization 116. Warfarin is a vitamin K antagonist commonly used as 
anticoagulant in a variety of patients but with significant effects on vascular 
calcification. The importance of fully carboxylated MGP for the inhibiton of vascular 
calcification was shown in numerous animal studies using vitamin K antagonists 117-
119. In addition to inhibition of MGP-activation through vitamin K antagonists, CKD 
patients have recently been shown to have lower vitamin K levels as result of dietary 
restrictions also leading to undercarboxylated MGP 120, 121.  
In conclusion, the development of ectopic calcification is not fully understood so far. It 
has active (e.g. osteochondrogenic transdifferentiation of VSMC) and passive (e.g. 
matrix mineralization) components and a variety of cells and tissues are affected and 
involved.  
1.3.3.2 Dyscalc1 as Genetic Factor Causing Ectopic Calcification 
Several publications show that the occurrence of dystrophic calcification in mice is 
strain specific 122-124. In 1996, Ivandic et al. could define a locus on mouse 
chromosome 7 to be responsible for this dystrophic calcification by using a linkage 
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map approach and quantitative trait locus analysis 125. This gene locus was termed 
Dyscalc1. This finding was confirmed by van den Broek and Brunnert who found the 
same locus to be responsible for calcification in DBA/2 mice 126, 127. Further work of 
Ivandic and his group revealed three additional gene loci to be involved in dystrophic 
calcification 128. By fine mapping, the gene encoding the ATP-binging cassette C6 
(ABCC6) was found to be a prime candidate gene for Dyscalc1 129. Subsequently, 
Meng et al. identified ABCC6 as major causal gene for dystrophic calcification 130. 
ABCC6 deficient mice were shown to develop ectopic calcification similar to those in 
patients with pseudoxanthoma elasticum (PXE), a disease caused by autosomal 
recessive mutations in the ABCC6 gene This finding further confirmed the role of 
ABCC6 in dystrophic calcification 131. 
 
1.4 Therapeutic Strategies against Calcification 
Due to the very high prevalence of unwanted calcification in various diseases, it is of 
great interest to develop potent therapeutic strategies.  
 
1.4.1 Fetuin-A as Calcification Inhibitor  
To date fetuin-A is the sole calcification inhibitor protein that acts systemically. In 
contrast, MGP and other intrinsic calcification inhibitors, all act locally. Triffitt et al. 
described in 1976 that fetuin-A has a strong binding affinity to HAP which explains its 
enrichment in bone 132. Terkeltaub and colleagues confirmed this finding by stating 
that fetuin-A is a crystal-bound inhibitor of neutrophil stimulation by HAP 133. Schinke 
et al. demonstrated in vitro that fetuin-A inhibited HAP formation in mineralizing 
calvaria cells 10. Additionally, Reynolds et al. demonstrated that VSMC calcification 
induced by high extracellular mineral ions could be inhibited using fetuin-A 134. In 
order to verify these findings in vivo, fetuin-A deficient mice were generated 135. 
When maintained on a mixed C57BL/6 and 129Sv genetic background, ectopic 
calcifications developed only rarely. In contrast, fetuin-A deficiency in DBA/2 mice 
resulted in a stable phenotype of severe ectopic calcification affecting various organs 
and tissues 136. In search of a molecular mechanism explaining these findings, Heiss 
et al. proposed the fetuin-A dependent formation of soluble, colloidal particles 
consisting of calcium, phosphate and fetuin-A. Those particles were named 
calciprotein particles (CPPs) and range from 50 to 300 nm in size depending on their 
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particular state 137. In those particles, fetuin-A has been shown to bind HAP via 
negative charges in its domain D1. The ripening of CPPs is a multistep process 
which could be clarified by Heiss et al. 138. As a first step, fetuin-A by its aspartic and 
glutamic acid side chains in D1 binds spontaneously formed pre-nucleation clusters 
of calcium and phosphate resulting in calciprotein monomers (CPM) 138. By doing so, 
fetuin-A inhibits mineral precipitation and crystal growth. CPMs aggregate to form 
transiently stable, spherical CPPs with a size of up to 100 nm in diameter called 
primary CPPs. Primary CPPs gradually transform into ellipsoid-shaped, crystalline 
particles, called secondary CPPs with a diameter up to 200 nm. Secondary CPPs 
consist of a mineral core shielded by a protein layer. Fetuin-A was reported to be 
essential for the formation and stabilization of primary CPPs. Albumin and other 
acidic plasma proteins were found to subsequently contribute to the protein shell of 
CPPs 139. Heiss et al. proposed that formation of CPPs enables transport and 
clearance of calcium phosphate mineral in the body 137. This was confirmed in an 
animal study by Herrmann et al. 140. CPPs were found in the ascites fluid of a 
peritoneal dialysis patient suffering from sclerosing calcifying peritonitis, revealing 
their existence in vivo 139. Transmission electron microscopy confirmed the similarity 
of these particles with synthetic CPPs.  
Additionally, protein-mineral complexes containing fetuin-A have been found in 
serum of rats treated with either etidronate 141 or adenine 142 and most recently in 
dialysis patients with CKD 143. Smith and colleagues described the accumulation of 
CPPs in serum of CKD patients, but not in serum of healthy individuals 144. All these 
findings suggest that CPP formation occurs whenever mineral concentrations in 
blood exceed a critical threshold and homeostasis is disturbed. To prevent ectopic 
precipitation, CPPs must be cleared from circulation. In 2012, the underlying 
mechanism could be clarified by Herrmann and colleagues 140. It was demonstrated 
that CPPs injected in mice were rapidly cleared by phagocytes of the monocytic 
phagocyte system and were found to accumulate in liver Kupffer cells and MARCO 
positive macrophages in the spleen. Binding and uptake assays with inhibitors and 
scavenger receptor A (SR-A) deficient bone marrow-derived macrophages revealed 
that SR-A is the receptor responsible for CPP uptake and clearance 140. 
Pasch et al. found that the kinetics of CPP formation can be used to assess overall 
calcification propensity in biological fluids 145. Transition from primary to secondary 
CPPs can be monitored using a nephelometer-based precipitation assay and half-
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maximal transition time T50 is a robust predictor of calcification propensity. This 
finding could be confirmed in a cohort study with predialysis CKD patients 146.  
Several studies report on the importance of fetuin-A as calcification inhibitor in a 
variety of diseases in humans. Thus, low fetuin-A levels have been described to be 
associated with vascular calcification and cardiovascular mortality in patients on 
dialysis 105, mitral annular calcification and aortic stenosis in patients with coronary 
heart disease 147, aortic valve calcification 148, atherosclerosis 149, vascular 
complications in systemic lupus erythematosus patients 150 and in calciphylaxis 146.  
1.4.2 Low Molecular Weight Compounds Influencing HAP Formation 
Low molecular weight compounds have been shown to play a critical role in HAP 
formation and ectopic calcification. Those compounds include magnesium, 
pyrophosphate, bisphosphonates and sodium thiosulfate. 
A variety of publications demonstrated a beneficial effect of magnesium on 
calcification. High magnesium levels prevented calcification in bovine VSMC treated 
with calcification media 80 as well as phosphate-induced calcification in human 
VSMC 151. Additionally, animal studies underlined these findings. Luoma et al. 
reported that magnesium had a positive effect on nephrocalcinosis and aortic 
calcification in rats on high phosphate diet 152. In a mouse model of PXE, 
development of connective tissue calcification could be prevented by elevated dietary 
magnesium uptake 81. The Framingham Heart Study revealed that magnesium intake 
is beneficial. It was shown to be inversely correlated with coronary artery 
calcification 153. Magnesium ions inhibit HAP crystal growth. Boskey et al. described 
that magnesium inhibits formation of Ca-acidic phospholipid phosphate complexes by 
competing with calcium for binding sites on the phospholipid molecules and thereby 
inhibiting the formation of HAP crystals 154. 
Another low molecular weight inhibitor of calcification is pyrophosphate 155. Already in 
1968, Schibler and colleagues reported that aortic calcification in rats induced by 
vitamin D3 was inhibited by pyrophosphate and polyphosphates 156. This finding led 
to the development of synthetic bisphosphonates, potent inhibitors of soft tissue 
calcification and bone resorption 79. The group of McKee could further clarify the role 
of pyrophosphate in calcification in an in vitro assay with osteoblasts. They stated 
that pyrophosphate inhibits mineralization by binding to mineral, up-regulating 
osteopontin and inhibiting alkaline phosphatase activity 78.  
Sodium thiosulfate (STS) was described to be a chelating agent for cations like 
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calcium and was reported to possess antioxidative properties making it an interesting 
compound for treatment of CUA. Animal studies revealed a positive effect of STS on 
vascular calcification 157 but not in nephrocalcinosis 158. Additionally, clinical studies 
show successful treatment of calciphylaxis with STS 96, 159, 160. Furthermore, 
Adirekkiat and colleagues reported that STS delays the progression of coronary 
artery calcification in hemodialysis patients 161. Recently, it was shown that STS 
protects human aortic smooth muscle cells from osteoblastic transdifferentiation 162. 
 
1.5 Imaging of Calcification 
For a wide range of diseases and their therapies it is of great importance to monitor 
calcification progression and therapeutic process longitudinally. Therefore, different in 
vivo imaging techniques have been established. State-of-the-art modalities comprise 
computer tomography, ultrasound and magnetic resonance imaging. For imaging of 
calcification, the use of biomarkers seems to be beneficial due to higher specificity in 
contrast to the listed methods 163. The mineral binding property of fetuin-A provoked 
the idea to utilize the protein for the detection of calcifications. Fluorescence 
molecular tomography (FMT) is a non-invasive imaging method detecting molecular 
events in intact tissues using fluorescence 164. An advantage of this technique is the 
deep tissue penetration without losing much signal due to light scattering by the use 
of near infrared fluorophores 164. The major disadvantage of FMT is the low spatial 
resolution of about 1 mm in whole animal imaging 165. To date, several probes for 
FMT are available addressing widespread biological questions. Osteosense® is a 
commercially available fluorescence-labeled bisphosphonate suitable for the 
detection of calcification in FMT 166.   
 
1.6 Metabolic Syndrome 
In the past decades, lifestyle and dietary habits of the western population have 
seriously changed in that caloric intake increased whereas physical activity 
decreased. This led to a high prevalence of obesity and thus to metabolic changes 
which are described by the term metabolic syndrome (MetS) 167. Four main 
parameters describe the metabolic syndrome: abdominal obesity, hypertension, 
dyslipidemia and insulin resistance. Insulin resistance seems to be the major risk 
factor for development of MetS 168. To date there is no generally accepted definition 
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of MetS. The World Health Organization (WHO) proposed a classification of MetS 
when diabetes mellitus, impaired glucose tolerance and impaired fasting glucose or 
insulin resistance have been diagnosed and additionally two of the following criteria 
are fulfilled: 
• Blood pressure: ≥ 140/90 mmHg 
• Dyslipidemia: triglycerides (TG): ≥ 1.695 mmol/L and high-density lipoprotein 
cholesterol ≤ 0.9 mmol/L (male), ≤ 1.0 mmol/L (female) 
• Central obesity: waist:hip ratio > 0.90 (male); > 0.85 (female), or body mass 
index > 30 kg/m2 
• Microalbuminuria: urinary albumin excretion ratio ≥ 20 µg/min or 
albumin:creatinine ratio ≥ 30 mg/g 169 
Abdominal obesity is characterized by enrichment of highly hormonally active 
adipocytes with increased lipolysis 170. Thus, lipid homeostasis is disturbed and 
additionally, proinflammatory cytokines like TNF-α and IL-6 are secreted 171. Both 
parameters have been reported to increase risk for insulin resistance. As a 
consequence of the altered metabolism in adipocytes, adiponectin, the main 
hormone produced by adipocytes, is downregulated. Adiponectin is described to be 
anti-atherogenic and anti-inflammatory and promotes insulin sensitivity 172. All these 
factors lead to disturbed glucose and lipid metabolism with accumulation of 
triglyceride and fatty acid-derived metabolites in muscle and liver, which in turn leads 
to increased circulating free fatty acids which finally results in insulin resistance 173. 
After sensing high blood glucose levels by Langerhans islets in the pancreas, insulin 
is secreted into the circulation and binds to insulin receptor on various cell types, 
mainly liver and muscle cells. This binding is followed by signal cascades resulting in 
glucose uptake through translocation of the glucose transporter GLUT4 to the cell 
membrane and subsequent glucose storage in cells. Additionally, insulin inhibits 
lipolysis in adipose tissue 174. Dysbalance of energy uptake and consumption like in 
MetS provokes an increase of circulating glucose and free fatty acids followed by an 
excess release of insulin by β-cells called hyperinsulinemia 175. Pathologically 
elevated insulin levels in turn cause downregulation of insulin receptors resulting in a 
vicious circle of insulin resistance 176. 
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1.6.1 Lipid Metabolism 177, 178  
Lipids taken up via the food are enzymatically digested by pancreatic lipase (PNLIP) 
into free fatty acids (FFA) and monoacylglycerol. FFA and monoacylglycerol are 
endocytosed by intestinal cells where they are reassembled. Together with 
apolipoprotein B-48 (ApoB) they form nascent chylomicrons circulating in the lymph 
duct. Nascent chylomicrons pass over into the blood via the thoracic duct. In the 
blood, the nascent chylomicrons mature by taking up apolipoprotein E (ApoE) and 
apolipoprotein C-II (ApoC2). Mature chylomicrons can be processed by lipoprotein 
lipase (LPL) on the endothelial surface to provide cells of the periphery (mainly 
muscle cells and adipocytes) with free fatty acids. The remaining particles contain a 
relatively higher amount of cholesterol than chylomicrons and are transported to the 
liver where they are taken up by a specific remnant receptor recognizing ApoE 
(LDLR). In the hepatocytes, remnants are processed in the lysosomes resulting in 
glycerol and fatty acids which can be stored. In conditions of elevated energy needs, 
hepatocytes reassemble the stored components to rebuild triglycerides. Together 
with cholesterol, cholesteryl esters and apolipoprotein B-100 (ApoB100), triglycerides 
form nascent very low-density lipoproteins (VLDL), which are released into the 
bloodstream. By contact and exchange with circulating high-density lipoproteins 
(HDL), VLDL enrich ApoE and ApoC2 on their surface and are then considered as 
mature VLDL. Mature VLDL circulate and comparable to chylomicrons provide 
peripheral tissues with fatty acids by activation of LPL on endothelial cells via ApoC2. 
The remaining particle is called intermediate-density lipoprotein (IDL) and carries 
lower amounts of triglycerides. It can be either reabsorbed by the liver (again by 
interaction of ApoE with LDLR) or processed by hepatic lipase (LIPC) resulting in a 
cholesterol rich particle, the low-density lipoprotein (LDL). LDL in turn transfer 
cholesterol to cells of peripheral tissues or are internalized by the liver through 
binding to LDLR. Additionally, high-density lipoproteins (HDL) are formed in the 
circulation and play an important role in cholesterol metabolism. Apolipoprotein A-I 
(ApoA1) is secreted by the liver and by binding to ATP-binding cassette transporter 
A1 (ABCA1) picks up cholesterol from chylomicrons and tissues to form nascent 
HDL. Processing of the cholesterol through plasmatic lecithin-cholesterol 
acyltransferase (LCAT) results in esterified cholesterol in the particles and additional 
accumulation of apolipoprotein A-II (ApoA2) and ApoE leads to mature circulating 
HDL. Mature HDL can be directly taken up by the liver via scavenger receptor B-I 
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(SR-B1) and cholesterol is stored in hepatocytes or processed for excretion. In 
addition to the direct pathway, mature HDL interact with VLDL and exchange of 
triglycerides and cholesteryl ester is mediated by cholesteryl ester transfer protein 
(CETP). This results in newly formed IDL and triglyceride containing HDL, which are 
processed by hepatic lipase. The HDL pathway (direct and indirect) is also termed 
reverse cholesterol transport and has been shown to play a critical role in 
atherosclerosis 179. 
 
              
Figure 1. Schematic view of lipid metabolism.  
Figure modified from 178. 
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1.6.2 Dyslipidemia  
One of the hallmarks of MetS is a dysregulation in lipid metabolism called 
dyslipidemia, which contributes to the development of atherosclerosis. As a result of 
insulin resistance, fasting and postprandial triglyceride-rich lipoproteins (TRL) are 
elevated, as well as small dense LDL. In contrast, the amount of high-density 
lipoproteins is decreased 180. In the liver, insulin resistance induces overproduction 
and –secretion of VLDL, which is processed by lipoprotein lipase into IDL and LDL. 
Through the influence of cholesterylester transfer protein (CETP), triglycerides and 
cholesterol are exchanged resulting in atypical small dense LDL which are highly 
proatherogenic 167. Accordingly, several previous studies state that 
hypertriglyceridemia is strongly associated with atherogenesis 181. In addition to LDL 
and VLDL changes, HDL composition and amount can be dysregulated representing 
another risk factor for atherosclerosis. HDL is commonly known as “good” 
cholesterol, while LDL is “bad” cholesterol. Consequently, high levels of HDL 
correlate with lower risk of atherosclerosis 182. However, Navab and colleagues 
reported on a patient group with normal HDL levels but increased risk for 
cardiovascular events and subsequently detected a proinflammatory, dysfunctional 
HDL subset 183 184. Zheng et al. found that the dysfunctional HDL particles contained 
ApoA1 that was oxidized by a myeloperoxidase and thus no longer bound ABCA1, 
resulting in defective reverse cholesterol transport 185. These changes also play a 
critical role in chronic kidney disease (CKD), which is known to be accompanied by 
increased oxidative stress as well as a proinflammatory microenvironment 186.  
1.6.3 Atherosclerosis and Cardiovascular Calcification 
Metabolic syndrome is associated with increased risk for cardiovascular disease 
(CVD) 187. A broad range of factors play together in the development of CVD 
including inflammation, hyperlipidemia, thrombogenicity, increased mineral load and 
lack of protective factors, remodeling of the vessel wall associated with endothelial 
dysfunction, pathological myocardial remodeling associated with micro-angiopathy, 
autonomous neuropathy, deranged myocardial metabolism and impaired myocardial 
function 188. Patients with CKD face an exceedingly high risk of atherosclerosis 
development and progression due to the combined presence of inflammation 189, 
hyperphosphatemia and an enhanced calcium x phosphorus ion product combined 
with fetuin-A deficiency 190, oxidative stress 191 and dysfunctional HDL 186.  
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In atherosclerosis, two distinct mechanisms of calcification have been demonstrated 
affecting either the media or the intima of the vessel wall. Recent studies 
demonstrated that microcalcifications in the atherosclerotic plaque are associated 
with a higher risk of plaque rupture 192, 193. Additionally, microcalcifications were 
shown to be associated with inflammation, cellular and lipid pools and are caused by 
proinflammatory cytokine release, VSMC apoptosis and matrix degradation. In 
contrast, macrocalcification is not accompanied by inflammation and is related to a 
more fibrous and stable plaque phenotype. Macrocalcification is driven by a 
regulated mineralization process and characterized by VSMC survival 106. Shanahan 
and others studied the role of VSMC in calcification in great detail. Macrophages 
present at the sites of lipid accumulation were shown to release proinflammatory 
cytokines such as TNF-α, driving VSMC  into a phenotypic change towards 
osteoblasts 194. Such osteogenic VSMC release vesicles, which lead to HAP 
deposition in the plaque. This is a highly regulated process preventing VSMC from 
calcium overload and apoptosis 195 but might be disturbed by overwhelming amounts 
of extracellular calcium and loss of inhibitors resulting in plaque-destabilizing 
microcalcifications 106. In addition to the described mechanism also phosphate, 
advanced glycation endproducts (AGE) and advanced oxidation protein products 
(AOPP) have been demonstrated to catalyze the conversion of VSMC to osteoblast-
like cells resulting in bone matrix protein formation and plaque calcification 190. 
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Figure 2. Mechanisms of atherosclerotic calcification.  
In atherosclerosis, proinflammatory stimuli like oxLDL promote macrophage infiltration into the vessel 
wall. There, activated macrophages express proinflammatory cytokines that induce VSMC apoptosis 
and osteogenic differentiation. Apoptotic VSMCs release apoptotic bodies and matrix vesicles which 
serve as nidus for calcification and lead to further macrophage activation. A strategy of VSMCs for 
survival is the formation of vesicles to dispose of excess intracellular calcium. In the absence of 
inhibitors those vesicles promote hydroxyapatite formation. The presence of collagenous matrix 
enables deposition of hydroxyapatite and formation of macrocalcification. In contrast degradation of 
matrix is correlated with formation of microcalcification. Macrocalcification is a regulated process 
associated with a stable plaque phenotype whereas microcalcification is associated with inflammation, 
formation of cellular lipid pools and plaque rupture. Figure modified from 106.  
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but also interfere with activation of proteins involved in calcification inhibition 196. As 
MGP is a strong inhibitor of vascular calcification acting by inhibition of bone 
morphogenetic protein 2 and 4 (BMP-2 and -4) 197, 198, suppression of 
osteochondrogenic transdifferentiation of vascular smooth muscle cells 108 and direct 
inhibition of crystal growth 199, VKA treatment contributes to vascular calcification in 
atherosclerosis (also see chapter 1.3.3.1). Since intimal calcification of 
atherosclerotic plaques is considered a risk factor for plaque rupture, there is an 
urgent need for alternative anticoagulation treatments not interfering with 
γ−carboxylation of MGP. To date, several alternative anticoagulants have been 
developed. Factor Xa is inhibited by rivaroxaban 200 and apixaban 201; fondaparinux 
and heparin derivatives promote antithrombin, thereby indirectly inhibiting thrombin 
action 202 and dabigatran as well as ximelagatran are direct inhibitors of thrombin 203. 
Recent animal studies confirm the beneficial effect of alternative anticoagulants on 
atherosclerosis development 204. Borissoff et al. stated that the use of dabigatran is 
remarkably effective in impeding the onset and progression of cardiovascular 
disease 205. Additionally, Kadoglou and colleagues found that dabigatran attenuates 
arterial thrombosis, reduces lesion size and may promote plaque stability in Apoe-/- 
mice 206. Lee et al. described that direct thrombin inhibition by dabigatran improved 
endothelial function and reduced atherosclerotic lesion size, collagen content, and 
oxidative stress in hypercholesterolemic atherosclerosis 207. Comparable studies with 
rivaroxaban described similar effects. It was shown that administration of rivaroxaban 
downregulated expression of inflammatory mediators and promotes lesion stability in 
apolipoprotein E-deficient mice 208. 
1.6.4 Fetuin-A in Insulin Signaling, Lipid Metabolism and Atherosclerosis 
Several studies suggest an association of fetuin-A with MetS 60, 61, 209-212. This 
association dates back to a publication from 1989, where Auberger et al. found that 
pp63 is an inhibitor of the insulin receptor tyrosine kinase 55. Three years later, pp63 
was shown to be identical with rat fetuin 56, 213 but the initially described activity was 
discussed controversially 213, 214. In addition to rat fetuin, studies with mouse fetuin 
revealed insulin receptor tyrosine kinase inhibition 215. Also bovine fetuin was 
described as inhibitor of insulin receptor tyrosine kinase 216 and the human homolog 
Ahsg was shown to inhibit insulin receptor autophosphorylation 217. Chen and 
colleagues found that Ahsg inhibits insulin-stimulated Elk-1 phosphorylation in rat 
adipose cells, but no classical inhibition of insulin receptor could be shown 218. 
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Mathews and colleagues studied the influence of fetuin on insulin sensitivity in mice. 
They analyzed fetuin-A deficient mice maintained on a mixed genetic background of 
C57BL/6N and 129Sv and found that those mice had improved insulin sensitivity, 
were resistant to weight gain, obesity and were protected against insulin resistance 
associated with aging 58, 219. However, when these mice were backcrossed onto the 
pure strains C57BL/6N and DBA/2, association with insulin signaling and metabolic 
syndrome could not be demonstrated 9, 215, 220.  
In addition to the association of fetuin-A with insulin signaling, several studies 
suggest a role of fetuin-A in in lipid metabolism. Kumbla et al. described an 
association of fetuin-A with lipoprotein-like particles, floating at the density of HDL 24. 
These authors also demonstrated that bovine fetuin-A stimulated exogenous fatty 
acid incorporation into cellular triglycerides in vitro 25 and proposed a multifunctional 
role for fetuin-A in lipid transport 26. Several studies in animals and humans report on 
elevated fetuin-A levels in hyperlipidemia 52, 221, 222, 223, 52, 224. An in vitro study by 
Dasgupta et al. could demonstrate that free fatty acids enhance fetuin-A expression 
in a human liver cell line 225. Recently, Fetuin-A has been called the missing link 
between fatty acid-induced inflammation and toll-like receptor 4 (TLR4) signaling, 
causing fat inflammation and metabolic syndrome 57. 
However, the role of fetuin-A in atherosclerosis remains controversial. While 
Stenvinkel and others state that decreased serum fetuin-A levels are associated with 
cardiovascular disease 226, especially in CKD 227, 228, others reported that elevated 
fetuin-A levels are related with intima-media thickness in patients with atherosclerotic 
vascular disease 229 or with carotid arterial stiffness 230. 
 
1.7 Animal Models 
Mice deficient for fetuin-A and on the genetic background DBA/2 serve as a model 
for ectopic calcification 136. Initially the fetuin-A gene deletion was maintained on a 
mixed genetic background of C57BL/6 and 129Sv mice. These mice had no overt 
phenotypic changes 135. Only when fed a mineral- and vitamin D-rich diet, did the 
animals develop extraossous calcified lesions 136. For further analysis, the mice were 
backcrossed onto two pure genetic backgrounds: C57BL/6, a commonly used strain 
of laboratory animals and DBA/2 known to be a calcification-sensitive strain due to 
ABCC6 alterations (see chapter 1.3.3.2) 126, 127. DBA/2 mice deficient for fetuin-A 
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developed severe spontaneous soft tissue calcification affecting almost all major 
organs 136 including the heart 231 and finally resulting in increased mortality.  
In contrast, C57BL/6 Ahsg-/- mice did not show spontaneous development of ectopic 
calcification. Only after CKD induction by uninephrectomy and high phosphate diet, 
calcified lesions were found in myocardium, aorta, lung, kidney and aortic valve in 
those mice 232. The combination of fetuin-A deficiency with Apoe deficiency resulted 
in an accelerated phenotype of atherosclerotic calcification when compared to Apoe 
single knockout mice 228. Apoe deficient mice are commonly used as model organism 
for atherosclerosis due to their impaired lipid metabolism 233. They have been shown 
to spontaneously develop atherosclerotic lesions on a standard chow diet 234. When 
additionally fed with a high fat diet, this phenotype can be accelerated and plaques 
can be found early and in a more advanced state 235. 
 
1.8 Experimental Aims 
Ectopic calcification is a critical phenomenon occurring in different diseases like CKD 
and atherosclerosis. It is of great importance to understand the underlying 
mechanisms and to find therapeutic approaches to prevent and resolve ectopic 
calcification.  
DBA/2 mice deficient for fetuin-A have been described to spontaneously develop soft 
tissue calcification 136. Throughout this study D2,Ahsg-/- mice served as a disease 
model to study the influence of different treatments in calcification progression. 
Additionally, these mice served as model to find new modalities for the visualization 
of ectopic calcification. STS has been described in a range of clinical case studies to 
have a beneficial effect on the outcome of patients suffering from calciphylaxis 236-238. 
It seemed promising to test this compound in DBA/2 fetuin-A deficient animals to 
prevent ectopic calcifications. Additionally fetuin-A itself was tested regarding its 
ability to inhibit development of calcified lesions. Further strategies were application 
of low molecular compounds. Magnesium was reported to be a potent inhibitor of 
calcification in different in vitro experiments 80, 151, 152 and consequently was tested in 
DBA/2 fetuin-A deficient mice to prevent lesion formation. Phosphate concentration is 
a critical factor for calcification propensity in CKD patients 239, 240 and thus it was 
applied in different concentrations to study the influence on calcification in DBA/2 
fetuin-A deficient mice. Furthermore, it was found that lesions in DBA/2 fetuin-A 
deficient mice first developed in microvasculature and contained coagulation 
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factors 241. This finding prompted us to test anticoagulants to prevent ectopic 
calcification. 
Additionally, fetuin-A plays a role in atherosclerosis, which has been confirmed in 
mice with combined Apoe/Ahsg deficiency 228. These mice served as a model to 
study the influence of different anticoagulants on cardiovascular calcification, but also 
to clarify the role of fetuin-A in lipid metabolism. Warfarin was used as a traditional 
anticoagulant, but with the known severe effect of promoting cardiovascular 
calcification 196. In contrast, rivaroxaban as direct factor Xa inhibitor should not 
interfere with activation of calcification inhibitors. The influence of fetuin-A on 
atherosclerosis development should be studied by using the identical experimental 
setup for Apoe deficient animals as established atherosclerosis model in comparison 
to Apoe/Ahsg double knockout mice. 
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2. Materials and Methods 
 
2.1 Animals 
All mice were kept in a 12 hours dark / 12 hours light rhythm in the animal facility of 
the Uniklinik Aachen, receiving normal chow (ssniff® R/M-H, V1535-0, Soest, 
Germany, 3.3% crude fat, 19.0% crude protein, 4.7% sugar, metabolizable energy 
12.8 MJ/Kg, see supplemental table 1 for details) and drinking water ad libitum when 
not stated otherwise. Mice on DBA/2 background lacking the fetuin-A gene and their 
wildtype littermates were used, as well as C57BL/6N mice deficient for either Apoe 
alone or Apoe and Ahsg in combination. Male and female mice were used for this 
study. The age of the mice is stated in the respective passage. All experiments were 
conducted according to recommendations by the Federation for Laboratory Animal 
Science Association (FELASA) and approved by the Landesamt für Natur-, Umwelt- 
und Verbraucherschutz NRW (LANUV).  
 
2.2 Imaging 
2.2.1 Protein Labeling 
Bovine fetuin-A (Sigma, Taufkirchen, Germany) was purified via size exclusion 
chromatography before being coupled to an Alexa fluorescence dye (either Alexa 
Fluor® 488, Alexa Fluor® 546 or Alexa Fluor® 680, Life Technologies GmbH, 
Darmstadt, Germany). The coupling reaction was performed according to the labeling 
protocol provided by Invitrogen. The same procedure was applied to label bovine 
serum albumin (Sigma, Taufkirchen, Germany) and osteopontin. 
2.2.2 Animals 
Mice on DBA/2 background lacking the fetuin-A gene were used, as well as DBA/2 
wildtype mice and C57BL/6N Apoe single and Ahsg/Apoe double deficient mice. The 
DBA/2 mice were at least 7 weeks old, guaranteeing that they show severe soft 
tissue calcification. C57BL/6N Ahsg/Apoe deficient mice were at least 40 weeks old 
ensuring the spontaneous development of atherosclerotic plaques. Male and female 
mice were used for this experimental setup.  
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2.2.3 Histology 
Five hours before finalization by an overdose of isofluran (Forene, AbbVie, 
Wiesbaden, Germany) overdosing, the mice were injected with either unlabeled or 
Alexa Fluor 488 coupled fetuin-A. The animals received 100 µl / 25 g body weight of 
a 7 mg/ml protein solution (in saline/PBS). After sacrification the animals were 
perfused with 20 ml ice cold phosphate buffered saline (PBS, Dulbecco, Biochrom 
AG, Berlin, Germany), the organs (kidney, lung, heart) were harvested and frozen in 
TissueTek (Sakura, Alphen aan den Rijn, Netherlands) and sections of 6 µm were 
made from each organ. The sections were fixed in ice cold acetone.  
Sections with unlabeled Fetuin-A were blocked with 10% goat serum (Dako, 
Hamburg, Germany) and subsequently incubated for one hour with a polyclonal 
rabbit anti bovine Fetuin-A antibody (AS 237). This antibody was detected with a 
secondary goat anti rabbit Alexa Fluor 546 antibody (Molecular Probes, Life 
Technologies GmbH, Darmstadt, Germany) incubated for an additional hour. DAPI 
staining (Sigma, Taufkirchen, Germany) was performed as nuclear stain. Sections 
with Alexa Fluor 488 labeled Fetuin-A were stained with DAPI only. 
Hematoxylin/Eosin-staining (H/E) as well as Von-Kossa-staining were performed on 
cryosections of the same animals. For H/E staining the sections were fixed with ice 
cold acetone and subsequently washed with deionized water. After 5 minutes 
incubation with hematoxylin (Carl Roth, Karlsruhe, Germany), the slides were 
developed for 10 minutes in tap water. Counterstaining was performed with eosin 
(Carl Roth, Karlsruhe, Germany) for 3 minutes. After that, the slides were rinsed in 
deionized water and dehydrated before being coverslipped.  
Von-Kossa staining was performed according to the following protocol. The sections 
were fixed in ice cold acetone and subsequently rinsed with deionized water followed 
by 5 minutes staining in 1% silver nitrate (Carl Roth, Karlsruhe, Germany). After 10 
minutes washing with deionized water, the silver nitrate was developed in sodaformol 
for one minute followed by 10 minutes washing in deionized water, 5 minutes in 5% 
sodium thiosulfate (Dr. Franz Köhler Chemie GmbH, Bensheim, Germany) and an 
additional washing step with deionized water. Counterstaining was performed using 
0.1% safranin-O (Carl Roth, Karlsruhe, Germany).  
Additionally, sections from non-injected mice were incubated with Alexa Fluor 488 
coupled fetuin-A for one hour after fixation with ice cold acetone and they were 
counterstained with DAPI.  
Materials and Methods  29 
 
Stained sections were analyzed using a Leica DMRX microscope (Leica 
Microsystems GmbH, Wetzlar, Germany) equipped with DISKUS software (Carl H. 
Hilgers, Technisches Büro, Königswinter, Germany). Processing of the pictures was 
performed with Adobe Photoshop (Adobe Systems GmbH, München, Germany). 
2.2.4 FMT-Measurements 
In vivo imaging of calcified lesions was performed using the FMT™ 2500 (Perkin 
Elmer, Waltham, USA). The mice were depilated in the scanning area and a baseline 
measurement was taken for both wavelengths of interest (680 nm and 750 nm), while 
the animals were anesthetized with isofluran (Forene, AbbVie, Wiesbaden, 
Germany). After this procedure the animals received both OsteoSense 750 (Perkin 
Elmer, Waltham, USA) (2 nmol in a volume of 150 µl) and fetuin-A Alexa 680 (50 µl 
of a 7 mg/ml solution) via intraperitoneal injection. 24 h after this application, FMT 
scan was repeated as described above and the fluorescence intensity was detected. 
Reconstruction of the data was performed by VisEn medical software.   
2.2.5 Two-Photon Laser Scanning Microscopy 
Mice on the genetic background C57BL/6N lacking the genes for apolipoprotein E 
and/or fetuin-A and older than 40 weeks were used as model organisms for calcifying 
atherosclerosis. The animals received an intraperitoneal injection of either fetuin-A 
(50 µl of a 14 mg/ml solution), albumin (85 µl of a 8 mg/ml solution) or osteopontin 
(140 µl of a 5 mg/ml solution), all coupled with Alexa Fluor 546 as described in 2.2.1 
24 h before starting the experiment. Control animals were left untreated. After 24 h, 
the carotid arteries of the animals were excised and mounted on a perfusion 
chamber, which allowed the microscopic observation under physiological pressure. 
The two-photon laser scanning microscopy was performed using an Olympus 
FV1000MPE multiphoton system integrated with an Olympus BX61WI microscope 
(Olympus Deutschland GmbH, Hamburg, Germany) and a MaiTai HP laser (Newport 
Spectra-Physics GmbH, Darmstadt, Germany). Reconstruction of the data was 
performed with ImageJ. 
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2.3 Inhibition of ectopic calcification with STS/FetA 
2.3.1 Study Design and Application  
DBA/2 mice deficient for fetuin-A were included in this experiment when they were 
three weeks of age. The study included four treatment groups (n≥6 per group) 
receiving either bovine fetuin-A, sodium thiosulfate (Dr. Franz Köhler Chemie GmbH, 
Bensheim, Germany), a combination of both or 0.9% NaCl as control via 
intraperitoneal injection according to the study design in figure 3. 
 
 
Figure 3. Study design.  
 
2.3.2 X-ray Analysis 
X-ray pictures of the mice were taken 1 day prior and after the treatment of 21 days. 
The animals were anaesthetized with isoflurane and radiography was performed with 
the Senographe DMR X-ray System (GE Medical Systems S.A.). Sagital and 
abdominal pictures of the whole animal were recorded. 
2.3.3 Sample Preparation 
Mice were sacrificed with an overdose of isoflurane, exsanguinated, perfused with 
ice-cold PBS and organs were harvested. A piece of each of the following tissues 
(kidney, heart, lung, brown adipose tissue of the neck) was frozen in liquid nitrogen 
for calcium measurement, another piece was embedded in Tissue-Tek O.C.T. 
compound and snap frozen for histology. 
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2.3.4 Histology 
6 µm thick sections were prepared and fixed with zinc fixative (BD Biosciences, 
Heidelberg, Germany). H/E staining was performed as described in 2.1.3. The 
sections were analyzed using a Leica DMRX microscope (Leica Microsystems 
GmbH, Wetzlar, Germany) and DISKUS software (Carl H. Hilgers, Technisches Büro, 
Königswinter, Germany). 
2.3.5 Calcium Measurement in Organs 
Calcium content in the tissue (kidney, lung, heart) was determined using a 
colorimetric o-cresolphthalein based assay (Randox Laboratories, Crumlin, UK). The 
snap frozen wet tissue samples were weighed and 200 µl of 0.6 M HCl were added. 
After 12 to 24 hours, the tissue samples were homogenized using a mixer mill 
(Qiagen GmbH, Hilden, Germany) for 3 min at 30 Hz. Homogenates were centrifuged 
for 10 minutes at 14000 rpm. 70 µl of supernatant were neutralized with the same 
volume of ammonium chloride buffer (pH 10.5). The subsequent preparation of the 
samples and the standard were performed according to the manufacturer’s protocol 
in a 96-well plate (TPP Techno Plastic Products AG, Trasadingen, Switzerland), 
which was measured in a plate reader (FLUOstar OPTIMA, BMG LABTECH GmbH, 
Ortenberg, Germany) at 546 nm after 30 minutes.  
2.3.6 Detection of bFetA on Sections  
Sections of heart, lung and kidney of each animal were fixed with ice-cold acetone, 
blocked with goat serum and incubated with a polyclonal rabbit anti bovine fetuin-A 
antibody (AS237) diluted 1:5000 for one hour. Detection of the antibody was 
achieved with a secondary Alexa Fluor 546 goat anti rabbit antibody (Life 
Technologies GmbH, Darmstadt, Germany). DAPI staining was used as nuclear 
stain. The sections were analyzed using a Leica DMRX microscope (Leica 
Microsystems GmbH, Wetzlar, Germany) and DISKUS software (Carl H. Hilgers, 
Technisches Büro, Königswinter, Germany). Processing of the pictures was done 
with Adobe Photoshop (Adobe Systems GmbH, München, Germany). 
2.3.7 Detection of anti-bFetA Antibodies in Serum 
Human serum (1:100), fetal calf serum (1:100) and purified bovine fetuin-A (250 ng) 
were diluted with SDS sample buffer (0.25 M TRIS (AppliChem GmbH, Darmstadt, 
Germany), 8.2% SDS (AppliChem), 20% glycerin (Fluka, St. Louis, MO, USA), 10% 
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ß-mercaptoethanol (AppliChem GmbH, Darmstadt, Germany), bromophenol blue 
(SERVA, Heidelberg, Germany) followed by a 5 minutes denaturation step at 96°C. 
10 µl of the diluted samples were separated by SDS-PAGE on a 10% polyacrylamide 
gel. Afterwards the separated samples were blotted onto a nitrocellulose membrane. 
Staining of the membranes with Ponceau S enabled visualization and marking of the 
standard (LMW marker, GE Healthcare, Freiburg, Germany). After blocking with 2% 
ovalbumin (Carl Roth, Karlsruhe, Germany) at 4 °C over night, the membranes were 
incubated with serum of either fetuin-A treated, fetuin-A/STS treated or control 
animals for one hour. Rabbit anti bovine fetuin-A antibody (AS237) diluted 1:5000 
served as positive control. Detection of binding was achieved with a secondary anti 
mouse IgG antibody or swine anti rabbit antibody (Dako, Hamburg, Deutschland), 
respectively, each coupled with horse radish peroxidase and diluted 1:5000. 
Subsequently, the membranes were incubated with chemiluminescence solution and 
pictures were taken using an ImageQuant LAS 4000 Mini (GE Healthcare, Freiburg, 
Germany). 
 
2.4 Influence of Magnesium and Phosphate on Hydroxyapatite 
Formation 
2.4.1 Study Design and Application  
DBA/2 mice deficient for fetuin-A were included in this experiment when they were 
three to four weeks of age. The animals were split into four groups (n≥6 per group) 
and received either a 1% supplemented magnesium diet or a high phosphate 
containing diet with 0.8% phosphate or a low phosphate diet with 0.2% phosphate 
according to the study design in figure 4. Control mice received normal chow (ssniff 
S0382-E124, Soest, Germany, 5.1% crude fat, 17.6% crude protein, 11.3% sugar, 
metabolizable energy 15.5 MJ/Kg, see supplemental table 2 for details). Exact 
composition of the diet can be found in the supplement. The animals received the 
respective diets for a treatment period of 8 weeks.   
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Figure 4. Study design.  
 
2.4.2 Computer Tomographic Analysis 
24 hours before starting the experiment and after the treatment period of 8 weeks, 
computer tomographic measurements of each animal were performed. The mice 
were anaesthetized with isoflurane and put in the computer tomograph (Somatom 
Definition, Siemens Medical Solutions, Forchheim, Germany). The settings of the CT 
scan were as follows: 65 kV, 0.5 mA, 720 projections were acquired over 90 
seconds. Analysis of the CT scans was performed with Philips Imalytics Research 
Workstation (Philips Technologie GmbH, Aachen, Germany). For this purpose, 2 
classes were defined: bone and calcified lesions. A threshold of 1600 was set and 
every signal above this threshold was defined as “bone”. In the next step, the bone 
related signal was overlayed with the class “calcified lesions” at the same threshold. 
Subsequently, the bones were reclassed as “bone”. The volumes of both classes 
were determined by the software. 
2.4.3 Sample Preparation 
Mice were sacrificed with an overdose of isoflurane and exsanguinated, perfused 
with ice-cold PBS and organs were harvested. A piece of each of the following 
tissues (kidney, heart, lung, brown adipose tissue of the neck) was frozen in liquid 
nitrogen for calcium measurement, another piece was embedded in Tissue-Tek 
O.C.T. compound and deep-frozen for histology. 
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2.4.4 Histology 
6 µm thick sections of the Tissue-Tek embedded organs were fixed with zinc fixative. 
Von Kossa staining was performed according to the protocol described in 2.1.3. The 
sections were analyzed using a Leica DMRX microscope (Leica Microsystems 
GmbH, Wetzlar, Germany) and DISKUS software (Carl H. Hilgers, Technisches Büro, 
Königswinter, Germany). 
2.4.5 Calcium Measurement 
Calcium content measurement of the tissues (kidney, lung, heart, brown adipose 
tissue of the neck) was performed as described in 2.3.5. 
 
2.5 Influence of Anticoagulants on Ectopic Calcification 
2.5.1 Study Design and Application  
DBA/2 mice deficient for fetuin-A were included in this experiment when they were 
four weeks of age. The animals were split into three groups (n=10 per group) and 
received either a diet (Ssniff EF R/M control E15000, Soest, Germany, 4.2% crude 
fat, 20.8% crude protein, 10.8% sugar, metabolizable energy 15.4 MJ/Kg, see 
supplemental table 3 for details) supplemented with 5 g/kg Rivaroxaban® (Bayer AG, 
Leverkusen, Germany) or a diet supplemented with 10 g/kg Rivaroxaban® or normal 
chow as control according to the study design in figure 5. The animals received the 
respective diets for a treatment period of 12 weeks and bodyweight was determined 
every week. At time points 0, 4, 8 and 12 weeks, plasma samples were taken for the 
analysis of Rivaroxaban® levels. 
 
 
Figure 5. Study design.  
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2.5.2 Computer Tomographic Analysis 
24 hours before starting the experiment, after 4 and 8 weeks and after the full 
treatment period of 12 weeks, computer tomographic measurements of each animal 
were performed as described in 2.4.2.  
2.5.3 Sample Preparation 
Mice were sacrificed with an overdose of isoflurane and exsanguinated, perfused 
with ice-cold PBS and organs were harvested. Blood was collected in heparin and 
citrate tubes to enable preparation of plasma. A piece of each of the following tissues 
(kidney, heart, lung, brown adipose tissue of the neck) was frozen in liquid nitrogen 
for calcium measurement, another piece was embedded in Tissue-Tek O.C.T. 
compound and deep-frozen for histology. 
2.5.4 Histology 
6 µm thick sections of the Tissue-Tek embedded organs were fixed with zinc fixative. 
Von Kossa staining was performed according to the protocol described in 2.1.3. The 
sections were analyzed using a Leica DMRX microscope (Leica Microsystems 
GmbH, Wetzlar, Germany) and DISKUS software (Carl H. Hilgers, Technisches Büro, 
Königswinter, Germany). 
2.5.5 Calcium Measurement 
Calcium content determination of the tissues (kidney, lung, heart, brown adipose 
tissue of the neck) was performed as described in 2.3.5. 
2.5.6 Rivaroxaban® Plasma Level and Coagulation State 
At time points 0, 4, 8 and 12 weeks plasma samples were obtained using heparin 
tubes (Sarstedt, Nümbrecht, Deutschland) and subsequently frozen in liquid nitrogen. 
Rivaroxaban® plasma levels measurements were performed by Bayer AG. In 
addition citrate plasma (Sarstedt, Nümbrecht, Deutschland) was obtained at the time 
point of sacrification for the determination of coagulation state, which was also 
measured by Bayer AG. 
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2.6 Fetuin-A in Atherosclerosis  
2.6.1 Animals and Study Design 
Male and female mice on the genetic background C57BL/6N deficient for Apoe or 
Apoe and Ahsg were used in this study. The Apoe deficient animals were obtained 
from Charles River and kept in-house a week before starting the experiment. 
Apoe/Ahsg double deficient animals were bred in-house. All mice were taken into the 
experiment at age 8 weeks. Plasma samples were taken using heparin tubes and 
subsequently, the animals were fed a high fat and cholesterol containing Western 
type diet (Ssniff TD88137 mod., 21.2% crude fat (<5% polyunsaturated fatty acids), 
17.5% crude protein, 33.2% sugar, 0.2% cholesterol, metabolizable energy 
18.8 MJ/Kg) for the following 12 weeks. After this atherosclerosis inducing period, the 
mice were divided in three treatment groups (n=15 per group). For the following four 
weeks they received either Western Diet supplemented with 5 g/kg Rivaroxaban® or 
Western diet supplemented with 3 g/kg Warfarin (Sigma, Taufkirchen, Germany) and 
1.5 g/kg Vitamin K1 (Sigma, Taufkirchen, Germany) or further on unsupplemented 
Western Diet as control (exact composition of the diet see supplemental table 4). 
Bodyweights were determined every week and heparin plasma was collected at 
these time points. Figure 6 shows a scheme of the study design.  
 
 
Figure 6. Study design.  
 
Materials and Methods  37 
 
2.6.2 Echocardiography 
After 12 weeks of atherosclerosis induction with Western Diet and at the end of the 
experiment after 4 weeks treatment with either Rivaroxaban®, Warfarin or control 
food, echocardiographic measurements were performed. The mice were 
anaesthetized with isoflurane and the thorax was depilated using depilatory cream 
(Reckitt Benckiser, Mannheim, Germany). The animals were fixed on a heated 
electrode plate and ECG was plotted. Using an ultrasound transducer and Vevo 770 
system (Visual Sonics, Toronto, Canada), the hearts of the mice were analyzed. The 
following settings were recorded: long axis view of the left ventricle in B-mode and 
M–mode, short axis view in B- and M-mode, four-chamber view in PW-mode and 
pulsed wave Doppler of the aortic arch. With Vevo software (Visual Sonics, Toronto, 
Canada) cardiac output, E/A ration, AV mean velocity, ejection fraction, fractional 
shortening and stroke volume were calculated. 
2.6.3 Finalization and Sample Preparation 
Mice were sacrificed with an overdose of isoflurane and exsanguinated, perfused 
with ice-cold PBS and organs were harvested. Blood was collected in heparin and 
citrate tubes to enable preparation of plasma. Heart and aorta were excised. The 
aorta was split into thoracic part including the aortic arch and carotids for histology 
and abdominal part for calcium analysis. The heart was divided in heart basis for 
histology and cardiac apex for calcium determination. Samples for histology were 
fixed in 4% paraformaldehyde and embedded in paraffin. Samples for calcium 
determination were weighed and frozen in liquid nitrogen. 
2.6.4 Cholesterol and Triglycerides 
Cholesterol and triglyceride levels were analyzed using kits from DiaSys (Cholesterol 
FS / Triglycerides FS, DiaSys Diagnostic Systems GmbH, Holzheim, Germany). 
Heparin plasma samples were diluted 1:5 in 0.9% NaCl. 10 µl of diluted serum were 
mixed with 100 µL cholesterol reagent. Similarly, 10 µL of diluted serum were mixed 
with triglyceride reagent. After incubation at room temperature for 20 minutes plasma 
triglycerides and cholesterol levels were measured by absorbance at 490 nm using a 
plate reader (FLUOstar OPTIMA, BMG Labtech GmbH, Ortenberg, Germany) and 
values were calculated with Excel. 
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2.6.5 Rivaroxaban® Level and Prothrombin Time 
Before starting the experiment, after 12 weeks of Western diet and after 4 weeks 
treatment, plasma samples were obtained using heparin tubes and subsequently 
frozen in liquid nitrogen. Rivaroxaban® plasma levels measurements were performed 
by Bayer AG. In addition citrate plasma was obtained at the time point of sacrifice for 
the determination of coagulation state, which was also measured by Bayer. 
2.6.6 Fetuin-A Level in Plasma 
Plasma samples of Apoe deficient mice before Western diet, after Western diet and 
after treatment and a standard sample were diluted 1:60 with SDS sample buffer 
(0.25 M TRIS (AppliChem GmbH, Darstadt, Germany), 8.2% SDS (AppliChem 
GmbH), 20% glycerin (Fluka, St. Louis, MO, USA), 10% ß-mercaptoethanol 
(AppliChem GmbH), bromophenol blue (SERVA, Heidelberg, Germany) followed by 5 
minutes heating step at 96°C. 10 µl of the diluted samples were separated by SDS-
PAGE on a 7.5% polyacrylamide gel. Afterwards the separated samples were blotted 
onto a nitrocellulose membrane. Staining of the membranes with Ponceau S enabled 
visualization and quality assessment of the blotting step. After blocking with 5% 
albumin at 37 °C for 30 minutes, the membranes were incubated with anti mouse 
fetuin-A antibody (AS 386), which was diluted 1:4000 for 45 minutes. Detection of 
binding was achieved with a secondary swine anti rabbit antibody (Dako, Hamburg, 
Germany) coupled with horseradish peroxidase and diluted 1:5000. Subsequently, 
the membranes were incubated with chemiluminescence solution and pictures were 
taken using an ImageQuant LAS 4000 Mini. The pictures were analyzed with ImageJ 
and the relative amount of fetuin-A was calculated with Excel. 
2.6.7 Calcium Measurement 
Calcium content measurement of heart apex and abdominal aorta was performed as 
described in 2.3.5. 
2.6.8 Calcium Mapping by CT 
In addition to the colorimetric calcium determination, calcium content of the aorta was 
determined by computer tomographic calcium mapping. The thoracic part of the 
aortas was analyzed in the CT under the following settings: 40 kV, 1.0 mA and 65 kV, 
0.5 mA, 2880 projections were acquired over 6 minutes. Evaluation with Philips 
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Imalytics Research Workstation (Philips Technologie GmbH, Aachen, Germany) 
enabled the determination of calcium content in the respective samples. 
2.6.9 Heart Valve Histology 
The paraffin embedded heart bases were cut in 5 µm thin sections along the short 
axis. After deparaffinization von Kossa staining was performed as described in 2.1.3. 
All sections were analyzed using a Leica DMRX microscope (Leica Microsystems 
GmbH, Wetzlar, Germany) and DISKUS software (Carl H. Hilgers, Technisches Büro, 
Königswinter, Germany). The calcified areas in the most calcified section of the mid-
level sections were measured with ImageJ and given as relative calcified area by 
calculation with Excel. 
2.6.10 Histologic Analysis of Aortic Arch Calcification  
After CT analysis the thoracic aorta of each mouse was embedded in paraffin. 
Longitudinal sections of 5 µm thickness were made. Every sixth section was 
deparaffinized and von Kossa staining was performed as described in 2.1.3. All 
sections were photographed using a Leica DMRX microscope (Leica Microsystems 
GmbH, Wetzlar, Germany) and DISKUS software (Carl H. Hilgers, Technisches Büro, 
Königswinter, Germany). In addition to the assessment of calcification, maximum 
thickness and plaque area were measured in the section showing the biggest plaque 
area. 
 
2.7 Linkage Mapping of Calcification Risk Modifier Genes in DBA/2, 
Ahsg-/- X BL/6,Ahsg-/- Intercross 
2.7.1 Animals 
Animals of both strains, DBA/2,Ahsg-/- and C57BL/6,Ahsg-/-, were crossed. 159 
randomly chosen progeny of the F2 generation were used for analysis.  
2.7.2 Computer Tomographic Analysis 
At the age of 12 weeks, computer tomographic measurements of each animal were 
performed as described in 2.4.2. Calcification was scored and animals were 
classified in 5 groups ranging from no calcification to severe calcification. 
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2.7.3 DNA Isolation and Genotyping 
After CT analysis, the mice were sacrificed by an overdose of isoflurane and the tail 
tips were cut. Tail tips were processed in 500 µl proteinase K solution (100 mM 
Tris/HCl pH 8,5, 10 mM EDTA, 0,2% SDS, 200 mM NaCl and 100 µg/ml proteinase 
K) at 55°C over night. Subsequently, the samples were centrifuged (10 min, 
14000 rpm). Supernatant was mixed with 500 µl isopropanol and centrifuged again (1 
min, 14000 rpm). The DNA pellet was washed with 250 µl 70% ethanol. After another 
centrifugation step (1 min, 14000 rpm), supernatant was discarded and the pellet was 
dissolved in 120 µl TE buffer (10 mM Tris, pH 8,0; 1 mM EDTA). Samples were 
stored at -20°C.  
 
2.8 Statistics 
Statistical analysis of all data was performed with Prism 4.0 and 5.0 software 
(Graphpad, La Jolla, CA, USA), respectively. T-test was used for comparison of 
single treatments versus control group. One-way ANOVA with Tukey’s multiple 
comparison test was applied to test for overall differences in non-size matched 
experimental groups. Analysis of data with two factors was achieved using two-way 
ANOVA with Bonferroni post test.   
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3. Results 
 
3.1 Imaging of Ectopic Calcification 
Fetuin-A is a potent inhibitor of unwanted calcification 9. Mice deficient for fetuin-A 
develop ectopic calcified lesions and thus serve as a model for calcification related 
diseases. The affected organs are kidneys, pancreas, gonads, lung, heart, brown 
adipose tissue and the skin 136, 241. Another calcification model is the C57BL/6 
apolipoproteinE / fetuin-A double deficient mouse. In contrast to DBA/2,Ahsg 
deficient animals, these mice do not show organ calcification but develop calcifying 
atherosclerosis when ageing or fed a high phosphate containing diet 228. 
It is of great interest to visualize the formation, progression and localization of 
calcified lesions in the above mentioned animal models to address basic research 
questions as well as to monitor therapeutic approaches. 
3.1.1 Fetuin-A Histology 
Fetuin-A shows a strong binding to hydroxyapatite 132. This property was used for the 
development of a novel imaging method 242. Here, fetuin-A was covalently coupled to 
a fluorescent dye and injected i.p. into DBA/2 fetuin-A deficient mice at ages 3 to 5 
months when extensive soft tissue calcified lesions had developed in all organs 
studied. 
Figure 7 illustrates typical examples of calcified lesions in the myocard (Fig. 7 A-E), 
kidney (Fig. 7 F-J) and lung (Fig. 7 K-O). The calcified lesions ranged in size from 
few micrometers (Fig. 7 E) to several hundred micrometers (Fig. 7 H). Only few 
lesions had small or intermediate size suggesting that calcification proceeded very 
rapidly once started. Hematoxylin and eosin stained sections show an overview on 
the tissue morphology (Fig. 7 A, F, K). Calcified lesions are typically stained blue by 
haematoxylin. Von Kossa staining served as traditional calcification staining and 
stained lesions black (Fig. 7 B, G, L).  
Unlabeled bovine fetuin-A was injected into mice. 24 hours post injection, the animals 
were sacrificed and organs were harvested. Cryosections of heart, kidney and lung 
were incubated with a polyclonal anti-bovine fetuin-A antibody to detect injected 
fetuin-A which accumulated at sites of calcification (Fig 7 C, H, M).  
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Fluorescence-labeled fetuin-A readily stained calcified lesions both in vivo when 
injected into mice (Fig. 7 D, I, N) and when incubated on sections (Fig. 7 E, J, O).  
 
Figure 7. Staining methods detecting calcified lesions in fetuin-A deficient mice.  
A-E myocard, F-J kidney and K-O lung. A, F, K Hematoxylin eosin stained sections showed large 
lesions in myocard (A) and lung (K) but no lesions could be detected in kidney (F). B, G, L von Kossa 
staining demonstrated calcified lesions in myocard (A), lung (K) and kidney (F). C, H, M show calcified 
lesions in a mouse injected with a single bolus of unlabeled bovine fetuin-A. Bound fetuin-A was 
detected using a rabbit anti-bovine-fetuin-A primary antibody and a red fluorescent secondary 
antibody. D, I, N depict cryosections from a mouse injected i.p. with a single bolus of Alexa Fluor® 
488-labeled bovine fetuin-A. E, J, O show sections prepared from a non-injected mouse which were 
post-stained with Alexa Fluor® 488-labeled bovine Fetuin-A. Note that established histology methods 
detected only large calcified lesions whereas fetuin-A, unlabeled, or Alexa Fluor® 488-labeled, 
injected into live animals or applied to histological sections also detected much smaller lesions. Size 
bars depict 200 µm. 
 
Serial sections from myocard showed that fetuin-A was able to depict small lesions 
that were not detected by H&E or von Kossa staining (Fig. 8). The H&E stained 
section only showed a lesion with a diameter of 100 µm (Fig. 8 A), von Kossa 
staining enabled the additional detection of a smaller lesion with a size of 30 µm (Fig. 
8 B). Finally, fetuin-A staining facilitated the detection of a calcified lesion with a 
diameter of only 10 µm (Fig. 8 C). 
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Figure 8. Serial sections of the heart from a fetuin-A deficient mouse.  
Hematoxylin eosin staining showed only one large lesion (A), von Kossa staining also detected a 
smaller lesion depicted in the top right area of (B) and (C) (arrows), whereas injection of Alexa Fluor® 
488-labeled fetuin-A in addition detected a very small lesion in the middle of the section (C) 
(arrowhead).  
3.1.2 Fetuin-A in Fluorescence Molecular Tomography 
In addition to histological detection of calcification, a method for the detection and 
quantification of calcified lesions in vivo was established. Fluorescence Molecular 
Tomography is an optical in vivo imaging method, which makes use of near-infrared 
fluorophores. That enables the detection of signal deriving not only from the surface 
but also from deeper regions in the body 164. OsteoSense® as bisphosphonate is an 
established staining probe detecting bone mineral and was used to detect 
calcifications in mice. Fetuin-A was established as new staining probe for calcified 
lesions.  
Figure 9 shows 2D reflectance images of isolated organs dissected from wildtype and 
fetuin-A deficient mice. The organs were brown fat tissue isolated from the neck (bf), 
heart (he), lung (lu), kidneys (ki). These organs are known to calcify in D2,Ahsg-/-, 
but not in wildtype mice. Accordingly, tissues from wildtype mice showed low signal 
with OsteoSense® at both 1-fold and 10-fold sensitivity setting of the instrument (Fig. 
9 A and C, respectively), and with fetuin-A as a probe (Fig. 9 B). Fetuin-A 
background staining was detected in the lung and in the kidneys of wildtype mice 
suggesting retention of fetuin-A in these organs even in the absence of any 
calcification. The organs of the D2,Ahsg-/- animal showed low signal in all analyzed 
organs when detected with OsteoSense®, but high signal in lung and kidneys and 
lower signal in brown fat and heart when detected with fetuin-A.  
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Figure 9. FMT signal intensity in organs of wildtype and fetuin-A deficient DBA/2 mice.  
Shown is the fluorescence quantification of brown fat in the neck, heart, lung and kidney of both 
OsteoSense 750® (A, B, C, F) and Alexa Fluor® 680 labeled fetuin-A (B, E) in counts per energy in 
wildtype (A-C) and fetuin-A deficient (D-F) mice. Note that lung and kidneys stained with fetuin-A 
yielded the highest signals. 
 
Besides imaging of isolated organs, FMT allows to observe probe distribution in live 
animals in vivo. The 2D modality provides an anatomical overview of organs, but 
analysis is limited to a tissue depth of about 1 cm. In addition, FMT suffers from 
inherent signal variations depending on the optical transparency of the tissue. Figure 
10 shows the results of a 2D scan of a D2,Ahsg+/+ wildtype and of a D2,Ahsg-/- 
fetuin-A deficient mouse. Wildtype mice (Fig. 10 A, B) injected with either 
Osteosense® or fetuin-A, and D2, Ahsg-/- mice injected with Osteosense® showed 
no signal at the sensitivity settings that yielded strong signals when D2,Ahsg-/- mice 
were injected with fetuin-A (Fig. 10 D). At tenfold increased sensitivity OsteoSense® 
depicted the spine in the D2,Ahsg+/+ mouse and the brown fat in the neck of the 
D2,Ahsg-/- mouse (Fig. 10 E, F). 
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Thus, in 2D reflectance mode, both Osteosense® and Fetuin-A probes stained brown 
fat in the neck. In addition, fetuin-A stained the kidney. Differential kidney retention of 
fetuin-A, but not of Osteosense® suggested binding of fetuin-A to contents of the 
fluid filled kidney cyst of this hydronephrotic kidney, as well as binding to the 
damaged kidney parenchyma.  
 
Figure 10. 2D in vivo OsteoSense® and fetuin-A (Alexa Fluor® 680) FMT in wildtype and fetuin-A 
deficient mice.  
Fluorescence was recorded in 2D-mode. A, B and E show the fluorescence measured in a wildtype 
mouse, C, D and F depict a fetuin-A deficient animal. Both animals received equal amounts of 
OsteoSense 750® and Alexa Fluor® 680-labeled fetuin-A. The detected signal for the wildtype mouse 
was low for both agents (A, B, E), whereas the knockout animal showed high fluorescence in the 
fetuin-A channel in contrast to the OsteoSense fluorescence (C, D, F). Alexa Fluor®-labeled fetuin-A 
strongly stained brown fat in the neck and kidneys. 
 
In contrast to 2D modality, 3D tomography allows the detection of fluorescence signal 
in the whole body. Figure 11 shows the results of 3D fluorescence tomography of a 
representative DBA/2 wildtype mouse (Fig. 11 A, B, E) and a representative DBA/2 
fetuin-A deficient mouse (Fig. 11 C, D, F) both injected with a mixture of 
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OsteoSense® 750 and Alexa 680-labeled fetuin-A. OsteoSense® staining dimly 
depicted the spine, gut and thorax (Fig. 11 A), which became more apparent at 10-
fold increased sensitivity (Fig. 11 E). Like in 2D mode, fetuin-A Alexa 680 staining 
outlined the gut, the kidneys and the brown fat in the neck (Fig. 11 B). Staining of the 
digestive tract suggested that both OsteoSense® 750 and fetuin-A Alexa 680 were at 
least partially excreted through this route and stained the contents of the gut. When 
the gut was emptied the signal remained in the feces confirming excretion of the 
fluorescence dye via the gut (not shown). Strong staining of brown fat in the neck of 
D2,Ahsg-/- mice suggested that this tissue was heavily calcified.  
 
Figure 11. Three-dimensional in vivo OsteoSense® 750 and Fetuin-A Alexa Fluor® 680 
fluorescence molecular tomography in wildtype and Fetuin-A deficient mice.  
Whole body fluorescence was recorded in 3D-mode. A, B and E show the fluorescence measured in a 
wildtype mouse, C, D and F depict a D2,Ahsg-/- animal. Both animals received equal amounts of 
OsteoSense 750® and Alexa Fluor® 680-labeled fetuin-A. The fluorescence signal for OsteoSense 
750® was low, however it was higher in the wildtype than in the fetuin-A deficient mouse (A, C). The 
fetuin-A signal was higher, in the knockout mouse it could be detected in the neck and in the left 
kidney but also in the gut (B, D). At 10-fold stronger signal amplification OsteoSense 750® depicted 
brown fat and the spine in the fetuin-A deficient mouse (F). 
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Co-registration of the FMT signals with computed tomography in wildtype and 
fetuin-A deficient mice improved localization of the 3D FMT signals. To this end 
images from FMT and CT were fused using the software package "Amide" (Fig. 12). 
Due to restrictions in the volume rendering module of the software, a comparison 
between the signal strength received from OsteoSense® and fetuin-A Alexa 680 as 
shown in figures 9, 10 and 11 could not be performed.  
D2,Ahsg+/+ wildtype mice injected with OsteoSense® (Fig. 12 A) showed weak 
fluorescence co-localized with the spine suggesting that OsteoSense® bound to 
physiologically mineralized areas whereas staining with fetuin-A Alexa 680 
(Fig. 12 B) gave a low signal in the digestive tract of the wildtype mouse. D2,Ahsg-/- 
mice injected with OsteoSense® (Fig. 12 C) showed the highest signal in the neck 
and in the thorax and a weaker signal in the digestive tract. A minor signal of fetuin-A 
Alexa 680 (Fig. 12 D) was detected in neck and thorax, strong signal was detected in 
the kidney and the digestive tract.  
 
Figure 12. Combined FMT and CT in wildtype and fetuin-A deficient mice.  
Whole body fluorescence was recorded in FMT 3D-mode and fused with the corresponding CT-picture 
with AMIDE software. A and B show a wildtype mouse, C and D depict a fetuin-A deficient animal. 
Both animals received equal amounts of OsteoSense 750® (A and C) and Alexa Fluor® 680-labeled 
fetuin-A (B and D). OsteoSense 750® stained mainly the neck and thorax of the fetuin-A deficient 
animal, whereas Alexa Fluor® 680-labeled fetuin-A showed the highest signal in the abdomen 
(namely the kidney and the gut) of the mouse. 
Results  48 
 
3.1.3 Fetuin-A as Imaging Agent in 2-Photon Laser Scanning Microscopy 
In atherosclerosis, plaque calcification is a common event. Macrocalcifications are 
usually associated with a stable plaque phenotype whereas microcalcifications 
increase the risk of plaque rupture 106. Therefore, it is of great interest to establish 
imaging methods for the analysis of plaque composition. Two-Photon Laser 
Scanning Microscopy (TPLSM) offers the possibility of deep tissue imaging under 
normal arterial pressure. C57BL/6,Ahsg/Apoe double deficient mice were used as 
model organism for calcifying atherosclerosis 228. It was hypothesized that fluorescent 
fetuin-A detects plaque in the vessels due to binding of fetuin-A to the calcified cells 
or uptake by macrophages.  
Alexa 546-labelled fetuin-A was injected i.p. into aged Ahsg/Apoe double deficient 
mice. 24 hours after injection, the mice were sacrificed and the carotid arteries were 
isolated. Carotid arteries were mounted in a perfusion chamber, which allowed the 
observation of the vessel under physiological parameters.   
Figure 13 shows photographs taken from three distinct regions of a representative 
carotid artery. A plaque-free area in the A. carotis communis (Figure 13 A) served as 
an internal control and showed no red fetuin-A Alexa 546 signal. Fluorescence signal 
recorded in the blue channel of the microscope represents autofluorescence derived 
from collagen fibers of the adventitia (Fig. 13 A). The shoulder region of the plaque 
(Figure 13 B) showed strong red staining in the media suggesting enrichment of 
fetuin-A in the vascular smooth muscle cells. In the plaque itself, fetuin-A demarcated 
foam cells by red fluorescence suggesting robust uptake and intracellular localization 
of fetuin-A (Fig. 13 C).   
In addition to fetuin-A, two other proteins were tested regarding their staining capacity 
in atherosclerotic plaque. Osteopontin is a well-known mineral binding protein 243 and 
thus it was likely that fluorescence-labeled osteopontin could serve as calcification 
marker like fetuin-A. In addition, serum albumin the most abundant plasma protein, 
which associates with CPPs after their initial stabilization by fetuin-A 139, was also 
tested as an imaging agent for calcified lesions. Figure 14 gives an overview of the 
results obtained from C57BL/6,Ahsg/Apoe-/- mice either untreated or injected with 
fetuin-A, osteopontin or albumin, respectively.  
In the untreated control animal, red fluorescence signal could neither be detected in 
the A. carotis communis, nor in the shoulder or plaque region of the untreated carotid 
artery (Fig. 14 A, E, I). Pictures of the fetuin-A injected animal showed a fluorescence 
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pattern similar to the one shown in figure 13. The plaque free area had blue 
autofluorescence deriving from collagen fibers of the adventitia (Fig. 14 B). In the 
shoulder region of the atherosclerotic plaque, the vascular smooth muscle cells show 
enrichment of fetuin-A indicated by strong red staining in the media (Fig. 14 F). 
Deeply in the plaque, red fluorescence also appeared in the lumen of the vessel due 
to fetuin-A accumulation in atherosclerotic foam cells (Fig. 14 J). An 
C57BL/6,Ahsg/Apoe double deficient mouse injected with osteopontin Alexa 546 
showed weak red fluorescence in plaque free areas of the A. carotis communis and 
the shoulder region of plaque increasing slightly in the plaque area, indicating 
unspecific binding of osteopontin (Fig. 14 C, G, K). Staining with albumin Alexa 546 
led to a weak red fluorescence signal in the plaque (Fig. 14 L), the A. carotis 
communis as well as the shoulder region of the plaque remained unstained 
(Fig. 14 D, H).  
In conclusion, only injection of fetuin-A resulted in a differential staining of calcified 
VSMC and of foam cells. 
 
Figure 13. Two-photon microscopy of an atherosclerotic carotid artery stained with fetuin-A 
Alexa Fluor® 546.  
A C57BL/6,Ahsg/Apoe double deficient mouse was injected with fetuin-A Alexa Fluor® 546. After 24 h 
the carotid artery was isolated and mounted on a perfusion chamber for two-photon microscopy under 
physiological pressure. (A) depicts a plaque free area serving as internal negative control. The blue 
signal derives from autofluorescence of collagen fibers. (B) Shoulder region of the plaque. Red 
fluorescence signal evolving from injected fetuin-A Alexa Fluor® 546 was detected in the media of the 
carotid artery. (C) Atherosclerotic plaque in the bifurcation zone of the carotid artery. Fetuin-A Alexa 
Fluor® 546 signal was found in the media as well as in the lumen of the vessel, where it depicts 
atherosclerotic foam cells.  
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Figure 14. Plaque staining using fetuin-A, albumin and osteopontin.  
B6 Apolipoprotein E/fetuin-A double deficient mice older than 40 weeks were injected with fetuin-A 
Alexa 546, albumin Alexa 546 or osteopontin Alexa 546, respectively or were left untreated as control 
animals. 24 hours after the application of fluorescent proteins, mice were sacrificed and the carotid 
arteries were extracted and mounted on a perfusion chamber for observation with 2-photon 
microscopy. A, E and I show plaque free area, shoulder region of the plaque and plaque of the carotid 
artery of a control animal, respectively. Blue signal derives from autofluorescence of collagen fibers. B, 
F and J depict the carotid artery of a fetuin-A injected mouse. In the plaque free area, only blue 
collagen autofluorescence is visible (B). VSMC in the media of the plaque shoulder region show strong 
red signal originating from fetuin-A Alexa 546 taken up by these cells (F). Deeply in the plaque, 
fetuin-A Alexa 546 is enriched due to high calcification load and thus a strong red signal was 
detectable (J). C, G and K display the plaque free area, shoulder region and plaque of an animal 
treated with osteopontin Alexa 546. Red signal is visible in all three areas due to unspecific binding of 
osteopontin. The highest amount of red signal was detectable in the plaque (K). D, H and L show 
pictures of an albumin-treated animal. In the plaque free area and the shoulder of the plaque, no 
signal deriving from albumin Alexa 546 was detected. In contrast, weak signal in the plaque was 
visible indicating a binding or uptake of albumin Alexa 546 by foam cells.  
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3.1.4 Summary 
Taken together, it could be shown that fetuin-A coupled to fluorophores is a potent 
probe for the visual detection of calcification used in histology, TPLSM and in vivo 
imaging. Fluorescently labeled fetuin-A enables staining of calcified lesions when 
applied in vivo (chapter 3.1.1, 3.1.2 and 3.1.3), and also stains calcified lesions on 
histological sections (chapter 3.1.1). Fetuin-A accumulates at calcified lesions in 
different calcification models, namely it binds to ectopic mineral depositions in organs 
of DBA/2 fetuin-A deficient mice (chapter 3.1.1 and 3.1.2) as well as calcified 
atherosclerotic plaque in C57BL/6,Ahsg/Apoe double deficient mice (chapter 3.1.3). 
 
3.2 Therapy of Soft Tissue Calcification 
Ectopic calcification is the deposition of hydroxyapatite in soft tissues in different 
human diseases, e.g. calciphylaxis 96 or pseudoxanthoma elasticum 81. It is of great 
interest to establish appropriate animal models for the investigation of underlying 
mechanisms of ectopic calcification as well as for testing new therapeutic strategies. 
Mice deficient for fetuin-A develop severe soft tissue calcification when maintained 
against the calcification sensitive genetic background DBA/2 136. These animals can 
serve as model organisms for the analysis of experimental therapies regarding their 
efficiency in inhibition or regression of ectopic calcified lesions. 
3.2.1 Inhibition of ectopic calcification with Sodium Thiosulfate and Fetuin-A 
Sodium thiosulfate (STS) is a chelating agent used as an antidote for cyanide 
poisoning 244 and treatment of intoxication with chemotherapy 245. Recent 
publications have further suggested that sodium thiosulfate may serve as a therapy 
for calciphylaxis 237, 246. Studies with calcification models in rats underlined the 
beneficial effect of sodium thiosulfate treatment in the control of calcification 157, 158. In 
contrast, a previous study with DBA/2 fetuin-A deficient mice did not show an effect 
of sodium thiosulfate in the reduction of calcification 247. However, it was not analyzed 
if sodium thiosulfate could inhibit the formation of calcified lesions at an early state. 
Here, sodium thiosulfate was applied to three-week old spontaneously calcifying 
D2,Ahsg-/- mice, suffering only from few early state calcified lesions. In addition, it 
was tested whether fetuin-A or a combination of fetuin-A and sodium thiosulfate 
could inhibit formation of ectopic calcification.  
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Analysis of the animals by X-ray after the treatment period of three weeks provided a 
first overview on the distribution of calcification (Fig. 15). Mice untreated or treated 
with sodium thiosulfate alone displayed calcified spots in the neck, in the area of the 
kidneys and in the axillae (Fig. 15 A, B, E, F), whereas mice treated with fetuin-A or a 
combination of fetuin-A and sodium thiosulfate did not show ectopic calcification in 
these regions.  
 
Figure 15. X-ray analysis of DBA/2 fetuin-A deficient mice treated with sodium thiosulfate and 
fetuin-A.  
3-week-old mice were left untreated (A, E) or received 1.6 mg/g bodyweight sodium thiosulfate (B, F), 
0.24 mg/g bodyweight fetuin-A (C, G) or a combination of fetuin-A and sodium thiosulfate (D, H) 5 
times a week for a total treatment period of 3 weeks. Untreated animals and sodium thiosulfate treated 
animals had calcifications in the neck, axillae and kidney area (white arrows). In contrast, fetuin-A 
treated mice, and mice receiving a combination of fetuin-A and thiosulfate did not develop detectable 
calcified lesions in the same areas. 
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Further analysis by H&E staining revealed that kidney, heart, lung and brown adipose 
tissue of the untreated and sodium thiosulfate treated animals were heavily calcified 
(Fig. 16 A-H), whereas the corresponding organs of the fetuin-A and fetuin-A / 
sodium thiosulfate treated animals were much less calcified (Fig. 16 I-P). The kidneys 
only showed few small roundish calcified spots, the lesions in the lung were of similar 
size and shape. Myocard calcification was accompanied by heavy fibrotic 
remodeling. Brown adipose tissue showed the most severe ectopic calcification 
indicated by lesions ranging from about 20 micrometers to several hundred 
micrometers in size. 
 
Figure 16. Hematoxylin eosin staining of organs after treatment with sodium thiosulfate and 
fetuin-A.  
The mice were left untreated as control (A-D) or received 1.6 mg/g bodyweight sodium thiosulfate (E-
H), 0.24 mg/g bodyweight fetuin-A (I-L) or a combination of fetuin-A and sodium thiosulfate (M-P) for a 
treatment period of 3 weeks. Shown are cryosections with a thickness of 6 µm of kidney (A, E, I, M), 
heart (B, F, J, N), lung (C, G, K, O) and brown adipose tissue (D, H, L, P).  Scale bars indicate 200 µm 
(kidney, heart, lung) and 1000 µm (brown adipose tissue), respectively. 
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To confirm the findings of x-ray analysis and histology, a colorimetric assay was 
performed to determine the organ calcium content in kidney, lung and heart. The 
results are displayed in figure 17. Animals treated with sodium thiosulfate did not 
show a significant reduction of calcium content in comparison to untreated animals in 
kidney (6.607 ± 5.183 mg/g organ vs. 1.105 ± 0.873 mg/g organ) and lung (9.869 ± 
3.264 mg/g organ vs. 3.364 ± 2.929 mg/g organ). Unexpectedly, the calcium contents 
were even higher than those of untreated control animals. Only the calcium content 
of the heart showed a slight decrease compared with control mice (7.719 ± 
5.196 mg/g organ vs. 9.483 ± 6.633 mg/g organ). In contrast, the calcium content in 
mice treated with fetuin-A alone or a combination of fetuin-A and sodium thiosulfate 
was reduced in all analyzed organs compared to the control mice. In the kidneys of 
fetuin-A treated mice the Ca content was 0.160 ± 0.110 mg calcium /g organ. The 
calcium content of fetuin-A / STS-treated mice had a similar range (0.179 ± 
0.023 mg/g organ). A similar pattern could be observed in the lung, the fetuin-A 
treated mice accumulated 1.483 ± 0.460 mg calcium/g organ, the mice treated with a 
combination of STS and fetuin-A had a mean value of 1.285 ± 0.531 mg/g organ. 
Also in the heart, treatment with fetuin-A (3.742 ± 1.667 mg/g organ) and with 
fetuin-A / STS (3.733 ± 1.485 mg/g organ) could reduce the amount of calcium. 
Taken together, the results of x-ray analysis, histology and organ calcium content 
showed a marked reduced of tissue calcium content in mice treated with fetuin-A. 
 
Figure 17. Organ calcium content after treatment with sodium thiosulfate and fetuin-A.  
3-week-old mice were left untreated as control or received 1.6 mg/g bodyweight sodium thiosulfate, 
0.24 mg/g bodyweight fetuin-A or a combination of fetuin-A and sodium thiosulfate. Calcium content 
was measured in kidney, lung and heart of the animals. Treatment with fetuin-A or a combination of 
fetuin-A and sodium thiosulfate could reduce the amount of calcium in all analyzed organs, sodium 
thiosulfate alone led to an increase in calcium content in kidney and lung. Student’s t-test was used to 
test for statistical significance, *p<0.05. 
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Injected bovine fetuin-A was detected in sections of heart, lung and kidney of each 
animal using a polyclonal rabbit anti bovine fetuin-A antibody (AS237) and indirect 
immunofluorescence. Fluorescence signal was only found in mice treated with 
fetuin-A (Fig. 18 G-I) or with a combination of fetuin-A and STS (Fig. 18 J-K), but not 
in animals treated with STS (Fig. 18 D-F) or control mice (Fig. 18 A-C). Furthermore, 
injected bovine fetuin-A was only detected at sites of ectopic calcification suggesting 
fetuin-A binding to calcified lesions. 
 
Figure 18. Immunhistochemical detection of bovine fetuin-A after treatment with sodium 
thiosulfate and fetuin-A.  
The mice were left untreated as control (A-C) or received 1.6 mg/g bodyweight sodium thiosulfate 
(D-F), 0.24 mg/g bodyweight fetuin-A (G-I) or a combination of fetuin-A and sodium thiosulfate (J-L) for 
a treatment period of 3 weeks. Shown are cryosections with a thickness of 6 µm of lung (A, D, G, J), 
heart (B, E, H, K) and kidney (C, F, I, L), Red signal indicating bovine fetuin-A is found in fetuin-A and 
fetuin-A/STS treated animals but not in STS treated or control mice and is restricted to areas of 
ectopic calcification. Scale bars indicate 200 µm. 
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Next, it was tested whether injection with bovine fetuin-A induced antibody production 
that might neutralize the action of injected bovine fetuin-A. Human serum, fetal calf 
serum and purified bovine fetuin-A were analyzed by immunoblotting. Sera from 
fetuin-A treated, STS/fetuin-A treated or control mice or with a rabbit anti bovine 
fetuin-A antibody (AS237) as a positive control were tested. No antibodies against 
bovine fetuin-A were detected in the sera of fetuin-A or STS/fetuin-A treated mice 
(Fig. 19 A, B), suggesting that mice did not develop immune response against bovine 
fetuin-A after injection for three weeks. Unexpectedly, antibodies contained in the 
sera of bovine fetuin-A injected mice decorated bovine albumin in fetal calf serum 
and in low molecular weight marker, suggesting that injection with large amounts of 
bovine fetuin-A triggered no antibody formation against the major component bovine 
fetuin-A, but did cause antibody production against bovine albumin, which may be a 
minor contaminant of the commercial bovine fetuin-A preparations used for the 
injections. This finding indicates that bovine fetuin-A in large dose acted as a 
tolerogen rather than an antigen, while the contaminating bovine albumin was 
antigenic.  
 
 
Figure 19. Detection of anti-bFetuin-A antibodies.  
3-week-old mice were left untreated as control or received 0.24 mg/g bodyweight fetuin-A or a 
combination of fetuin-A and 1.6 mg/g bodyweight sodium thiosulfate for 3 weeks. Serum of mice 
treated with fetuin-A (A) or fetuin-A and STS (B) or control mice (C) was used to detect fetuin-A in 
human serum (HS), fetal calf serum (FCS) or purified bovine fetuin-A (bFetA). No antibody production 
against injected bovine fetuin-A could be observed. Instead, a band in FCS and the marker 
corresponding to albumin was detected, indicating antibody production against albumin. A rabbit anti 
bovine fetuin-A antibody (AS237) served as positive control (D). 
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3.2.2 Influence of Magnesium and Phosphate on Ectopic Calcification 
Magnesium is a potent calcification inhibitor 80, 151, 152. DBA/2 mice are calcification-
prone and have lower serum magnesium levels than C57BL/6 mice. This may partly 
explain the different phenotype of fetuin-A deficiency in both mouse strains – 
widespread calcification in D2,Ahsg-/- mice and no overt calcification in B6,Ahsg-/- 
mice. Thus, treatment with magnesium seemed to be a promising therapeutic 
strategy to prevent calcification in D2,Ahsg-/- mice. In addition, the influence of 
dietary phosphate (high amount of 0.8% phosphate vs. low amount of 0.2% 
phosphate) on calcification phenotype in DBA/2 fetuin-A deficient mice was studied. 
Computer tomography of the animals before and after the treatment enabled a 
longitudinal analysis of the progression of ectopic calcification. A first approximation 
of the extent of calcification was done by calculating the volume of calcified tissue 
without skeletal bone in the thorax of the mice using a Philips Imalytics Research 
Workstation (Philips Technologie GmbH, Aachen, Germany) (Fig. 20). Before 
treatment, the animals had a mean calcification volume of 6.86 ± 11.73 mm2. After a 
treatment period of 8 weeks, untreated control mice showed a mean volume of 
99.24 ± 36.17 mm2. After 8 weeks of continuous feeding of D2,Ahsg-/- mice with 1% 
magnesium instead of 0.2%, the mice had strongly reduced calcification with a mean 
calcified tissue volume of only 13.83 ± 2.63 mm2. Feeding 0.8% phosphate instead of 
the usual 0.4%, greatly increased the amount of tissue calcification was to a mean 
value of 317.56 ± 129.66 mm2. In contrast, feeding low phosphate (0.2% instead of 
0.4%) reduced the mean calcified tissue volume to 54.52 ± 18.35 mm2. Because of 
the high anti-calcification activity of dietary magnesium we started feeding all 
D2,Ahsg-/- mice, old and young, high magnesium diet instead of standard chow 
(ssniff® R/M-H, V1535-0, Soest, Germany, 3.3% crude fat, 19.0% crude protein, 
4.7% sugar, metabolizable energy 12.8 MJ/Kg, 0.22% magnesium, see supplemental 
table 2 for details). Unexpectedly within one week of feeding high magnesium diet, 
older mice had a dramatic increase in mortality that prompted us to revert to standard 
chow to rescue our D2,Ahsg-/- mouse colony. This phenomenon warrants further 
investigation. Potential reasons for increased mortality on high magnesium diet 
include the mobilization of calcified matrix components that may have caused cardiac 
events and stroke. 
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Figure 20. Computer tomography of DBA/2 fetuin-A deficient mice treated with magnesium or 
phosphate.  
The mice received either control food or 1 % magnesium or 0.8 % phosphate or 0.2 % phosphate 
supplemented food. Computer tomography of the mice was performed before and after the feeding 
period of 8 weeks. The degree of calcification was analyzed using Philips Imalytics Research 
Workstation. Mice treated with magnesium (E, F) showed less calcified tissue content than control 
animals (B, C). After feeding with high phosphate, the animals developed significantly more calcified 
tissue content than control animals (H, I). After feeding with low phosphate, the animals showed 
significantly less calcified tissue content than control animals (K, L). Student’s t-test was used to test 
for statistical significance, * p<0.05, ** p<0.01, *** p<0.005 (M). 
 
Further analysis by von Kossa histology underlined the findings of the computer 
tomography analysis. Kidney, heart, lung and brown adipose tissue of the control 
animals were heavily calcified (Fig. 21 A-D), whereas the corresponding organs of 
mice on high magnesium diet were less calcified (Fig. 21 E-H). Feeding 0.8% 
phosphate increased the amount of calcification and led to a higher number of 
calcified lesions in all analyzed tissues. The size of the lesions was likewise 
increased compared to control mice (Fig. 21 I-L). In contrast, animals receiving lower 
amounts of phosphate showed reduced calcification in all organs analyzed 
(Fig. 21 M-P).  
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Figure 21. Von Kossa staining of organs after treatment with magnesium and phosphate.  
The mice received normal chow (0.2% magnesium, 0.4% phosphate) as control (A-D) or received 
1.0% magnesium (E-H) or 0.8% phosphate (I-L) or 0.2% phosphate (M-P) via food for a treatment 
period of 8 weeks. Shown are cryosections with a thickness of 6 µm of kidney (A, E, I, M), heart (B, F, 
J, N), lung (C, G, K, O) and brown adipose tissue (D, H, L, P). Scale bars indicate 200 µm (kidney, 
heart, lung) and 1000 µm (brown adipose tissue), respectively.  
 
In addition to computer tomography and histology, a colorimetric assay was 
performed to determine the tissue calcium content in kidney, lung, heart and brown 
adipose tissue (BAT). The results are shown in Figure 22. Compared with mice on 
standard chow, mice on high magnesium had reduced tissue calcium content in all 
organs analyzed. Feeding with 0.8% phosphate instead of 0.4% in the normal chow 
increased the tissue calcium content in all organs analyzed except for kidneys. 
Reduction of the dietary phosphate intake resulted in decreased tissue calcium 
content in all organs except for BAT. In kidney, the mean tissue calcium content in 
control mice was 2.98 ± 1.98 mg/g organ, magnesium treated animals had a mean 
tissue calcium content of 0.25 ± 0.12 mg/g. High 0.8% phosphate diet led to a mean 
tissue calcium content of 1.74 ± 0.86 mg/g, whereas low 0.2% phosphate diet 
resulted in a mean tissue calcium content of 1.67 ± 0.72 mg/g. In the lung, feeding 
high 1.0% magnesium decreased the tissue calcium content (1.31 ± 1.48 mg/g organ 
vs. control 2.96 ± 1.33 mg/g organ), feeding high 0.8% phosphate increased the 
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tissue calcium content (8.40 ± 2.39 mg/g organ vs. control 2.96 ± 1.33 mg/g organ). 
Feeding low 0.2% phosphate resulted in 2.48 ± 1.27 mg/g lung tissue calcium 
content. In the heart, feeding high 1.0% magnesium decreased the myocardial 
calcium content (1.41 ± 0.98 mg/g organ vs. control 4.81 ± 1.55 mg/g organ) as did 
feeding with low 0.2% phosphate (3.33 ± 1.51 mg/g organ vs. control 4.81 ± 
1.55 mg/g organ), Feeding high 0.8% phosphate increased the myocardial calcium 
content (8.71 ± 2.54 mg/g organ vs. control 4.81 ± 1.55 mg/g organ). Brown adipose 
tissue, the most calcification-prone tissue in this study, reacted accordingly, in that 
mice on standard chow had a mean BAT calcium content of 24.85 ± 13.75 mg/g, 
mice fed 1.0% high magnesium had a reduced BAT calcium content of 4.53 ± 
5.77 mg/g organ and mice on 0.8% high phosphate had the highest BAT calcium 
content of 56.31 ± 32.87 mg/g. Feeding with 0.2% phosphate caused a slight 
increase of calcium content when compared with mice fed chow (31.19 ± 16.03 mg/g 
organ vs. control 24.85 ± 13.75 mg/g organ). 
Taken together, the results of computer tomographic analysis, histology and tissue 
calcium content showed a calcification reduction by 1.0% dietary magnesium 
supplementation. Reduced dietary 0.2% phosphate likewise led to reduced 
calcification, whereas feeding high 0.8% phosphate exacerbated calcification.  
 
Figure 22. Organ calcium content after treatment with 1% magnesium, 0.8% phosphate and 
0.2% phosphate.  
The mice were fed with normal chow (0.2% magnesium, 0.4% phosphate) or alternatively, the 
magnesium or phosphate content was changed to 1% magnesium, 0.8% phosphate or 0.2% 
phosphate. The tissue calcium content was measured in kidney, lung, heart and brown adipose tissue 
of the animals. Treatment with magnesium could reduce the amount of calcium in all analyzed organs. 
Treatment with 0.8% phosphate led to an increase in calcium content in lung, heart and brown 
adipose tissue, whereas reduction of phosphate led to a decrease of calcium content in kidney, lung 
and heart when compared to control animals. Student’s t-test was used to test for statistical 
significance, * p<0.05, ** p<0.01, *** p<0.005. 
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3.2.3 Influence of Anticoagulation on Ectopic Calcification 
We hypothesized that calcification and coagulation could be synergistic. Minerals like 
kaolin, calcium phosphate and polyphosphates are known triggers of the intrinsic 
blood coagulation cascade 248. The pro-thrombotic milieu of calcified lesions could 
form nuclei for further calcification forming a vicious cycle. Supporting this view 
calcified lesions in soft tissue of fetuin-A deficient DBA/2 mice contained coagulation 
components 241.  These findings suggest that inhibition of coagulation may reduce 
ectopic calcification in a pro-calcific milieu. To test this hypothesis, Rivaroxaban®, a 
factor Xa inhibitor was tested regarding its ability to decrease the development of 
calcified lesions in young fetuin-A deficient DBA/2 mice.  
 
Mice were weighed at the start of the experiment, after 4 and 8 weeks, and at the 
end of the experiment. In most animals, blood was collected at these time points. 
During the first weeks of treatment all mice gained weight. During the last four weeks, 
mice fed chow containing Rivaroxaban® reached a steady-state regardless of 
Rivaroxaban® concentration, whereas mice on Rivaroxaban®-fee chow continued to 
gain weight. Weight gain was associated with Rivaroxaban® plasma levels, which 
decreased after week 8. Animals fed chow supplemented with 5 g/kg Rivaroxaban® 
had a mean plasma level of 0.373 ± 0.076 mg/L after 4 weeks, 0.350 ± 0.0200 mg/L 
after 8 weeks, and 0.228 ± 0.074 mg/L after 12 weeks. Mice on chow supplemented 
with 10 g/kg Rivaroxaban® had an even more marked decrease of Rivaroxaban® 
plasma levels from 0.342 ± 0.145 mg/L and 0.351 ± 0.158 mg/L in week 4 and 8, 
respectively, to 0.107 ± 0.021 mg/L after 12 weeks. Nevertheless, prothrombin time 
(PT) as a parameter for coagulation state was elongated in all Rivaroxaban® treated 
mice. Control mice had a PT of 15.2 ± 5.9 sec, animals receiving 5 g/kg 
Rivaroxaban® supplemented food had a prolonged PT of 31.3 ± 10.1 sec, treatment 
with 10 g/kg Rivaroxaban® led to a mean PT of 22.8 ± 7.8 sec. 
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Figure 23. Body weight, Rivaroxaban® plasma levels and prothrombin time.  
3-week-old DBA/2 mice deficient for fetuin-A received Rivaroxaban® supplemented food (either 5 g/kg 
or 10 g/kg) for a treatment period of 12 weeks. Body weight was recorded before starting the 
experiment, after 4 and 8 weeks and at the end of the experiment (A). In addition, heparin plasma 
samples were obtained at these time points and Rivaroxaban® levels were analyzed (B). At the end of 
the experiment, citrate plasma was taken and the prothrombin time as indicator for coagulation state 
was determined (C) ANOVA analysis of variance was used to test for statistical significance, ** 
p<0.01. 
 
Longitudinal analysis with computer tomography did not reveal significant changes in 
calcification burden between untreated control mice and mice treated with 
Rivaroxaban®. At four weeks of age, the animals had a mean calcification volume of 
15.63 ± 11.00 mm2. After the treatment period, control mice had a mean calcification 
volume of 94.09 ± 43.06 mm2, mice treated with 5 g/kg food Rivaroxaban® had a 
mean calcified tissue volume of 137.49 ± 117.40 mm2 and animals which received 
10 g/kg Rivaroxaban® showed a mean calcified tissue volume of 146.95 ± 
66.32 mm2.  
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Figure 24. Computer tomography of DBA/2 fetuin-A deficient mice treated with Rivaroxaban®.  
The mice were left untreated as control (A, B, C) or received the anticoagulant Rivaroxaban® (5g/kg 
(D – F) or 10 g/kg (G – I), respectively). Computer tomography of the mice was performed before and 
after the treatment period of 12 weeks. The degree of calcification was analyzed using a Philips 
Imalytics Research Workstation. Statistical analysis with ANOVA revealed no significant difference 
between control animals and Rivaroxaban® treated animals (J). 
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The findings of the computer tomographic analysis represented a quantitative 
measure of soft tissue calcification. Further analysis with von Kossa histology 
confirmed the findings of the computer tomography. Kidney, heart, lung and brown 
adipose tissue of all animals were heavily calcified regardless of the treatment. 
Morphology and size of the lesions was comparable in all animals.  
 
 
Figure 25. Von Kossa staining of organs after treatment with Rivaroxaban®.  
Mice received normal chow as control (A-D) or received 5 g/kg Rivaroxaban® supplemented food 
(E-H) or 10 g/kg Rivaroxaban® supplemented food (I-L) for a treatment period of 12 weeks. Shown 
are cryosections with a thickness of 6 µm of lung (A, E, I, M), kidney (B, F, J, N), heart (C, G, K, O) 
and brown adipose tissue (D, H, L, P). Scale bars indicate 200 µm (kidney, heart, lung) and 1000 µm 
(brown adipose tissue), respectively.  
 
Tissue calcium content was analyzed as an additional measure of ectopic 
calcification. After 12 weeks of feeding chow with 5 g/kg or 10 g/kg Rivaroxaban® 
supplemented food, no significant differences compared to control animals could be 
observed. In kidney, control animals had a mean tissue calcium content of 7.76 ± 
3.94 mg/g organ. Treatment with 5 g/kg Rivaroxaban® supplemented food resulted in 
9.80 ± 3.94 mg kidney calcium/g, treatment with 10 g/kg Rivaroxaban® led to a slight 
decrease in kidney calcium content to 2.73 ± 2.65 mg/g. Feeding Rivaroxaban® did 
not cause a significant change in lung calcium content. Control mice had a value of 
5.83 ± 4.37 mg calcium/g of lung tissue, 5 g/kg Rivaroxaban® treated animals 8.73 ± 
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5.45 mg calcium/g and 10 g/kg Rivaroxaban® treated mice 7.26 ± 3.98 mg calcium/g 
lung tissue. Calcium content in the heart of the mice showed similar results, the 
values did not differ significantly. Control animals had a mean myocardial calcium 
content of 5.91 ± 2.68 mg/g, animals treated with 5 g/kg Rivaroxaban® had a mean 
value of 6.94 ± 2.09 mg/g and treatment with 10 g/kg Rivaroxaban® led to a mean 
myocardial calcium content of 4.28 ± 1.13 mg/g. As expected, the highest calcium 
content was detected in brown adipose tissue (BAT) reflecting the severe calcification 
of this tissue. The mean BAT calcium content of control animals was 60.13 ± 
70.75 mg/g organ, mice fed with 5 g/kg Rivaroxaban® in their food had a mean BAT 
calcium content of 37.32 ± 25.97 mg/g, supplementation with 10 g/kg Rivaroxaban® 
led to a mean BAT calcium content of 42.18 ± 26.87 mg/g.  
The results obtained from measurement of tissue calcium content resemble the 
findings from computer tomography analysis and histology. Collectively the data 
indicate that Rivaroxaban® treatment had no effect on soft tissue calcification in 
fetuin-A deficient DBA/2 mice. 
 
Figure 26. Organ calcium content after treatment with Rivaroxaban®.  
The mice were fed with normal chow or received 5 g/kg Rivaroxaban® supplemented food or 10 g/kg 
Rivaroxaban® supplemented food for a treatment period of 12 weeks. Calcium content was measured 
in kidney, lung, heart and brown adipose tissue of the animals. Treatment with Rivaroxaban® did not 
affect tissue calcium content, only kidneys of 10 g/kg Rivaroxaban® treated animals showed a lower 
but not significantly decreased amount when analyzed with ANOVA. 
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3.2.4 Summary 
In conclusion, ectopic calcification in fetuin-A deficient DBA/2 mice was successfully 
reduced with i.p. injections of bovine fetuin-A protein (chapter 3.2.1), with low dietary 
phosphate and high dietary magnesium (chapter 3.2.2). Parenteral i.p. treatment with 
sodium thiosulfate (chapter 3.2.1) or oral/dietary Rivaroxaban® (chapter 3.2.3) had 
no effect on the amount of calcification, whereas dietary high 0.8% phosphate led to 
exacerbation of ectopic calcification (chapter 3.2.2).  
3.3 Fetuin-A in Atherosclerosis 
Calcification in atherosclerosis has long been a controversial issue. Two different 
forms are known, microcalcification and macrocalcification. Macrocalcifications are 
commonly thought to stabilize plaques whereas microcalcifications may induce and 
propagate inflammation, and contribute to instable forms and plaque rupture 106. 
Patients at risk of atherosclerosis frequently receive anticoagulants. The most 
common anticoagulant warfarin, a coumarin-derivative, can promote unwanted 
calcification 196. Its major activity, the inhibition of vitamin K-dependent activation of 
coagulation factors by preventing gamma-carboxylation of Glu residues, likewise 
represses proper gamma carboxylation of matrix-GLA-protein, an important tissue 
resident calcification inhibitor of the vasculature. Thus, new anticoagulant substances 
need to be tested regarding their calcification risk. Rivaroxaban® is a factor Xa 
inhibitor and does not interfere with MGP post-translational processing. In this study, 
Apolipoprotein E-deficient atherosclerosis prone C57BL/6 mice were crossed with 
fetuin-A deficient Ahsg-/- mice to derive the atherosclerosis and calcification-prone 
double-deficient mouse strain B6,Ahsg-/-,Apoe-/-. These mice were treated with 
either warfarin or Rivaroxaban®. While characterizing the double deficient mice it 
became clear that fetuin-A is involved in lipid metabolism 58, 220 and thus differences 
in atherosclerosis development in Apoe deficient animals compared to Ahsg/Apoe-/- 
double knockout mice are of interest. 
3.3.1 Body weight 
Body weight of all mice was recorded weekly. All animals gained weight during the 
Western Diet feeding period, demonstrating that atherosclerosis induction might have 
been successful. The following treatment period of 4 weeks with either 
warfarin/vitamin K1 or Rivaroxaban® did not result in a significant weight loss 
indicating that the supplemented food was eaten. Ahsg/Apoe double deficient 
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females had less body weight than Apoe single deficient females before and after the 
Western Diet feeding period, male mice deficient for Ahsg/Apoe-/- were lighter than 
Apoe knockout animals after treatment (Fig 27 D).  Generally female mice gained 
less weight than male mice. 
 
Figure 27. Body weight of the mice.  
8-week-old Apoe deficient mice or Ahsg/Apoe double deficient mice received Western Diet for a period 
of 12 weeks followed by treatment with Warfarin supplemented food (B), Rivaroxaban® supplemented 
food (C) or control food (A) for 4 weeks. Body weight was recorded before feeding Western Diet, after 
12 weeks on Western Diet and after 4 weeks feeding period. (D) shows body weight arranged 
according to genotypes. Student’s t-test was used to test for statistical significance, * p<0.05, ** 
p<0.01. 
3.3.2 Plasma Parameters 
Plasma triglyceride (TG) levels were measured as an indicator of dyslipidemia. After 
12 weeks feeding a high fat containing Western Diet, the animals had significantly 
elevated plasma TG. The plasma TG levels of Apoe deficient mice increased from 
170.86 ± 14.58 mg/dL before Western Diet to 340.31 ± 108.62 mg/dL after 12 weeks 
and stayed in the same range after the subsequent treatment period of 4 weeks 
(317.91 ± 75.80 mg/dL). Animals deficient for Apoe and Ahsg showed an increase 
from 160.39 ± 18.73 mg/dL to 303.30 ± 105.68 mg/dL after Western Diet and a mean 
value of 315.58 ± 97.94 mg/dL after 4 weeks of treatment with Warfarin or 
Rivaroxaban®. The different treatments with either Warfarin/vitamin K1 or 
Rivaroxaban® had no effect on TG levels.  
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Comparison of TG levels of the genotypes revealed no differences between Apoe 
and Ahsg/Apoe deficient animals.  
Elevated plasma cholesterol level is another indicator of dyslipidemia that is tightly 
associated with the development of atherosclerotic plaques 167. Measurement of 
cholesterol levels in mice before starting the experiment, after 12 weeks Western Diet 
and after 4 additional weeks of treatment with Warfarin/vitamin K1 or Rivaroxaban® 
revealed a strong increase in cholesterol level during the experimental treatment. 
Apoe deficient mice showed a significant increase from 232.37 ± 32.61 mg 
cholesterol /dL before Western Diet to 556.26 ± 137.36 mg/dL and 605.04 ± 
133.90 mg/dL after Western Diet and treatment period, respectively. Mice deficient 
for ApoE and fetuin-A showed a similar pattern with slightly higher values then Apoe 
deficient animals. Before Western Diet feeding, cholesterol content in plasma was 
293.30 ± 57.47 mg/dL, after 12 weeks of Western Diet an increase to 655.61 ± 
189.89 mg/dL could be observed which was also stable after the four weeks of 
subsequent treatment (685.24 ± 200.30 mg/dL). The different treatments with either 
Warfarin/vitamin K1 or Rivaroxaban® had no effect on cholesterol levels. In contrast, 
genotype had an effect on cholesterol levels, Ahsg/Apoe double deficient mice 
significantly higher cholesterol levels after Western Diet feeding (Fig. 29 E). 
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Figure 28. Plasma triglycerides.  
8-week-old Apoe deficient mice (A, B) or Ahsg/Apoe double deficient mice (C, D) received Western 
Diet for a period of 12 weeks followed by treatment with Rivaroxaban® supplemented food, Warfarin 
supplemented food or control food for 4 weeks. Plasma triglycerides were measured in heparin 
plasma before starting the experiment, after Western Diet and after the treatment period of 4 weeks. 
Western Diet led to an increase of plasma triglycerides in both male and female regardless of the 
genotype (E). The following treatment with Warfarin/vitamin K1 or Rivaroxaban® had no effect on 
triglyceride levels, only Apoe deficient females showed a slight reduction after the treatment period. 
ANOVA analysis of variance was used to test for statistical significance, * p<0.05, ** p<0.01, *** 
p<0.001. 
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Figure 29. Plasma cholesterol levels.  
8-week-old Apoe deficient mice (A, B) or Ahsg/Apoe double deficient mice (C, D) received Western 
Diet for a period of 12 weeks followed by treatment with Rivaroxaban® supplemented food, Warfarin 
supplemented food or control food for 4 weeks. Plasma cholesterol levels were measured in heparin 
plasma before starting the experiment, after Western Diet and after the treatment period of 4 weeks. 
Western Diet led to an increase of plasma cholesterol in both male and female regardless of the 
genotype. The following treatment with Warfarin/vitamin K1 or Rivaroxaban® had no effect on 
cholesterol levels. After Western Diet feeding period Ahsg/Apoe double deficient mice had significantly 
higher cholesterol levels than Apoe single deficient mice (E).  ANOVA analysis of variance was used 
to test for statistical significance, * p<0.05, ** p<0.01, *** p<0.001. 
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Plasma cholesterol and triglyceride levels were correlated with body weight and 
fetuin-A content in plasma. Representative graphs of individual animals are shown in 
figure 30. Statistical analysis of the differences before and after Western Diet feeding 
revealed positive correlation of plasma cholesterol levels with triglycerides in ApoE 
deficient animals (Fig. 31 F) and in Ahsg/Apoe double deficient animals (Fig. 31 I). In 
addition, cholesterol levels correlated with bodyweight in Ahsg/Apoe double deficient 
mice (Fig. 31 H). Changes in fetuin-A content did not correlate with body weight gain 
and lipid alterations (Fig. 31 A-C). 
 
 
 
 
Figure 30. Typical parameters of female Apoe-/- and Ahsg/Apoe double deficient mice.  
8-week-old ApoE deficient mice (A) or Ahsg/Apoe double deficient mice (B) received Western Diet for 
a period of 12 weeks followed by treatment with Rivaroxaban® supplemented food, Warfarin 
supplemented food or control food for 4 weeks. Plasma cholesterol and triglyceride levels were 
measured in heparin plasma immediately before starting feeding Western Diet and after feeding 
Western Diet for 4 weeks. Additionally, body weight was recorded and plasma fetuin-A was 
determined in Apoe deficient animals using immunoblotting.  
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Figure 31. Correlation of body weight and plasma parameters of Apoe and Ahsg/Apoe deficient 
mice.  
8-week-old Apoe deficient mice (A-F) or Ahsg/Apoe double deficient mice (G-I) received Western Diet 
for a period of 12 weeks. Plasma cholesterol and triglyceride levels were measured in heparin plasma 
before starting the experiment and after Western Diet. Additionally, bodyweight was recorded and 
fetuin-A content was determined in plasma samples of Apoe deficient animals. Calculated differences 
between the values before and after 12 weeks Western Diet feeding are plotted. Statistical analysis 
revealed significant positive correlation of cholesterol and triglycerides in both genotypes and of 
cholesterol and bodyweight in Ahsg/Apoe double deficient mice. 
 
During the treatment period of four weeks following the initial atherosclerosis 
induction, blood samples were obtained every week. Rivaroxaban® plasma levels 
were measured in collaboration with Bayer. Values were above 0.1 mg/L at all time 
points indicating a regular intake of Rivaroxaban® supplemented food. Plasma levels 
Results  74 
 
of ApoE deficient animals were slightly higher than those of ApoE / fetuin-A double 
deficient mice but decreased in the last treatment week.  
 
Figure 32. Rivaroxaban® plasma levels.  
Apoe deficient mice (A) or Ahsg/Apoe double deficient mice (B) received Western Diet for a period of 
12 weeks followed by treatment with Rivaroxaban® supplemented food, Warfarin supplemented food 
or control food for 4 weeks. Rivaroxaban® plasma levels were measured in heparin plasma each 
week during the treatment period of 4 weeks and were shown to be stable over the whole time. 
Statistical analysis was performed using ANOVA. 
 
Prothrombin time (PT) was measured as a parameter for the coagulation state of the 
mice. Citrate plasma was taken at the end of the experiment and PT was measured 
at Bayer Pharma company. Mice fed with Rivaroxaban® supplemented food showed 
a slightly increased mean PT regardless of their genotype, whereas treatment with 
warfarin/vitamin K1 unexpectedly did not cause a prolongation of PT in both 
genotypes. Apoe deficient mice fed with control food had a mean PT of 16.0 ± 
7.8 sec, warfarin fed animals had a PT of 15.3 ± 8.5 sec, Rivaroxaban® increased 
the PT to 17.8 ± 3.3 sec. The mean PT in Ahsg/Apoe double deficient mice was 
13.9 ± 2.4 sec in control animals, 13.8 ± 2.4 sec in warfarin/vitamin K1 fed animals 
and 16.0 ± 1.9 sec in Rivaroxaban® fed mice. Thus Rivaroxaban® feeding had the 
expected anticoagulative effect, but due to low Rivaroxaban® plasma levels (Fig. 32), 
only minor changes could be observed. Warfarin treatment had no influence on PT 
because of simultaneous application of vitamin K1. Warfarin is an antagonist of 
vitamin K by inhibiting vitamin K epoxide reductase, an enzyme that recycles 
oxidized vitamin K1 to its reduced form. Reduced, thus active vitamin K1 is needed 
for γ-carboxylation of blood coagulation proteins but also proteins not involved in 
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blood clotting, such as MGP. Substitution of warfarin treated mice with vitamin K1 
has been shown to prevent unwanted bleeding by restoring carboxylation of 
coagulation factors in the liver but does not restore carboxylation of extrahepatic 
MGP 118, 196.   
 
Figure 33. Prothrombin time.  
Apoe deficient mice or Ahsg/Apoe double deficient mice received Western Diet for a period of 12 
weeks followed by treatment with Rivaroxaban® supplemented food, Warfarin supplemented food or 
control food for 4 weeks. Prothrombin time as a proxy of coagulation state was measured in citrate 
plasma after 4 weeks treatment. PT was unaffected by warfarin treatment, but was slightly prolonged 
by Rivaroxaban®. Statistical analysis was performed using ANOVA and no significance could be 
observed. 
3.3.3 Functional Changes in the Heart 
After the initial atherosclerosis inducing period and at the end of the experiment, mice 
were analyzed by echocardiography. Ultrasound was chosen to monitor putative 
myocard remodeling following cardiovascular calcification. The following parameters 
were analyzed: E/A ratio as an indicator of mitral valve calcification, aortic valve (AV) 
mean velocity to determine aortic valve calcification, ejection fraction as a measure of 
remodeling of the left ventricle due to increased systolic pressure. In addition 
fractional shortening, stroke volume and cardiac output were measured. No 
significant changes could be observed in any of these parameters (data in 
supplemental figure 1) following feeding with Warfarin or Rivaroxaban®. In contrast, 
the different genotypes of mice had marked differences in ECG parameters. 
Parameters describing the function of the left ventricle were significantly lower in 
Ahsg/Apoe double deficient animals compared to Apoe single deficient mice (Fig. 34 
C-F) suggesting impaired cardiac function. Unfortunately, no measurements were 
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taken before the western diet feeding. Thus, it remained unclear, if Ahsg/Apoe 
double deficient mice generally have lower left ventricular function than wildtype and 
Apoe single deficient mice of whether the reduced left ventricular function was 
caused by the western diet feeding.  
 
Figure 34. Echocardiographic analysis.  
Apoe deficient mice or Ahsg/Apoe double deficient mice received Western Diet for a period of 12 
weeks followed by treatment with Rivaroxaban® supplemented food, warfarin supplemented food or 
control food for 4 weeks. Echocardiographic ultrasound was performed after the western diet feeding 
period and at the end of the experiment. Analysis included parameters for valve function (E/A ratio (A), 
AV mean velocity (B)) as well as parameters for remodeling of the left ventricle (ejection fraction (C), 
fractional shortening (D), stroke volume (E), cardiac output (F)). Ahsg/Apoe double deficient mice had 
significantly lower values for ejection fraction, fractional shortening, stroke volume and cardiac output 
compared to Apoe single deficient animals. ANOVA analysis of variance was used to test for statistical 
significance, * p<0.05, ** p<0.01, *** p<0.001. 
3.3.4 Calcification in Heart and Aorta 
Tissue calcium content in the heart apex and abdominal aorta of the mice was 
analyzed using a colorimetric calcium assay. After treatment with Rivaroxaban® or 
warfarin/vitamin K1, the tissue calcium content of heart apices was unaffected. Apoe 
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deficient female mice fed with Rivaroxaban® had significantly increased myocardial 
apex calcium content of 0.263 ± 0.048 mg/g compared to untreated mice with 0.186 ± 
0.053 mg/g organ. Generally treated mice did not have significantly elevated tissue 
calcium levels except for one group, warfarin treated female Ahsg/Apoe double 
deficient mice that had 1.064 ± 0.217 mg/g tissue calcium content vs. 0.620 ± 0.105 
mg/g in female control mice. A similar increase was observed in male Ahsg/Apoe 
double deficient mice, but did not attain statistical significance (1.150 ± 0.727 mg/g 
vs. 0.835 ± 0.604 mg/g in male control animals).   
Calcium mapping of computer tomographic data enabled quantification of calcium in 
the aortas of mice treated with either Rivaroxaban®, warfarin/vitamin K1, or left 
untreated. Aortas of Apoe deficient animals were analyzed in toto, aortas of 
Ahsg/Apoe double deficient mice were only analyzed in their thoracic part. This might 
explain the higher calcium values in ApoE deficient mice and prohibits comparison 
between both genotypes. Apoe deficient mice fed with control diet had a mean value 
of 0.20 ± 0.11 mg, warfarin treated mice had a value of 0.16 ± 0.10 mg and treatment 
with Rivaroxaban® resulted in 0.11 ± 0.08 mg calcium content in the total aorta. 
Analysis of the thoracic aorta of Ahsg/Apoe double deficient mice fed with control diet 
revealed a mean value of 0.03 ± 0.04 mg calcium, warfarin treatment resulted in 
0.02 ± 0.03 mg calcium and Rivaroxaban® treated mice displayed a mean calcium 
content of 0.04 ± 0.07 mg.  
In conclusion, all different treatments resulted in the same range of calcium amount 
and significant changes could not be observed. Differences between genotypes were 
not analyzed as explained above. 
 
Results  78 
 
 
Figure 35. Calcium content in heart and aorta.  
8-week-old Apoe deficient mice (A, B, E, F) or Ahsg/Apoe double deficient mice (C, D, G, H) received 
western diet for a period of 12 weeks followed by 4 weeks feeding of Rivaroxaban®, warfarin or 
control diet. Calcium content of the heart apex and abdominal aorta was measured with a colorimetric 
assay. Apoe deficient female mice treated with Rivaroxaban® had a significantly higher heart calcium 
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content than control mice, aortic calcium content was significantly higher in warfarin treated females. 
ANOVA analysis of variance was used to test for statistical significance, * p<0.05. 
 
 
Figure 36. Computer tomographic calcium mapping of aorta.  
8-week-old Apoe deficient mice (A, B) or Ahsg/Apoe double deficient mice (C, D) received western 
diet for a period of 12 weeks followed by feeding with Rivaroxaban®, warfarin or control diet for 4 
weeks. Calcium content of the thoracic part of the aorta (C, D) or of the complete aorta (A, B) was 
determined using calcium mapping of computer tomographic data. No significant differences could be 
observed between treatment groups using ANOVA. 
 
Coronary sections were prepared from paraffin-embedded heart valves of Apoe 
single deficient mice and Ahsg/Apoe double deficient mice and were stained with von 
Kossa stain to demonstrate calcification. Calcified areas are given as relative area of 
total valve area. No significant changes could be observed following Rivaroxaban® 
or warfarin/vitamin K1 feeding. The calcified areas in of Apoe deficient mice were 
slightly larger than in Ahsg/Apoe double deficient mice.  
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Figure 37. Histology of relative calcified area of heart valves.  
Apoe deficient mice (A, B) or Ahsg/Apoe double deficient mice (C, D) received western diet for 12 
weeks followed by feeding Rivaroxaban®, warfarin / vitamin K1 or control diet for another 4 weeks. 
Relative calcified area of heart valves was determined by von Kossa staining of paraffin sections. No 
significant differences between treatment groups were determined by ANOVA. 
 
Thoracic parts of aortas of Apoe single deficient mice and Ahsg/Apoe double 
deficient mice were embedded in paraffin and 6 µm thin sections were cut. 
Subsequent von Kossa staining enabled analysis of atherosclerotic plaque 
parameters and plaque calcification. Figure 38 shows typical views of aorta sections 
from mice of all experimental groups. Table 1 summarizes the number of calcified 
aortic plaques per genotype and treatment. Apoe deficient mice had comparable 
numbers of calcified plaques in all treatment groups indicating no effect of the 
different treatments. Ahsg/Apoe double deficient mice had significantly less calcified 
plaque than Apoe single deficient mice except for mice treated with 
warfarin/vitamin K1.  
 
 
We
ste
rn
 D
iet
Wa
rfa
rin
Ri
va
ro
xa
ba
n
0
1
2
3
4
 
ca
lc
ifi
ed
 a
re
a 
[%
]
A
 
We
ste
rn
 D
iet
Wa
rfa
rin
Ri
va
ro
xa
ba
n
0
1
2
3
4
 
ca
lc
ifi
ed
 a
re
a 
[%
]
C
 
0
1
2
3
4
Western Diet
Warfarin
Rivaroxaban
male                           female
ca
lc
ifi
ed
 a
re
a 
[%
]
B
 
0
1
2
3
4
Western Diet
Warfarin
Rivaroxaban
male                           female
ca
lc
ifi
ed
 a
re
a 
[%
]
D
Results  81 
 
 
Figure 38. Von Kossa staining of aortic arches.  
8-week-old Apoe deficient mice (A, B, C) or Ahsg/Apoe double deficient mice (D, E, F) received 
western diet for 12 weeks followed by 4 weeks feeding with Rivaroxaban®, warfarin/vitamin K1, or 
control diet. Sections of aortic arches were stained with von Kossa and typical examples from of each 
treatment group are shown. Scale bar 500 µm.   
 
Table 1. Calcified plaques per genotype and treatment group.  
8-week-old Apoe deficient mice (A, B, C) or Ahsg/Apoe double deficient mice (D, E, F) received 
Western Diet for a period of 12 weeks followed by a feeding period with Rivaroxaban® supplemented 
food, Warfarin supplemented food or control food over 4 weeks. First numbers indicate number of 
animals with calcified plaque, second numbers represent total group number.   
  Control Warfarin Rivaroxaban 
Apoe -/- 7/11 6/10 7/12 
Ahsg,Apoe-/- 1/10 6/14 2/15 
 
Maximum plaque thickness was significantly higher in Apoe single deficient mice than 
in Ahsg/Apoe double deficient mice (209.41 ± 65.20 µm vs. 164.04 ± 58.86 µm). The 
different treatments with warfarin or Rivaroxaban® did not cause changes of plaque 
thickness within genotypes. Accordingly the mean plaque size was significantly 
elevated in Apoe deficient mice compared to Ahsg/Apoe double deficient mice (0.23 
± 0.10 mm2 vs. 0.14 ± 0.12 mm2) but no treatment-related differences within 
genotypes were found.  
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In conclusion, Apoe deficient mice had larger plaques with an increased tendency to 
calcify compared to Ahsg/Apoe double deficient mice regardless of the treatment, 
whereas Ahsg/Apoe double deficient mice only had calcified atherosclerotic plaque 
following warfarin feeding. 
 
Figure 39. Plaque morphology.  
8-week-old Apoe deficient mice (A, D) or Ahsg/Apoe double deficient mice (B, E) received Western 
Diet for a period of 12 weeks followed by feeding Rivaroxaban® supplemented food, 
Warfarin/vitamin K1 supplemented food or control food over 4 weeks. Plaque size and maximal 
thickness were calculated using Discus software. The different treatments did not cause changes in 
plaque thickness and area but Apoe deficient mice showed significantly increased values in contrast to 
Ahsg/Apoe double deficient mice. ANOVA analysis of variance was used to test for statistical 
significance, ** p<0.01. 
 
3.4 Linkage Mapping of Calcification Risk Modifier Genes in DBA/2, 
Ahsg-/- x BL/6,Ahsg-/- Intercross 
To date, the exact genetic mechanisms underlying calcification propensity are not 
fully understood. Several calcification-related genes have been identified by genetic 
linkage analysis of calcification-prone vs. calcification-resistant strains of mice. 
Dyscalc1 (dystrophic calcification) is a prime example of a calcification related gene 
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locus 125. Fine mapping of Dsycalc1 revealed Abcc6 (ATP-binding cassette C6) as a 
candidate gene 130. It was indeed shown that Abcc6 deficiency led to calcification, 
and furthermore, that Abcc6 deficient mice have reduced serum fetuin-A levels, and 
that development of ectopic calcifications can be prevented by overexpressing 
fetuin-A 249. This finding suggests that fetuin-A acts downstream or together with 
Abcc6 9. Fetuin-A deficiency in DBA/2 mice leads to spontaneous ectopic calcification 
whereas C57BL/6,Ahsg-/- mice do not show spontaneous lesion formation. We 
hypothesized that an intercross of these strains and subsequent linkage mapping 
may reveal additional genes involved in calcification propensity. 
3.4.1 Computer Tomographic Analysis 
Computer tomographic analysis of the thoracic part of 159 F2-animals of an 
C57BL/6N x DBA/2 Ahsg-/- intercross was performed and the mice were scored 
according to their calcification load as shown in figure 40. 64 mice did not show 
calcified lesions. 25 mice displayed only minor calcification restricted to one area in 
the neck. 45 animals had at least two distinct calcified areas in the neck. 21 mice 
showed additional calcification of the brown adipose tissue of kidneys. 4 mice were 
heavily calcified with involvement of organs like heart and lung. In summary, 64 mice 
did not develop calcification until the age of 12 weeks whereas 95 animals were 
affected. Detailed information of the animals including sex, offspring and fur color is 
listed in supplemental table 6. 
 
 
Figure 40. Calcification scoring in DBA/2,Ahsg-/- X BL/6,Ahsg-/- mice.  
12-week-old fetuin-A deficient mice of the F2 generation were scored regarding calcification severity. 
64 mice did not show calcified lesions (A), whereas 95 animals developed ectopic calcification differing 
in severity (B-E). 
 -  -/+  +  ++  +++
64 25 45 21 4
 no calcification calcification
64 95
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4. Discussion 
 
4.1 Fetuin-A as Imaging Agent 
Calcification is a severe medical complication of several therapies or diseases, 
including bioprosthetic implants like heart valves and vessel conduits, the skin in 
scleroderma, lupus or calciphylaxis disease, as well as highly prevalent diseases of 
the ageing population, atherosclerosis and chronic kidney disease. Thus, the 
visualization of early stages of the calcification processes is of great interest. It can 
be helpful to pursue the progress of calcification-related diseases as well as 
longitudinally monitor therapeutic effects. Several modalities have been established 
in the past years. One of the most promising modalities is the use of fluorescence 
probes. According to New et al., in contrast to CT measurements, the use of specific 
probes in fluorescence molecular tomography can yield the detection of earliest 
stages of calcification 163. Thus the use of fetuin-A known as calcification-binding 
protein is an interesting option.  
 
Fluorescent fetuin-A was established as a novel probe for the detection of 
calcification. Compared to common histological methods, fetuin-A enabled the 
detection of much smaller lesions, which could not be visualized by H&E and von 
Kossa suggesting a high affinity of fetuin-A to calcified lesions (Fig. 7 and 8). This 
finding prompted us to develop labeled fetuin-A probes as in vivo imaging agent for 
all calcification-related issues. To test the probes, mice lacking the gene for fetuin-A 
on the calcification sensitive strain DBA/2 were employed. These mice develop the 
strongest soft tissue calcification described in literature spread over the major 
organs 9. This phenotype is fully developed with an age of 12 weeks and thus 
DBA/2,Ahsg-/- mice represent a stable model for the analyses. Moreover, using 
these animals competition with endogenous fetuin-A could be avoided. In the 2D 
imaging modality of FMT, signal strength of labeled fetuin-A in isolated organs 
correlated with known calcification propensity of DBA/2,Ahsg-/- mice. Brown adipose 
tissue of the neck, lung and kidneys, tissues known to readily calcify 136, 241, indeed 
yielded the highest fluorescent signal. In DBA/2 wildtype mice, fetuin-A staining was 
strongest in the lung and in the kidneys suggesting retention of fetuin-A in these 
organs even in the absence of any calcification. In contrast, OsteoSense®, a 
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commercially available bisphosphonate probe claimed to stain microcalcifications and 
remodeling bone 166 did not reveal differences in calcification amount (Fig. 9). This 
finding was confirmed in 2D in vivo imaging of live mice. Fetuin-A enabled the 
detection of calcification in brown adipose tissue in the neck and kidney of 
DBA/2,Ahsg-/- mice while OsteoSense® only depicted the spine and brown adipose 
tissue in the neck (Fig. 10). Thus, fetuin-A had a higher specificity for ectopic 
calcification while OsteoSense® decorated mineralized bone, especially the spine. 
Due to poor spatial resolution in 3D imaging modality, a combination of computed 
tomography with FMT was required for the unambiguous localization of fluorescence 
signals (Fig. 11 and 12). This method enabled qualitative interpretation of signal 
location but quantification of organ-specific enrichment remained a challenge.   
 
In addition to ectopic calcification in DBA/2,Ahsg-/- mice, fetuin-A demarcated 
atherosclerotic lesions in a model for atherosclerosis, the C57BL/6,Ahsg/Apoe double 
deficient mice (Fig. 13). Reynolds et al. postulated that vascular smooth muscle cells 
under calcification stress develop a protective mechanism against calcification by 
uptaking fetuin-A 134. This finding could explain the strong staining detected in the 
shoulder regions of atherosclerotic plaque in mice injected with fetuin-A, because in 
this area, the vascular smooth muscle cells in the media of the vessel are exposed to 
particularly high calcification stress. Another possible mechanism is based on the 
high apoptosis rate of VSMCs in these regions 250. Apoptotic cells present a matrix 
for the deposition of mineral and thus fetuin-A could be sequestered at these sites 
along with calcifying debris. 
In addition to fetuin-A, osteopontin and albumin were likewise tested for their staining 
potential of atherosclerotic regions (Fig. 14). Osteopontin like fetuin-A is a mineral 
binding protein 243 or mineral chaperone 251 and therefore was tested as possible 
candidate. Albumin in contrast does not have specific hydroxyapatite binding sites 
but binds calcium ions 137. Due to this property and because it is the most abundant 
serum protein and thus present in high amounts in the atherosclerotic lesions, it 
seemed reasonable to also test this protein for its staining potential in calcifying 
atherosclerosis. As fetuin-A is the protein with the most specific binding of 
hydroxyapatite 137, it was not surprising that fetuin-A yielded much higher signal in 
the atherosclerotic lesions analyzed by TPLSM than osteopontin and albumin.  
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In conclusion, the data show that fluorescence-labeled fetuin-A is a powerful tool for 
the visualization of calcification with different application possibilities. Due to its 
specific hydroxyapatite binding capacity it can help to monitor calcification-related 
disease progression and therapeutic success. 
 
4.2 Treatment of Ectopic Calcification in DBA/2,Ahsg-/- Mice 
Ectopic calcification is a severe complication in a variety of diseases. Calciphylaxis in 
CKD patients 96 and atherosclerosis 106 are two of the most notorious entities. To 
alleviate the increased morbidity and mortality associated with calcification several 
therapeutic strategies to prevent and resolve ectopic calcification have been 
explored 153, 252, 253.  
4.2.1 Sodium Thiosulfate and Fetuin-A 
Sodium thiosulfate (STS) has been described as a potent therapeutic agent in 
calciphylaxis patients 159, 246, 254-256. It was shown that STS was able to prevent 
development of vascular calcification in uremic rats 157. In contrast, STS was not of 
significant benefit in an animal model of calcium stone disease 158. Treatment of 
DBA/2,Ahsg-/- mice at the age 6 weeks with STS also did not cause any therapeutic 
benefit 247, and pre-existing lesions could not be resolved. However, it remained 
unclear whether inhibition of de novo formation of calcified lesions was achieved with 
STS in this model. Mice at the age of 3 weeks were employed in the current thesis 
because at this age the first ectopic calcifications were observed. Again, no beneficial 
effect of STS could be observed, prevention of lesion formation could not be 
demonstrated. Tissue calcium content in contrast was increased in kidney and lung 
of STS treated animals when compared to untreated control animals. This might be in 
part explained by intra-individual variation of calcification development. On the other 
hand kidney and lung are highly capillarized organs with functions in filtering, and 
retention of dissolved lesions might have led to increased calcium levels here. 
Further explanations unraveling the failure of STS to prevent lesion formation deal 
with the mechanism of ectopic calcification in DBA/2,Ahsg-/- mice. Thus, the rats in 
the study of Pasch et al. developed vascular calcifications, which might have been 
associated with an osteoblastic transdifferentiation of VSMC. Also human 
calciphylaxis has been described to be promoted by remodeling of vascular smooth 
muscle cells 97. Recently, Zhong et al. could demonstrate that STS protected human 
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aortic smooth muscle cells from osteoblastic transdifferentiation 162. Calcified lesions 
in DBA/2,Ahsg-/- mice have been reported not to be associated with osteoblastic 
activity but that development is a passive mechanism without cell contribution 9. In 
addition, rats in the Pasch study as well as calciphylaxis patients still express fetuin-A 
although circulating levels might be reduced whereas mice in the current work 
completely lacked fetuin-A. Fetuin-A has been described to be the responsible 
protein for transport and clearance of hydroxyapatite by forming CPPs 137, 140. Thus if 
fetuin-A is missing altogether, precipitating hydroxyapatite can no longer be removed 
although STS might increase solubility and decrease formation. To this end, injection 
of bovine fetuin-A was tested regarding the ability to prevent formation of ectopic 
calcifications. 0.24 mg/g bodyweight bovine fetuin-A were injected five days a week, 
corresponding to approximately 20% of plasma level in wildtype mice. Analysis of the 
animals revealed that fetuin-A indeed reduced the amount of calcified lesions in 
contrast to untreated control animals and animals treated with STS (Fig. 15, 16 
and 17). Interestingly, injection of bovine fetuin-A did not cause immune responses in 
the mice suggesting that the applied dose induced high-dose tolerance. In contrast, 
antibody formation against bovine serum albumin, which was present in small 
amounts in the applied fetuin-A preparation due to technical reasons could be 
detected by Western Blot. Combination of fetuin-A with STS did not induce a further 
reduction of calcification, suggesting that the mechanisms of calcification inhibition of 
STS do not play a role in this experimental setup of DBA/2,Ahsg-/- mice or that 
possible effects are far exceeded by the action of fetuin-A.  
4.2.2 Magnesium 
Several studies reported a beneficial effect of magnesium on calcification. Most of the 
studies were performed in VSMC culture 80, 151 or an animal model of aortic 
calcification 152. In addition, magnesium intake was described to be inversely 
correlated with coronary artery calcification 153. Like STS treatment, the beneficial 
action of magnesium might be due to inhibition of osteochondrogenic conversion of 
VSMC and thus might directly or indirectly prevent cardiovascular calcification. 
Magnesium was also shown to prevent calcification in a mouse model of PXE, 
Abcc6-/- mice 81. Additionally magnesium reduced nephrocalcinosis in a rat 
model 152. Boskey et al. could show that magnesium inhibits the formation of 
hydroxyapatite 154. Collectively these findings and further knowledge that the 
calcification-sensitive DBA/2 mice have lower serum magnesium compared to 
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calcification-resistant mouse strains including C57BL/6 257 strongly suggested that 
magnesium supplementation should prevent ectopic calcification in DBA/2,Ahsg-/- 
mice. Indeed treatment with 1.0% magnesium in the food significantly reduced the 
number and size of calcified lesions compared to untreated littermates when starting 
the magnesium rich diet at the age of 3 weeks. This was confirmed in CT 
quantification of calcified lesion area (Fig. 20) as well as by organ calcium content 
(Fig. 22). In addition, histological analysis of heart, lung, kidney and brown adipose 
tissue underlined the dramatic decrease of ectopic calcifications in magnesium 
treated mice (Fig. 21).  
Changes in bone mineralization as a consequence of high dietary magnesium intake 
were not tested in the current study. A recent animal study in rats suggested that 
high magnesium intake did not negatively affect bone physiology. On the contrary, 
increased bone mineral density and bone size were reported as a consequence of 
improved bone metabolism 258. However, the diet used in this study contained 0.1% 
magnesium and 0.5% calcium, whereas the diet used in the current study contained 
1.0% magnesium and 0.9% calcium. Another study in rats with long-term excessive 
magnesium supplementation (0.2% magnesium, 0.7% calcium for 7 months) 
demonstrated several negative effects on bones including reduced mineral content 
and density 259.  
Further drawbacks of magnesium treatment like diarrhea, hypotension, nausea, 
muscle weakness, difficulty breathing and cardiac arrest 260 are related with reduced 
clearance due to kidney failure and thus might be accelerated in DBA/2,Ahsg-/- mice 
as well as in CKD patients. The mice in the current study indeed developed diarrhea, 
but did not show signs of the other side effects listed above. In contrast, feeding high 
magnesium diet instead of standard chow (0.2% magnesium, 1.0% calcium) to adult 
DBA/2,Ahsg-/- mice resulted in a dramatic increase in mortality within one week. This 
finding might be related to toxic effects of excess magnesium as a result of impaired 
clearance in adult DBA/2,Ahsg-/- mice that have reduced renal clearance. 
Alternatively the increased mortality on high magnesium diet could be due to adverse 
cardiac events and stroke as a result of partially dissolved calcified lesions that 
entered the circulation. However, it remains unclear if dietary magnesium is capable 
of resolving pre-existing lesions in addition to the proven benefit in the inhibition of de 
novo lesion development. 
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4.2.3 Role of Phosphate 
Phosphate regulation plays a central role in ectopic calcification especially in CKD 
patients 261-264. An increased serum phosphate level as a result of impaired renal 
excretion is directly associated with cardiovascular calcification 240, 265 but also has 
been reported to promote coronary atheroma burden in non-uremic patients 266.  
Underlying mechanisms leading to hyperphosphatemia in CKD start with the reduced 
ability of damaged kidneys to excrete excess phosphate. As a result, serum FGF23 is 
increased to maintain phosphate homeostasis. Elevated FGF23 in turn leads to the 
reduction of serum calcitriol thereby promoting the development of secondary 
hyperparathyroidism 267. Secondary hyperparathyroidism causes bone resorption and 
thus leads to a further increase in serum phosphate levels.   
To date, several strategies have been developed to normalize serum phosphate 
levels. Use of phosphate binders that increase intestinal phosphate retention and 
excretion have been reported to be an effective treatment of hyperphosphatemia 253. 
Calcimimetics have been developed to treat secondary hyperparathyroidism 268. 
Dietary phosphate restriction is obviously a conditio sine qua non in dialysis patient 
care 253. Although several studies report on the effectiveness of phosphate binders in 
different animal studies 269-273, the effect of dietary phosphate restriction on 
calcification has been studied in surprisingly little detail 274, 275. 
The current study aimed at clarifying the role of dietary phosphate on the outcome of 
ectopic calcification in DBA/2,Ahsg-/- mice. DBA/2,Ahsg-/- mice were described to 
develop secondary hyperparathyroidism and DBA/2 mice have slightly increased 
serum phosphate levels compared to C57BL/6 mice 136. Thus, reduction of dietary 
phosphate intake might be beneficial in preventing the development of ectopic 
calcification in DBA/2,Ahsg-/- mice. Reduction of dietary phosphate to 0.2% instead 
of 0.4% in control food indeed resulted in significantly decreased numbers and sizes 
of calcified lesions as shown by CT quantification (Fig. 20) and histology (Fig. 21). 
However, organ calcium levels were only slightly lower on low phosphate diet 
(Fig. 22). Whether low dietary phosphate could prevent development of secondary 
hyperparathyroidism in the current experimental setup needs to be clarified as well as 
a possible influence on bone mineralization although studies in Abcc6-/- mice treated 
with phosphate binders revealed no influence on mineralization process 273.  
Conversely, we asked whether elevated dietary phosphate could exacerbate the 
calcification phenotype of DBA/2,Ahsg-/- mice, the most calcifying mouse strain 
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described in literature 9. Recent animal studies reported on increased ectopic 
calcification as a result of high phosphate diet. El-Abbadi et al. stated that a high 
phosphate diet (0.9% phosphate and 0.6% calcium, control diet 0.5% phosphate and 
0.6% calcium) induced arterial medial calcification in uremic DBA/2 mice 276. 
Moreover, high phosphate diet (1.65% phosphate and 0.9% calcium, control diet 
0.7% phosphate and 0.9% calcium) induced extraosseous calcifications in 
nephrectomized C57BL/6,Ahsg-/- mice 228, 232. DBA/2,Ahsg-/- mice in the current 
study were fed for a period of three weeks with 0.8% phosphate and 0.9% calcium 
instead of 0.4% phosphate and 0.9% calcium. This study design led to a significant 
increase of calcified lesions throughout the body as confirmed by CT quantification 
(Fig. 20) and histology (Fig. 21). In addition, organ calcium content was significantly 
elevated except for kidney calcium content suggesting an increased deposition of 
hydroxyapatite (Fig. 22). It was not assessed whether bone mineralization was 
affected by high dietary phosphate intake although Lau et al. found decreased 
cortical thickness and density and increased cortical porosity in high phosphate 
treated CKD mice 277. Thus, both positive and negative influence of high phosphate 
on bone mineralization may be possible. Further studies in DBA/2,Ahsg-/- mice might 
elucidate the role of dietary phosphate on bone health. 
4.2.4 Influence of Coagulation on Ectopic Calcification 
In addition to deficiency of calcification inhibitors and disturbed mineral homeostasis, 
coagulation could play a role in the development of ectopic calcification. Calcified 
lesions in soft tissue of fetuin-A deficient DBA/2 mice contain components of the 
blood coagulation cascade and that lesion development starts in 
microvasculature 241. Furthermore, it was described that minerals, most important 
polyphosphates and calcium phosphate, are effective activators of the blood 
coagulation 248. In addition, a predisposing hypercoagulability state has been 
reported as a pathogenetic factor in calciphylaxis 278. Collectively these findings 
suggest a contribution of coagulation to the development of ectopic calcification.  
Thus, Rivaroxaban® a direct factor Xa inhibitor was tested regarding its ability to 
decrease the development of calcified lesions in young DBA/2,Ahsg-/- mice. After a 
treatment period of 12 weeks, computer tomography analysis of the animals revealed 
no benefit of Rivaroxaban® treatment on calcification development regardless of the 
applied concentration (Fig. 24). Von Kossa staining displayed a shift from brown 
adipose tissue towards lung and kidney in Rivaroxaban® treated animals compared 
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to control animals (Fig. 25). This finding was underscored by a slight increase in both 
lung and kidney tissue calcium, at least in animals treated with 5 g/kg Rivaroxaban®. 
Brown adipose tissue calcium content was decreased (Fig. 26) suggesting a filter 
mechanism similar to that proposed in STS treated mice (chapter 4.2.1). It was 
previously demonstrated that alkaline phosphatase-specific activity was dose-
dependently inhibited in Rivaroxaban® treated osteoblastic cell line SaOS2 279 
suggesting effective inhibition of calcification. This finding is puzzling and must be 
due to an off-target activity of Rivaroxaban®, because cell culture media are clotting 
deficient and contain no factor X that could be inhibited by Rivaroxaban®. Thus the 
observed inhibition of alkaline phosphatase remains mechanistically obscure. It was 
tentatively assigned to a reduced, yet equally unexplained osteoblastic activity of the 
SaOS2 cells. In any case, the development of calcified lesions in DBA/2,Ahsg-/- mice 
is not associated with osteoblastic activity 9. Furthermore, prothrombin time in 
Rivaroxaban® treated mice as a measure for coagulation state was not significantly 
elevated compared to control animals (Fig. 23 C) and additionally, Rivaroxaban® 
plasma levels were shown to be decreased in the last third of experimental period 
maybe as a result of reduced uptake (Fig. 23 B). Those findings indicate that the 
Rivaroxaban® serum concentration might have been too low for a significant 
inhibition of coagulation and thereby formation of calcified lesions, although 10 g/kg 
instead of 5 g/kg supplemented food did not result in increased plasma levels. This 
observation may be a drawback of oral application via dietary uptake and other 
application forms might offer an advantage in future studies. However, exact 
mechanisms of coagulation in development of ectopic calcification are not 
understood so far and contribution of coagulation might only play a minor role in the 
current animal model.  
 
In conclusion, fetuin-A as well as magnesium have been shown to be potent 
inhibitors of ectopic calcification in DBA/2,Ahsg-/- mice. It could be demonstrated that 
development of calcified lesions could be prevented in these mice although the ability 
to resolve existing lesions remains to be tested. Both, fetuin-A and magnesium have 
been described to be inhibitors of hydroxyapatite crystallization 154, 280 and thus, 
resolving capacity instead of prevention of lesion formation is questionable. The use 
of magnesium or fetuin-A are promising therapeutic approaches although the 
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mechanisms of ectopic calcification in DBA/2,Ahsg-/- mice and patients with 
calciphylaxis, cardiovascular calcifications, PXE or other diseases might differ.  
 
4.3 Fetuin-A and Atherosclerosis 
4.3.1 Influence of Anticoagulants on Calcification in Atherosclerosis 
For a long time, state-of-the-art prevention and treatment of thrombotic events was 
restricted to vitamin K-antagonists (VKA) like warfarin 281. VKA indirectly inhibit the 
activation of different coagulation factors by interfering with the vitamin K-epoxide 
reductase 282. VKA block vitamin K-dependent γ-carboxylation of the factors II, X, VII 
and IX and proteins C, S and Z resulting in impaired coagulation 283. Unfortunately, 
VKA also inhibit γ-carboxylation of other proteins which are not involved in 
coagulation. Among those are protein inhibitors of vascular calcification like 
osteocalcin, growth arrest specific gene 6-protein, protein S and MGP 196. As MGP is 
a very potent tissue-restricted inhibitor of vascular calcification 119, VKA treatment is 
associated with accelerated vascular calcification and subsequently increased 
cardiovascular mortality 117. Roijers et al. demonstrated that microcalcifications 
destabilizing atherosclerotic plaques are strongly correlated with uncarboxylated, 
non-functional MGP 284. In addition, MGP suppresses osteochondrogenic 
transdifferentiation of VSMC 108.  
Thus, development of alternative anticoagulants is of great importance and new 
compounds should be tested regarding their influence on calcification. Rivaroxaban® 
is a direct factor Xa inhibitor and should not interfere with MGP activation. In the 
current study, atherosclerosis prone C57BL/6 mice deficient for Apolipoprotein E 
alone or in combination with fetuin-A deficiency were treated with either warfarin or 
Rivaroxaban®. After 12 weeks feeding of Western Diet, all mice had significantly 
elevated triglyceride and cholesterol plasma levels, indicating dyslipidemia and 
atherosclerosis induction (Fig. 28 and 29). Analysis of myocard tissue calcium 
content with a colorimetric assay revealed no differences between control animals or 
mice treated with warfarin or Rivaroxaban® (Fig. 35 A-D). Only female Apoe-/- mice 
on Rivaroxaban® had increased calcium levels in the high physiological range. Aorta 
calcium content determined with a colorimetric assay likewise did not reveal 
differences between the treatment groups although warfarin application induced a 
slight increase of aortic tissue calcium in Ahsg/Apoe double deficient mice 
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(Fig. 35 E-H). Measuring tissue calcium content failed to reflect the large calcified 
lesions observed in histology of aortic arches (Fig. 38 and table 1). This discrepancy 
is most likely due to the fact that the limited availability of mouse tissue precludes 
simultaneous analysis of calcium content and histology in the same areas. Calcium 
content of the heart was measured in the apex but functional changes as a result of 
calcification predominantly affected the heart valves 285. Aortic tissue calcium content 
was measured in the abdominal section, but histology was performed in the aortic 
arch. It is known that plaque burden as well as calcification phenotype differ 
throughout the arterial tree 235. In addition, calcified lesions can be functionally 
relevant, yet quite small in relation to the entire specimen and thus detection of 
differences can go undetected using the colorimetric assay for tissue calcium content 
analysis. 
Histology of the heart valves did not reveal an effect of the different treatments on 
calcification (Fig. 37), which was confirmed by functional analysis with 
electrocardiography (supplemental figure 1). In contrast, von Kossa staining of aortic 
arches showed large differences between treatments in Ahsg/Apoe double deficient 
mice (Fig. 38 and table 1). The number of Apoe-/- mice with calcified plaque were 
similar regardless of treatment, but calcified plaque in Ahsg/Apoe double deficient 
mice was only significantly elevated when mice were treated with warfarin. Mice 
treated with Rivaroxaban® or control mice mostly did not develop calcifications. This 
finding suggests that lack of fetuin-A is somehow protective against plaque 
calcification unless warfarin impairs MGP function. Potential mechanisms for this 
unexpected observation are discussed in chapter 4.3.2. Plaque size and maximal 
plaque thickness were not affected by the different treatments (Fig. 39).  
The prothrombin time (PT) as a proxy of coagulation state did not increase after 
treatment with warfarin or Rivaroxaban® as expected. This may be due to insufficient 
dosing or uptake of the drugs. As the animals did not lose weight during the four-
week treatment period (Fig. 27), insufficient dietary uptake is unlikely. Previously, 
Rivaroxaban® in mice had only been administered by injection and thus the feeding 
experiment was a first. Previous work at Bayer company had shown that significant 
PT prolongation was observed at Rivaroxaban® plasma levels of at least 0.23 mg/L. 
Thus the Rivaroxaban® plasma levels of 0.2 mg/L attained in this study by feeding 
were simply to low for PT prolongation. Warfarin plasma levels were not determined, 
unaffected PT might be a result of insufficient dosage. Apart from that concurrent 
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substitution with vitamin K1 was performed to maintain coagulation function while 
inhibiting γ-carboxylation of extra-hepatic proteins like MGP 196. Other animal studies 
that analyzed influence of warfarin on vascular calcification applied similar 
concentrations of both warfarin and vitamin K1 and found a significant increase of 
vascular calcification compared to untreated animals 117, 118. However, PT as well as 
warfarin plasma level were not determined in those studies. Krüger et al. analyzed 
media calcification in DBA/2 mice, a calcification prone strain and thus a distinct 
mechanism of vascular calcification was studied here. Schurgers and colleagues 
found that warfarin treatment did not influence plaque size but increased vascular 
calcification in C57BL/6,Apoe-/- mice. Plaque size was as in the current thesis 
comparable but warfarin treatment significantly increased number of plaques with 
intimal calcification in contrast to the current study. However, reasons for these 
differences remain unclear and further analyses including determination of warfarin 
plasma levels, (un)carboxylated MGP and cellular factors affecting plaque 
calcification (osteochondrocytic differentiation of VSMC, apoptosis) would help to 
clarify the contrasting findings.    
A recent study in ApoE−/− mice treated with Rivaroxaban® revealed that 
Xa-inhibition does not affect lesion progression, but downregulates expression of 
inflammatory mediators and promotes lesion stability 208. This could be confirmed at 
least in part in this study, Rivaroxaban® treated animals did not develop lesions 
increased in size or maximal thickness compared to control animals (Fig. 39). 
Inflammation was not assessed in the current study. 
In conclusion, Rivaroxaban® did not promote calcification in atherosclerotic plaque of 
Apoe-/- and Ahsg/Apoe-/- mice as expected. In contrast, warfarin increased the 
incidence of calcified plaque in Ahsg/Apoe-/- mice but not in Apoe-/- mice. These 
observations suggest that fetuin-A protects against calcification in atherosclerosis.  
4.3.2 Role of Fetuin-A in Lipid Metabolism and Atherosclerosis 
The differences of lipid content and aortic calcification found in Apoe-/- mice 
compared to Ahsg/Apoe-/- mice suggest that in addition to the calcification inhibition 
fetuin-A may play a role in lipid transport.  
Numerous publications report on association of fetuin-A with insulin resistance, 
dyslipidemia, type-2 diabetes and MetS 60, 209, 211, 221, 286-289. This association is based 
on the finding that pp63, later identified as rat fetuin is an inhibitor of the insulin 
receptor tyrosine kinase 55. In addition to rat fetuin, studies with mouse fetuin and 
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bovine fetuin revealed insulin receptor tyrosine kinase inhibition 215, 216. Furthermore, 
the human homolog AHSG was shown to inhibit insulin receptor 
autophosphorylation 217. In contrast, Chen and colleagues found that AHSG inhibits 
insulin-stimulated Elk-1 phosphorylation in rat adipose cells, but no classical inhibition 
of insulin receptor could be shown 218. Mathews et al. studied the influence of 
fetuin-A on insulin sensitivity in mice. They analyzed fetuin-A deficient mice 
maintained on a mixed genetic background of C57BL/6N and 129Sv and found that 
those mice had improved insulin sensitivity, were resistant to weight gain, obesity and 
were protected against insulin resistance associated with ageing 58, 219. However, 
when these mice were backcrossed onto the pure strains C57BL/6N and DBA/2 
association with insulin signaling and metabolic syndrome could no longer be 
demonstrated 9, 220. In contrast, this present study detected no clear association of 
Ahsg genotype with body weight or serum lipids in untreated mice (Fig. 31 A-C). This 
casts serious doubt on the causative role of fetuin-A in insulin-resistance and 
subsequently in the development of MetS. It has also been argued that differences in 
the genetic background of the mice used in various studies might have a greater 
influence on insulin signaling than Ahsg genotype. C57BL/6 substrains displayed 
variances in insulin sensitivity. C57BL/6J mice carry a spontaneous mutation in 
nicotinamide nucleotide transhydrogenase (Nnt) affecting glucose homeostasis and 
insulin secretion 290. This mutation was associated with reduced insulin secretion and 
impaired glucose clearance 291. Also Apoe-/- mice used in the current study were 
commercially available only on C57BL/6J background whereas our own Ahsg/Apoe-/- 
mice were maintained on the genetic background C57BL/6N. Thus diverging 
C57BL/6 substrains may also contribute to differences found in lipid analysis.  
ApoE deficient mice were used in this study as established model for dyslipidemia 
and atherosclerosis development 234. ApoE is critically involved in the clearance of 
chylomicrons, VLDL and remnants from circulation and consequently mice deficient 
for ApoE display hypercholesterolemia as a result of impaired clearance of 
cholesterol enriched lipoproteins 292 ultimately leading to the development of 
atherosclerotic lesions in aorta and coronary arteries 235. Combining ApoE deficiency 
with fetuin-A deficiency in Ahsg/Apoe double knockout mice led to increased media 
calcification in a mouse model of uremia 228. Here, these mice were used for the first 
time to study the influence of fetuin-A in atherogenesis. Induction of atherosclerosis 
in the Apoe-/- model is achieved by feeding a high-fat and cholesterol containing 
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Western Diet causing elevated circulating cholesterol although the levels differ 
amongst substrains of Apoe-/- mice 293. In addition to impact of the respective 
genotype on lipid levels, it was reported that diet composition influences 
atherosclerosis 294. This is consistent with the finding of a previous study performed 
in our lab, which reported that Apoe-/- animals developed lower levels of circulating 
cholesterol than Apoe deficient mice used in other studies 220. The Western Diet used 
in this study consisted of 21% fat (>10% polyunsaturated fatty acids) and contained 
0.15% cholesterol (exact composition see supplemental table 5). Feeding Apoe-/- 
mice a diet rich in unsaturated linoleic acid resulted in reduced atherosclerosis 
associated with reduced total cholesterol levels and increased HDL cholesterol in 
Apoe-/- mice 295. This study reported on dramatically increased cholesterol levels in 
Ahsg/Apoe-/- mice after 15 weeks of Western Diet feeding. These findings suggest 
that Fetuin-A is critically involved in the efficient cholesterol clearance from blood 
although exact mechanisms are unclear to date. 
In comparison to the previous study 220, cholesterol levels in the current study were 
higher in Apoe-/- mice but comparable in Ahsg/Apoe-/- mice. The composition of 
Western Diet in the current study was more atherogenic with 21,2% crude fat by 
weight (41% of calories, <5% polyunsaturated fatty acids) and 0.2% cholesterol 
(exact composition in supplemental table 4) and thus provoked plaque formation in 
all mice. However, genotypic differences in dyslipidemia were reduced. Ahsg/Apoe-/- 
mice had similar amounts of triglycerides and only slightly elevated cholesterol levels 
compared to Apoe-/- mice (Fig. 28 and 29). These observations indicate an important 
role for fetuin-A in lipid metabolism. Recently, Fetuin-A has been called the “missing 
link” between fatty acid-induced inflammation and toll-like receptor 4 (TLR4) 
signaling 57, causing fat inflammation and metabolic syndrome. Pal et al. proposed a 
direct binding of free fatty acids to fetuin-A and subsequent induction of TLR4 
signaling by fetuin-A. However, no binding of fetuin-A to fatty acids could be 
confirmed in our lab 296 and also no proinflammatory activity of fetuin-A could be 
demonstrated (unpublished data). Kumbla et al. found that bovine Fetuin-A is 
associated with lipoprotein-like particles with floating characteristics similar to high 
density lipoproteins 24. Fetuin-A was associated with cholesterol, cholesteryl ester, 
phospholipids, triglycerides and free fatty acids. This observation together with the 
results from the previous study 220 and the current study suggest that fetuin-A is 
involved in reverse cholesterol transport (RCT) and Ahsg-/- mice have impaired 
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cholesterol clearance resulting in increased circulating cholesterol levels. As 
mentioned above, Nnt mutation in C57BL/6J mice is associated with reduced insulin 
secretion and thus disturbed lipid metabolism. Mice carrying the mutation have been 
shown to gain more weight 291, which is consistent with the finding that bodyweight in 
C57BL/6J,Apoe-/- mice from the current study was higher than that of 
C57BL/6N,Apoe-/- mice in the previous study 220. In contrast to C57BL/6N,ApoE-/-, 
C57BL/6J,Apoe-/- mice in the current study developed cholesterol levels that were 
higher. However, the values were still lower than those of mice in comparable studies 
(see table 2).  
 
Table 2. Comparison of cholesterol levels in Apoe-/- mice after Western Diet. 
Study 
Genetic 
background 
Diet composition and 
duration 
Cholesterol 
[mg/dL] 
Current study C57BL/6J 
12 weeks 
21,2% w/w (41% of 
calories) fat 
0.2% w/w cholesterol 
556 
Fertig et al. 220 C57BL/6N 
15 weeks 
21% w/w fat 
0.15% w/w cholesterol 
311 
Plump et al. 292 C57BL/6 
21% w/w (42% of 
calories) fat 
0.15% w/w cholesterol 
1821 
Davis et al. 297 C57BL/6 
6 months 
40% fat of calories 
0.15% w/w cholesterol 
964 
Arbones-Mainar et al. 298 C57BL/6 
10 weeks 
20% w/w fat 
0.15% w/w cholesterol 
1160 
 
To conclude, differences found in cholesterol levels of Apoe-/- mice in the previous 
study 220 and the current study base on dietary differences and on diverging Nnt 
genotype. But even if mechanisms causing increased circulating cholesterol levels 
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differ in C57BL/6J,Apoe-/- (Nnt mutation) and C57BL/6N,Ahsg/Apoe-/- (impaired 
RCT), both result in dyslipidemia with comparable amounts of total cholesterol.  
The number of Ahsg/Apoe-/- mice with plaque calcification was significantly lower 
than that of Apoe-/- mice. This suggests that the major role of fetuin-A in this setup is 
not associated with its inhibitory effects on matrix mineralization but other 
mechanisms must be affected by fetuin-A. Additionally, Apoe-/- mice had increased 
plaque size and maximal plaque thickness compared to Ahsg/Apoe-/- mice (Fig. 39). 
Recently it was reported that fetuin-A is associated with endothelial dysfunction and 
atherosclerosis 299. Correlation analysis revealed that fetuin-A was positively 
correlated with triglyceride and asymmetric dimethyl arginine (ADMA) as marker for 
endothelial dysfunction and negatively correlated with HDL-C levels. This study was 
performed with human samples of patients with non-alcoholic fatty liver disease. In 
the current study correlation analysis did not reveal association of fetuin-A with 
triglycerides but correlation with ADMA and HDL-C was not assessed. Future 
analyses should include these parameters to further investigate the role of fetuin-A 
on endothelial dysfunction. Furthermore, Chatterjee et al. could demonstrate that 
fetuin-A is an efficient chemokine for macrophage migration and polarization 300. In 
atherosclerotic plaques, a 7-fold higher fetuin-A concentration was detected than that 
found in plasma 301. Thus, fetuin-A enrichment in plaque may attract macrophages 
which accelerates plaque progression in Apoe-/- compared to animals additionally 
deficient for fetuin-A. Enrichment of fetuin-A in atherosclerotic plaque could also be 
confirmed in the current study by TPLSM, where accumulation in foam cells of plaque 
and in VSMC was observed (Fig. 13) but macrophage migration and polarization was 
not analyzed. A possible switch in macrophage polarization towards M2 induced by 
fetuin-A 300 might support development of an inflammatory milieu thereby promoting 
osteochondrogenic differentiation of VSMC.  
Moreover, it was shown that HDL regulates differentiation and calcification of 
vascular cells by inhibiting the osteogenic activity that was induced by inflammatory 
cytokines 302. Thus if RCT is impaired due to fetuin-A deficiency, increased circulating 
HDL levels in fetuin-A might be protective and reduce osteochondrocytic conversion 
and calcification of VSMC in the atherosclerotic plaque.  
This current study did not distinguish between macro- and microcalcifications. 
Histology in Apoe-/- mice predominantly detected macrocalcifications (Fig. 38). In 
contrast, aorta tissue calcium content was higher in Ahsg/Apoe-/- mice than in 
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Apoe-/- mice suggesting a higher incidence of microcalcifications. These 
observations suggest that the pathology of micro- versus macrocalcification is very 
different, and furthermore that fetuin-A inhibits microcalcifications, but not 
macrocalcifications.  Macrocalcifications have been described as plaque-stabilizing 
and primarily non-inflammatory 105. In contrast, microcalcifications are highly inflamed 
and cause plaque rupture 106, 196.  
The incidence of heart valve calcification (Fig. 37) matched the findings in aortas in 
that Apoe-/- heart valves had more calcification than Ahsg/Apoe-/- heart valves. 
Paradoxically however, electrocardiography revealed slightly impaired left ventricular 
function in Ahsg/Apoe-/- compared to Apoe-/- mice (Fig. 34). Like in aortas this may 
be due to increased microcalcification in Ahsg/Apoe-/- compared to Apoe-/- heart 
valves resulting in vascular stiffening. However, no measurements were taken before 
Western Diet feeding, and thus it remains unclear if the echocardiography differences 
were due to vascular stiffening as a result of calcification or strain-related.  
Fetuin-A dependent inhibition of calcification is mediated by the formation of 
CPPs 137. CPPs and the contained hydroxyapatite are efficiently cleared by 
scavenger receptor A-mediated uptake by macrophages in liver and spleen 140. 
Herrmann et al. demonstrated that also macrophages in atherosclerotic plaques 
endocytosed CPPs, which could contribute to plaque calcification. Fetuin-A deficient 
mice will not form stable CPPs, and consequently CPP hydroxyapatite uptake by 
plaque macrophages should be reduced in fetuin-A deficient mice which might 
explain the reduced number of calcified plaques. However, currently little is known 
about the clearance of excess mineral in the absence of fetuin-A, especially in 
hyperlipidemia. It was reported that CPP endocytosis and lipoprotein uptake are both 
mediated by scavenger receptor A in macrophages 140 supporting the finding that 
elevated calcification in Apoe-/- is associated with increased plaque size and 
maximal plaque thickness. 
In conclusion, fetuin-A is a prototypic carrier protein with roles in mineralized matrix 
metabolism and lipid metabolism. The role of fetuin-A in atherosclerotic plaque 
calcification was found to be neutral or even pro-calcific, and predominantly 
determined by the lipid binding properties of fetuin-A, whereas the role in plaque 
microcalcification was anti-calcific, and predominantly determined by the fetuin-A role 
in mineralized matrix metabolism. This suggests that distinct mechanisms of 
calcification exist depending on the cellular and metabolic context. Calcification in 
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general and atherosclerotic plaque calcification in particular are complex in that low 
and high molecular weight calcification inhibitors like magnesium and MGP, carrier 
proteins including fetuin-A and ApoE, the metabolic state, and inflammation will all 
influence plaque formation and progression. Thus any therapy aiming at calcified 
plaque reduction will have to target the specific plaque stage. 
 
4.4 Linkage Mapping of Calcification Risk Modifier Genes in 
DBA/2,Ahsg-/- x BL/6,Ahsg-/- Intercross 
The genetics explaining calcification propensity are still not fully understood. Ivandic 
et al. linked so-called Dyscalc gene loci with dystrophic calcification 125. Fine mapping 
of one locus by Meng et al. identified Abcc6 as a risk gene for calcification 130. Initial 
studies on the role of Abcc6 as a calcification regulating gene were restricted to the 
myocardium 128, 129, 303. Abcc6 deficiency was associated with reduced plasma 
fetuin-A levels and development of ectopic calcifications were prevented by 
overexpressing fetuin-A 249. This finding suggested that fetuin-A acts downstream or 
together with Abcc6 9, and that the Abbcc6 knockout phenotype is in fact a mild 
phenocopy of the fetuin-A knockout against the genetic background DBA/2 
(D2,Ahsg-/- mice). 
In fact calcification in D2,Ahsg-/- mice affects almost all soft organs 136, not only the 
myocardium which calcified after freeze-thaw injury in calcification prone mice that 
were used to map Dyscalc loci and ultimately Abcc6 128, 129, 303. Importantly fetuin-A 
deficiency causes ectopic calcification in DBA/2 mice, but not in C57BL/6 mice 
(B6,Ahsg-/-). Thus, intercross of these strains and subsequent linkage mapping 
should help to reveal additional genes involved in calcification propensity without the 
phenotypic blurring induced by the freeze-thaw injury required to trigger myocardial 
calcification used in previous mapping studies of calcification-prone vs. calcification 
resistant mice. 
This current study included breeding and computer tomographic analysis of 159 F2 
animals of this intercross. 95 animals showed calcification ranging from very small 
isolated areas up to severe calcification spread over the whole body. 64 animals did 
not develop calcifications until the age of 12 weeks. Additionally, DNA samples of all 
mice were obtained. Future work will cover sequencing of these DNA samples to 
detect further risk modifier genes involved in dystrophic calcification. 
Discussion  101 
 
4.5 Perspectives 
Ectopic calcification is a common problem in a variety of diseases 82, 86, 96, 304. In the 
current thesis, DBA/2,Ahsg-/- mice were used to study the influence of different 
therapeutic approaches on the development of calcified lesions. It was demonstrated 
that parenteral fetuin-A and dietary magnesium as well as low dietary phosphate all 
prevented calcification. However, it was not tested whether pre-existing calcifications 
could also be resolved with any of the therapies. Furthermore, the exact mechanisms 
of ectopic calcification are not fully understood. It was described, that calcification in 
DBA/2,Ahsg-/- occurs spontaneously without contribution of osteoblastic activity 9, 
whereas calcification related with calciphylaxis or atherosclerosis is associated with 
VSMC transdifferentiation into an osteochondrocytic phenotype 97, 305. Thus, it 
remains to be investigated whether treatment with magnesium or fetuin-A is a 
valuable approach to treat ectopic calcification in patients with calciphylaxis, 
atherosclerosis or other calcification-related diseases. Dietary supplementation of 
magnesium has been demonstrated to be associated with reduced mortality from 
cardiovascular disease 306 but has not yet been tested in calciphylaxis. The role of 
fetuin-A in cardiovascular calcification is controversial. On the one hand, CKD 
patients have been described to have lower fetuin-A levels associated with an 
increased cardiovascular mortality 307, 308. Thus it seems reasonable to substitute 
fetuin-A in these patients. On the other hand, high serum fetuin-A levels were shown 
to be associated with metabolic syndrome and atherosclerosis 60, 209, 309|.  
In the current study, it was shown that fetuin-A was negatively associated with plaque 
calcification, area and thickness. In a previous study, it was demonstrated that 
Ahsg/Apoe double deficient mice had significantly higher cholesterol levels 220. Both 
findings suggest a role of fetuin-A in lipid metabolism, namely in reverse cholesterol 
transport. However, the models in both studies were not identical and it is of critical 
importance to verify the results with comparable settings. Furthermore, the exact role 
of fetuin-A in lipid metabolism needs to be determined. Therefore, lipoproteins of both 
Apoe-/- and Ahsg/Apoe-/- mice should be analyzed regarding their cholesterol 
content, apolipoprotein composition and functionality and whether fetuin-A is 
associated with particles of Apoe-/- mice. Additionally, plaques need to be analyzed 
in terms of lipid content, cellular aspects (transdifferentiated VSMC) and type of 
calcification. Circumstantial evidence suggests the presence of mixed 
CPP-lipoproteins, which may contribute to atherosclerosis especially in CKD patients 
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with combined dysregulation of mineral and lipid homeostasis 140, 241. Uptake of 
mixed CPP-lipoproteins by plaque macrophages via scavenger receptor A might lead 
to enrichment of both lipids and hydroxyapatite and cause an exacerbated 
phenotype. In conclusion, the study of the role of fetuin-A in atherosclerotic 
calcification provided insight into novel pathomechanisms and novel therapeutic 
strategies. 
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7. Abbreviations 
AAS    atomic absorption spectrophotometry 
ABCA1   ATP-binding cassette transporter A1 
Abcc6   ATP-binding cassette C6 
AGE    advanced glycation endproducts 
Ahsg    α2-Heremans-Schmid-glycoprotein 
AOPP   advanced oxidation protein products 
ApoA1   apolipoprotein A-I 
ApoA2   apolipoprotein A-II 
ApoB    apolipoprotein B-48 
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ApoC2   apolipoprotein C-II 
ApoE    apolipoprotein E 
AV    aortic valve 
B6    C57BL/6 mouse strain 
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Cbfa-1   core-binding factor subunit alpha-1 
CETP   cholesterylester transfer protein 
CKD    chronic kidney disease  
CPM    calciprotein monomer 
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CT    computer tomography 
CUA    calcified uraemic arteriolopathy 
CVD    cardiovascular disease 
D    domain 
D2    DBA/2 mouse strain 
ECG    electrocardiography 
FELASA   Federation for Laboratory Animal Science Association 
FetA    fetuin-A 
FETUB   fetuin-B 
FFA    free fatty acids 
FGF23   fibroblast growth factor 23 
FMT    fluorescence molecular tomography 
GLUT4   glucose transporter type 4 
HAP    hydroxyapatite 
HDL    high-density lipoprotein 
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HE    hematoxylin eosin staining 
HRG    histidine-rich glycoprotein 
i.p.    intraperitoneal 
IDL    intermediate-density lipoprotein 
IgG    immunoglobulin G 
IL-1β    interleukin-1beta 
KNG    kininogen 
LANUV   Landesamt für Natur-, Umwelt- und Verbraucherschutz  
LCAT   lecithin-cholesterol acyltransferase 
LDL    low-density lipoprotein 
LDLR   LDL receptor 
LPL    lipoprotein lipase 
MetS    metabolic syndrome 
MGP    matrix-GLA-protein 
OPN    osteopontin 
PBS    phosphate buffered saline 
pp63    phosphorylated N-glycoprotein 
PT    prothrombin time 
PTH    parathyroid hormone 
PXE    pseudoxanthoma elasticum 
RCT    reverse cholesterol transport 
Runx2   runt-related transcription factor 2 
SDS    sodium dodecyl sulfate 
SDS-PAGE  SDS polyacrylamide gel electrophoresis 
SR-A    scavenger receptor A 
SR-B1   scavenger receptor B-I 
STS    sodium thiosulfate 
TG    triglycerides 
TGF-β   transforming growth factor-beta 
TLR4    toll-like receptor 4 
TNF-α   tumor necrosis factor alpha 
TPLSM   two-photon laser scanning microscopy 
TRL    triglyceride-rich lipoprotein 
VKA    vitamin K antagonist 
VLDL   very low-density lipoprotein 
VSMC   vascular smooth muscle cells 
WHO    world health organization
Supplement  135 
 
8. Supplement 
8.1 Diets 
 
 
Supplemental table 1. Composition of standard chow. 
Status: 06/2005 
ssniff® R/M-H  
Alleinfuttermittel für die Haltung von Ratten und Mäusen 
 
Beschreibung 
Dieses Futtermittel ist für Ratten und Mäuse im Erhaltungsstoffwechsel vorgesehen. Aufgrund der 
ausgewogenen Nährstoffkonzentrationen bei mittlerer Energiedichte und niedrigem Nitrosamin-Ge-
halt ist es auch als Basisfutter für Langzeitstudien gut geeignet. 
 
 
Rohnährstoffe [%] 
Trockensubstanz 87,7 
Rohprotein (N x 6,25) 19,0 
Rohfett  3,3 
Rohfaser 4,9 
Rohasche 6,4 
N-freie Extraktstoffe 54,1 
Stärke 36,5 
Zucker 4,7 
 
Energie [MJ/kg] 
Bruttoenergie (GE) 16,3 
Umsetzbare Energie (ME) * 12,8  
Mineralstoffe  [%] 
Calcium 1,00 
Phosphor 0,70 
Natrium 0,24 
Magnesium 0,22 
Kalium 0,91 
Fettsäuren  [%] 
C 14:0 0,01 
C 16:0 0,47 
C 16:1 0,01 
C 18:0 0,08 
C 18:1 0,62 
C 18:2 1,80 
C 18:3 0,23 
C 20:0 0,01 
C 20:1 0,02 
C 20:5 ---- 
C 22:6 ---- 
Aminosäuren  [%] 
Lysin 1,00 
Methionin 0,30 
Met+Cys 0,65 
Threonin 0,68 
Tryptophan 0,25 
Arginin 1,14 
Histidin 0,44 
Valin 0,88 
Isoleucin 0,76 
Leucin 1,30 
Phenylalanin 0,85 
Phe+Tyr 1,43 
Glycin 0,80 
Glutaminsäure 3,90 
Asparaginsäure 1,61 
Prolin 1,25 
Alanin 0,79 
Serin 0,89  
Vitamine per kg 
Vitamin A 15.000 IE 
Vitamin D3 1.000 IE 
Vitamin E 110 mg 
Vitamin K (als Menadion) 5 mg 
Thiamin (B1) 18 mg 
Riboflavin (B2) 23 mg 
Pyridoxin (B6) 21 mg 
Cobalamin (B12) 100 µg 
Nicotinsäure 135 mg 
Pantothensäure 43 mg 
Folsäure 7 mg 
Biotin 525 µg 
Cholin-Cl 2.990 mg 
Inositol 100 mg 
Spurenelemente  per kg 
Eisen 179 mg 
Mangan 69 mg 
Zink 94 mg 
Kupfer 16 mg 
Iod 2,2 mg 
Selen 0,3 mg 
Cobalt 2,1 mg 
 
* ME berechnet nach der Schätzformel für Schweine, 
Anlage 4 der Futtermittelverordnung 
 
Hauptprodukte 
V1530-0 Mehl, einfach vermahlen 
V1534-0 10 mm Pellets 
V1535-0 15 mm Pellets 
 
 
Produktion und Vertrieb 
ssniff Spezialdiäten GmbH 
Phone: +49-(0)2921-9658-0 
Fax:  +49-(0)2921-9658-40 
E-Mail mail@ssniff.de 
www.ssniff.de 
Energiedichte [MJ ME/kg] und  
Protein-/Energie-Verhältnis [g XP/MJ ME] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
58 % aus
Kohlenhydraten 33 % aus
Protein
9 % 
aus Fett 
Futterzusammensetzung 
absteigende Reihenfolge der Gruppen (FMV) 
Getreide und Getreidenebenprodukte, Ölsaat-
produkte, Mineralstoffe, pflanzliche Öle, Vita-
mine, Spurenelemente. 
7
9
11
13
15
17
19
ME XP/ME
R/M-H Extr. R/M-H auto R/M-H R/M-H Ered I R/M-H Ered II
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Supplemental table 2. Composition of diets with different magnesium and phosphate 
concentrations. 
 ssniff Spezialdiäten GmbH page 1 of 1 
Table 1. Composition of the P and Mg adjusted diets (0.9 % Ca) 
Ingredient U 0.2 % P 0.2 % Mg 
0.4 % P 
0.2 % Mg 
0.4 % P 
1.0 % Mg 
0.8 % P 
0.2 % Mg 
Product No.  S0382-E122 S0382-E124 S0382-E126 S0382-E128 
Casein % 20.000 20.000 20.000 20.000 
Corn starch, pre-gelatinized % 37.600 37.600 36.250 37.390 
Maltodextrin, 10 DE % 15.000 15.000 15.000 15.000 
Sucrose % 10.000 10.000 10.000 10.000 
Cellulose powder % 5.000 5.000 5.000 5.000 
L-Cystine % 0.200 0.200 0.200 0.200 
Vitamin premix % 1.000 1.000 1.000 1.000 
Mineral premix  1), 2), 3) % 6.000 6.000 6.000 6.000 
Choline Cl (50 %) % 0.200 0.200 0.200 0.200 
Magnesium oxide, 60 % Mg % —— —— 1.350 —— 
Calcium carbonate % —— —— —— 0.210 
Soybean oil % 5.000 5.000 5.000 5.000 
Proximate contents      
Crude protein % 17.6 17.6 17.6 17.6 
Crude fat % 5.1 5.1 5.1 5.1 
Crude fibre % 5.0 5.0 5.0 5.0 
Crude ash % 4.9 4.9 6.1 5.7 
Starch % 36.2 36.2 34.9 36.0 
Sugar  % 11.3 11.3 11.3 10.7 
Calcium % 0.90 0.90 0.90 0.90 
Phosphorus % 0.20 0.40 0.40 0.80 
Magnesium % 0.20 0.20 1.00 0.20 
Sodium % 0.20 0.20 0.20 0.20 
Potassium % 0.88 0.88 0.88 0.90 
Vitamin A IU/kg 15,000 15,000 15,000 15,000 
Vitamin D3 IU/kg 1,500 1,500 1,500 1,500 
Vitamin E mg/kg 150 150 150 150 
Energy (Atwater) MJ/kg 15.5 15.5 15.3 15.4 
kcal% Protein  19 19 19 19 
kcal% Fat  12 12 13 13 
kcal% Carbohydrates  69 69 68 68 
 1) Mineral premix (1) provided per 100 g diet [S0382-E122]:  
  0.88 g Ca; 0.17 g P; 0.18 g Mg; 0.18 g Na; 0.86 g K 
 2) Mineral premix (2) provided per 100 g diet [S0382-E124 & E126]:  
  0.88 g Ca; 0.37 g P; 0.18 g Mg; 0.18 g Na; 0.86 g K 
 3) Mineral premix (3) provided per 100 g diet [S0382-E128]:  
  0.80 g Ca; 0.77 g P; 0.18 g Mg; 0.18 g Na; 0.88 g K 
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Supplemental table 3. Composition of diet supplemented with 5 g/kg or 10 g/kg Rivaroxaban®. 
 
Status: February 2006
Energy [MJ/kg]
Gross Energy (GE) 18.0
Metabolizable Energy (ME)
15.4 1)
15.0 2)
ssniff® EF R/M Control
Experimental diet for rats and mice (complete feed)
Virtually chlorophyll free, low fluorescence
Description
This experimental diet bases mainly on purified feed ingredients (purified diet); it is therefore ideally
composed for studies, in which an exact adjustment of the crude nutrient concentrations is neces-
sary. This experimental diet meets all nutrient requirements of adult as well as of growing rats and
mice. This feedingstuff serves also as the basis for almost all purified ssniff® diets.
Feed composition
On request
Crude Nutrients [%]
Dry matter 95.2
Crude protein (N x 6.25) 20.8
Crude fat  4.2
Crude fibre 5.0
Crude ash 5.6
N free extracts 59.4
Starch 46.8
Sugar 10.8
Minerals [%]
Calcium 0.90
Phosphorus 0.63
Sodium 0.19
Magnesium 0.21
Potassium 0.97
Fatty acids [%]
C 8:0 –––
C 10:0 –––
C 12:0 –––
C 14:0 0.02
C 16:0 0.45
C 16:1 0.02
C 18:0 0.19
C 18:1 1.07
C 18:2 2.12
C 18:3 0.26
C 20:0 0.02
C 20:1 –––
C 20:5 –––
C 22:6 –––
Amino acids [%]
Lysine 1.71
Methionine 0.69
Met+Cys 0.98
Threonine 0.93
Tryptophan 0.27
Arginine 0.76
Histidine 0.66
Valine 1.42
Isoleucine 1.09
Leucine 2.05
Phenylalanine 1.11
Phe+Tyr 2.22
Glycine 0.43
Glutamic acid 4.69
Aspartic acid 1.55
Proline 2.39
Alanine 0.68
Serine 1.24
Vitamins per kg
Vitamin A 15,000 IU
Vitamin D3 1,500 IU
Vitamin E 150 mg
Vitamin K (as menadione) 20 mg
Vitamin C 30 mg
Thiamin (B1) 16 mg
Riboflavin (B2) 16 mg
Pyridoxine (B6) 18 mg
Cobalamin (B12) 30 µg
Nicotinic acid 49 mg
Pantothenic acid 56 mg
Folic acid 19 mg
Biotin 310 µg
Choline-Chloride 1,040 mg
Inositol 80 mg
Trace elements per kg
Iron 166 mg
Manganese 98 mg
Zinc 65 mg
Copper 14 mg
Iodine 1.2 mg
Selenium 0.14 mg
Cobalt 0.15 mg
61 kJ%
Carbohydrates 30 kJ%
Protein9 kJ%
Fat
Main products
E15000-00 Meal / powder
E15000-04 10 mm pellets
Production and sale
ssniff Spezialdiäten GmbH
Phone:+49-(0)2921-9658-0
Fax: +49-(0)2921-9658-40
E-Mail mail@ssniff.de
www.ssniff.de / www.ssniff.com
66 kJ%
Carbohydrates
23 kJ%
Protein11 kJ%
Fat
1) ME calculated according to the pig formu-
la, Annex 4 of the German feed regulation
2) ME calculated with the Atwater factors
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Supplemental table 4. Composition of Western diet supplemented with 3 g/kg Warfarin and 1.5 
g/kg vitamin K1 or 5 g/kg Rivaroxaban®. 
 
Status: February 2006
Energy [MJ/kg]
Gross Energy (GE) 22.0
Metabolizable Energy (ME)
18.6 1)
19.1 2)
ssniff® EF R/M acc. TD88137 mod.
Experimental diet for rodent with butter fat & cholesterol
Western Type Diet
Description
This experimental diet contains high amounts of fat and cholesterol, however, the cholesterol con-
tent adjusted to the specific experimental design. The Western type diet will induce obesity and
promotes the development of atherosclerotic lesions (plaques) in the cardiovascular system and
diabetes type 2 (NIDDM). The time taken until first clinical symptoms or microscopic lesions occur
depends largely on the rat or mouse strain and the previous dietary history (fat supply).
Crude Nutrients [%]
Dry matter 94.6
Crude protein (N x 6.25) 17.5
Crude fat  21.2
Crude fibre 5.0
Crude ash 4.5
N free extracts 48.8
Starch 14.6
Sugar 33.2
Minerals [%]
Calcium 0.76
Phosphorus 0.46
Sodium 0.37
Magnesium 0.10
Potassium 0.54
Fatty acids [%]
C 4:0 0.80
C 6:0 0.53
C 8:0 0.29
C 10:0 0.63
C 12:0 0.72
C 14:0 2.21
C 16:0 5.74
C 16:1 0.38
C 17:0 0.13
C 18:0 2.04
C 18:1 4.63
C 18:2 0.38
C 18:3 0.11
C 20:0 0.04
C 20:1 0.02
C 20:4 –––
Cholesterol
[mg/kg] 2,071
Amino acids [%]
Lysine 1.42
Methionine 0.63
Met+Cys 1.00
Threonine 0.76
Tryptophan 0.23
Arginine 0.67
Histidine 0.52
Valine 1.19
Isoleucine 0.93
Leucine 1.70
Phenylalanine 0.90
Phe+Tyr 1.80
Glycine 0.36
Glutamic acid 3.84
Aspartic acid 1.27
Proline 1.97
Alanine 0.57
Serine 1.02
Vitamins per kg
Vitamin A 15,000 IU
Vitamin D3 1,500 IU
Vitamin E 150 mg
Vitamin K (as menadione) 20 mg
Vitamin C 1,030 mg
Thiamin (B1) 16 mg
Riboflavin (B2) 16 mg
Pyridoxine (B6) 18 mg
Cobalamin (B12) 30 µg
Nicotinic acid 45 mg
Pantothenic acid 55 mg
Folic acid 19 mg
Biotin 305 µg
Choline-Chloride 2,040 mg
Inositol 80 mg
Trace elements per kg
Iron 48 mg
Manganese 23 mg
Zinc 39 mg
Copper 11 mg
Iodine 0.28 mg
Selenium 0.14 mg
Cobalt 0.02 mg
Main products
E15721-30 Meal / Powder
E15721-34 10 mm pellets
Production and sale
ssniff Spezialdiäten GmbH
Phone:+49-(0)2921-9658-0
Fax: +49-(0)2921-9658-40
E-Mail mail@ssniff.de
www.ssniff.de / www.ssniff.com
1) ME calculated according to the pig formu-
la, Annex 4 of the German feed regulation
2) ME calculated with the Atwater factors
Feed composition
On request
41 kJ%
Carbohydrates 20 kJ%
Protein
43 kJ%
Carbohydrates
42 kJ%
Fat
15 kJ%
Protein
39 kJ%
Fat
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Altromin Spezialfutter GmbH & Co. KG
Im Seelenkamp 20  -  D-32791 Lage
Tel.: +49 (0)5232/6088-0   -   Fax: +49 (0)5232/6088-20
E-Mail: info@altromin.de  -  http://www.altromin.de
  Seite: 1
Nummer Lfd. Nummer Änderung 07.07.2009 11:15:51
Western Type diet   21% fat, 0.15% Cholesterol & 19.5% Casein (132010)20000020000000
Inhaltsstoff Einheit Bedarf Gehalt Differenz
mg/kgRohprotein / Crude Protein 312952,496
mg/kgRohfett / Crude Fat 210918,725
mg/kgRohfaser / Crude Fibre 19022,725
mg/kgRohasche / Crude Ash 56931,710
mg/kgFeuchtigkeit / Moisture 73907,914
mg/kgMonosaccharide(s) 28999,993
mg/kgDisaccharide(s) 16622,184
mg/kgPolysaccharide(s) 182915,383
kcal/kgUmsetzb. Energie/Metab. Energy 4200,420
mg/kgLysin / Lysine 23299,572
mg/kgMethionin / Methionine 9536,864
mg/kgCystin / Cystine 4415,981
mg/kgThreonin / Threonine 11143,776
mg/kgTryptophan 3051,413
mg/kgArginin / Arginine 18578,819
mg/kgHistidin / Histidine 7613,280
mg/kgIsoleucin / Isoleucine 11623,308
mg/kgLeucin / Leucine 22829,653
mg/kgPhenylalanin / Phenylalanine 12101,280
mg/kgValin / Valine 8972,706
mg/kgAlanin / Alanine 10671,665
mg/kgAsparaginsäure / Aspartic acid 13629,977
mg/kgGlutaminsäure / Glutamic acid 46380,424
mg/kgGlycin / Glycine 16135,904
mg/kgProlin / Proline 24850,278
mg/kgSerin / Serine 11180,302
mg/kgTyrosin / Tyrosine 12198,695
I.E./kgVitamin A 14999,996
I.E./kgVitamin D3 600,000
mg/kgVitamin E 115,640
mg/kgVitamin K3 als/as Menadion(e) 12,000
mg/kgVitamin B1 18,039
mg/kgVitamin B2 12,314
mg/kgVitamin B6 9,033
mg/kgVitamin B12 0,024
mg/kgNikotinsäure / Nicotinic acid 36,166
mg/kgPantothensre./Pantothenic acid 21,103
mg/kgFolsäure / Folic acid 2,19654
mg/kgBiotin 0,255
mg/kgCholinchlorid/Choline chloride 816,212
mg/kgInosit / Inositol 10,725
mg/kgVitamin C 35,100
mg/kgCalcium 8447,117
mg/kgGes.Phosphor / Phosphorus 4922,749
mg/kgVerd.Phosphor/Digest.Phosporus 3259,653
mg/kgMagnesium 1226,947
mg/kgNatrium / Sodium 3351,231
mg/kgKalium / Potassium 4005,816
mg/kgSchwefel / Sulfur 1969,250
mg/kgChlor / Chlorine 4658,437
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Supplemental table 5. Composition of Western diet used in 220. 
 
Altromin Spezialfutter GmbH & Co. KG
Im Seelenkamp 20  -  D-32791 Lage
Tel.: +49 (0)5232/6088-0   -   Fax: +49 (0)5232/6088-20
E-Mail: info@altromin.de  -  http://www.altromin.de
  Seite: 1
Nummer Lfd. Nummer Änderung 07.07.2009 11:15:51
Western Type diet   21% fat, 0.15% Cholesterol & 19.5% Casein (132010)20000020000000
Inhaltsstoff Einheit Bedarf Gehalt Differenz
mg/kgRohprotein / Crude Protein 312952,496
mg/kgRohfett / Crude Fat 210918,725
mg/kgRohfaser / Crude Fibre 19022,725
mg/kgRohasche / Crude Ash 56931,710
mg/kgFeuchtigkeit / Moisture 73907,914
mg/kgMonosaccharide(s) 28999,993
mg/kgDisaccharide(s) 16622,184
mg/kgPolysaccharide(s) 182915,383
kcal/kgUmsetzb. Energie/Metab. Energy 4200,420
mg/kgLysin / Lysine 23299,572
mg/kgMethionin / Methionine 9536,864
mg/kgCystin / Cystine 4415,981
mg/kgThreonin / Threonine 11143,776
mg/kgTryptophan 3051,413
mg/kgArginin / Arginine 18578,819
mg/kgHistidin / Histidine 7613,280
mg/kgIsoleucin / Isoleucine 11623,308
mg/kgLeucin / Leucine 22829,653
mg/kgPhenylalanin / Phenylalanine 12101,280
mg/kgValin / Valine 8972,706
mg/kgAlanin / Alanine 10671,665
mg/kgAsparaginsäure / Aspartic acid 13629,977
mg/kgGlutaminsäure / Glutamic acid 46380,424
mg/kgGlycin / Glycine 16135,904
mg/kgProlin / Proline 24850,278
mg/kgSerin / Serine 11180,302
mg/kgTyrosin / Tyrosine 12198,695
I.E./kgVitamin A 14999,996
I.E./kgVitamin D3 600,000
mg/kgVitamin E 115,640
mg/kgVitamin K3 als/as Menadion(e) 12,000
mg/kgVitamin B1 18,039
mg/kgVitamin B2 12,314
mg/kgVitamin B6 9,033
mg/kgVitamin B12 0,024
mg/kgNikotinsäure / Nicotinic acid 36,166
mg/kgPantothensre./Pantothenic acid 21,103
mg/kgFolsäure / Folic acid 2,19654
mg/kgBiotin 0,255
mg/kgCholinchlorid/Choline chloride 816,212
mg/kgInosit / Inositol 10,725
mg/kgVitamin C 35,100
mg/kgCalcium 8447,117
mg/kgGes.Phosphor / Phosphorus 4922,749
mg/kgVerd.Phosphor/Digest.Phosporus 3259,653
mg/kgMagnesium 1226,947
mg/kgNatrium / Sodium 3351,231
mg/kgKalium / Potassium 4005,816
mg/kgSchwefel / Sulfur 1969,250
mg/kgChlor / Chlorine 4658,437
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8.2 Electrocardiography after Treatment with Warfarin and 
Rivaroxaban® 
 
Supplemental figure 1. Echocardiographic analysis. ApoE deficient mice or ApoE / FetA double 
deficient mice received Western Diet for a period of 12 weeks followed by treatment with 
Rivaroxaban® supplemented food, Warfarin supplemented food or control food for 4 weeks. 
Echocardiographic ultrasound was performed after the Western Diet feeding period and at the end of 
the experiment. Analysis included parameters for valve function (E/A ration (A, G), AV mean velocity 
(B, H)) as well as parameters for remodeling of the left ventricle (ejection fraction (C, I), fractional 
shortening (D, J), stroke volume (E, K), cardiac output (F, L)). No significant differences between 
treatment groups could be observed when tested with ANOVA. 
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8.3 Linkage Mapping of Calcification Risk Modifier Genes in DBA/2, 
Ahsg-/- x BL/6,Ahsg-/- Intercross  
!Export! TBv554b41 19.10.12
!Animal!ID Animal!Num.Strain Sex Earmark Litter_no. Birthdate Mother Father Genotype Comments Use Death_date Ethics!project Fur!colour
331556 56 B6.D2O(FetA)tm F 56 54091 27.12.11 9,!10 17 FetA!O/O Wurf!3/1 ao78127:: 26.03.12 10531G1 brown
331557 57 B6.D2O(FetA)tm F 57 54091 27.12.11 9,!10 17 FetA!O/O ao78127:: 26.03.12 10531G1 brown
331558 58 B6.D2O(FetA)tm F 58 54091 27.12.11 9,!10 17 FetA!O/O ao78127:: 26.03.12 10531G1 grey
331559 59 B6.D2O(FetA)tm F 59 54091 27.12.11 9,!10 17 FetA!O/O ao78127:: 26.03.12 10531G1 black
331560 60 B6.D2O(FetA)tm F 60 54091 27.12.11 9,!10 17 FetA!O/O ao78127:: 26.03.12 10531G1 black
331561 61 B6.D2O(FetA)tm M 61 54091 27.12.11 9,!10 17 FetA!O/O ao78127:: 26.03.12 10531G1 black
331562 62 B6.D2O(FetA)tm M 62 54091 27.12.11 9,!10 17 FetA!O/O Versuch!G1,!JahnenODechent,!10531,!1319/12 ao78127:: 26.03.12 10531G1 brown
331563 63 B6.D2O(FetA)tm M 63 54091 27.12.11 9,!10 17 FetA!O/O Versuch!G1,!JahnenODechent,!10531,!1319/12 ao78127:: 26.03.12 10531G1 brown
331564 64 B6.D2O(FetA)tm M 64 54091 27.12.11 9,!10 17 FetA!O/O Versuch!G1,!JahnenODechent,!10531,!1319/12 ao78127:: 26.03.12 10531G1 black
333323 68 B6.D2O(FetA)tm F 68 54361 28.12.11 13,!14 21 FetA!O/O Wurf!4/1Versuch!G1,!JahnenODechent,!10531,!1319/12 ao78127:: 26.03.12 10531G1 brown
333324 69 B6.D2O(FetA)tm F 69 54361 28.12.11 13,!14 21 FetA!O/O Wurf!4/1Versuch!G1,!JahnenODechent,!10531,!1319/12 ao78127:: 26.03.12 10531G1 grey
333325 70 B6.D2O(FetA)tm F 70 54361 28.12.11 13,!14 21 FetA!O/O Wurf!4/1Versuch!G1,!JahnenODechent,!10531,!1319/12 ao78127:: 26.03.12 10531G1 black
333326 71 B6.D2O(FetA)tm F 71 54361 28.12.11 13,!14 21 FetA!O/O Wurf!4/1Versuch!G1,!JahnenODechent,!10531,!1319/12 ao78127:: 26.03.12 10531G1 black
333327 72 B6.D2O(FetA)tm F 72 54361 28.12.11 13,!14 21 FetA!O/O Wurf!4/1Versuch!G1,!JahnenODechent,!10531,!1319/12 ao78127:: 26.03.12 10531G1 black
333328 73 B6.D2O(FetA)tm F 73 54361 28.12.11 13,!14 21 FetA!O/O Wurf!4/1Versuch!G1,!JahnenODechent,!10531,!1319/12 ao78127:: 26.03.12 10531G1 black
333329 74 B6.D2O(FetA)tm F 74 54361 28.12.11 13,!14 21 FetA!O/O Wurf!4/1Versuch!G1,!JahnenODechent,!10531,!1319/12 ao78127:: 26.03.12 10531G1 black
333330 75 B6.D2O(FetA)tm F 75 54361 28.12.11 13,!14 21 FetA!O/O Wurf!4/1Versuch!G1,!JahnenODechent,!10531,!1319/12 ao78127:: 26.03.12 10531G1 black
333331 76 B6.D2O(FetA)tm F 76 54361 28.12.11 13,!14 21 FetA!O/O Wurf!4/1Versuch!G1,!JahnenODechent,!10531,!1319/12 ao78127:: 26.03.12 10531G1 black
333332 77 B6.D2O(FetA)tm F 77 54361 28.12.11 13,!14 21 FetA!O/O Wurf!4/1Versuch!G1,!JahnenODechent,!10531,!1319/12 ao78127:: 26.03.12 10531G1 black
333333 78 B6.D2O(FetA)tm M 78 54361 28.12.11 13,!14 21 FetA!O/O Wurf!4/1Versuch!G1,!JahnenODechent,!10531,!1319/12 ao78127:: 26.03.12 10531G1 grey
333334 79 B6.D2O(FetA)tm M 79 54361 28.12.11 13,!14 21 FetA!O/O Wurf!4/1Versuch!G1,!JahnenODechent,!10531,!1319/12 ao78127:: 26.03.12 10531G1 black
333335 80 B6.D2O(FetA)tm M 80 54361 28.12.11 13,!14 21 FetA!O/O Wurf!4/1Versuch!G1,!JahnenODechent,!10531,!1319/12 ao78127:: 26.03.12 10531G1 black
333336 81 B6.D2O(FetA)tm M 81 54361 28.12.11 13,!14 21 FetA!O/O Wurf!4/1Versuch!G1,!JahnenODechent,!10531,!1319/12 ao78127:: 26.03.12 10531G1 black
333337 82 B6.D2O(FetA)tm M 82 54361 28.12.11 13,!14 21 FetA!O/O Wurf!4/1Versuch!G1,!JahnenODechent,!10531,!1319/12 ao78127:: 26.03.12 10531G1 black
333338 83 B6.D2O(FetA)tm M 83 54361 28.12.11 13,!14 21 FetA!O/O Wurf!4/1Versuch!G1,!JahnenODechent,!10531,!1319/12 ao78127:: 26.03.12 10531G1 black
333339 84 B6.D2O(FetA)tm M 84 54362 28.12.11 7,!8 16 FetA!O/O Wurf!5/1Versuch!G1,!JahnenODechent,!10531,!1319/12 ao78127:: 26.03.12 10531G1 black
333340 85 B6.D2O(FetA)tm M 85 54362 28.12.11 7,!8 16 FetA!O/O Wurf!5/1Versuch!G1,!JahnenODechent,!10531,!1319/12 ao78127:: 26.03.12 10531G1 black
333341 86 B6.D2O(FetA)tm M 86 54362 28.12.11 7,!8 16 FetA!O/O Wurf!5/1Versuch!G1,!JahnenODechent,!10531,!1319/12 ao78127:: 26.03.12 10531G1 black
333342 87 B6.D2O(FetA)tm M 87 54362 28.12.11 7,!8 16 FetA!O/O Wurf!5/1Versuch!G1,!JahnenODechent,!10531,!1319/12 ao78127:: 26.03.12 10531G1 black
333343 88 B6.D2O(FetA)tm M 88 54362 28.12.11 7,!8 16 FetA!O/O Wurf!5/1Versuch!G1,!JahnenODechent,!10531,!1319/12 ao78127:: 26.03.12 10531G1 black
333344 89 B6.D2O(FetA)tm F 89 54363 02.01.12 7,!8 16 FetA!O/O Wurf!5/2Versuch!G1,!JahnenODechent,!10531,!1319/12 ao78127:: 26.03.12 10531G1 black
333345 90 B6.D2O(FetA)tm F 90 54363 02.01.12 7,!8 16 FetA!O/O Wurf!5/2Versuch!G1,!JahnenODechent,!10531,!1319/12 ao78127:: 26.03.12 10531G1 black
333346 91 B6.D2O(FetA)tm F 91 54363 02.01.12 7,!8 16 FetA!O/O Wurf!5/2Versuch!G1,!JahnenODechent,!10531,!1319/12 ao78127:: 26.03.12 10531G1 black
333347 92 B6.D2O(FetA)tm F 92 54363 02.01.12 7,!8 16 FetA!O/O Wurf!5/2Versuch!G1,!JahnenODechent,!10531,!1319/12 ao78127:: 26.03.12 10531G1 black
333348 93 B6.D2O(FetA)tm F 93 54363 02.01.12 7,!8 16 FetA!O/O Wurf!5/2Versuch!G1,!JahnenODechent,!10531,!1319/12 ao78127:: 26.03.12 10531G1 black
333349 94 B6.D2O(FetA)tm M 94 54363 02.01.12 7,!8 16 FetA!O/O Wurf!5/2Versuch!G1,!JahnenODechent,!10531,!1319/12 ao78127:: 26.03.12 10531G1 black
333350 95 B6.D2O(FetA)tm M 95 54363 02.01.12 7,!8 16 FetA!O/O Wurf!5/2Versuch!G1,!JahnenODechent,!10531,!1319/12 ao78127:: 26.03.12 10531G1 black
333351 96 B6.D2O(FetA)tm M 96 54363 02.01.12 7,!8 16 FetA!O/O Wurf!5/2Versuch!G1,!JahnenODechent,!10531,!1319/12 ao78127:: 26.03.12 10531G1 brown
333352 97 B6.D2O(FetA)tm M 97 54363 02.01.12 7,!8 16 FetA!O/O Wurf!5/2Versuch!G1,!JahnenODechent,!10531,!1319/12 ao78127:: 26.03.12 10531G1 black
333353 98 B6.D2O(FetA)tm M 98 54363 02.01.12 7,!8 16 FetA!O/O Wurf!5/2Versuch!G1,!JahnenODechent,!10531,!1319/12 ao78127:: 26.03.12 10531G1 black
333354 99 B6.D2O(FetA)tm M 99 54363 02.01.12 7,!8 16 FetA!O/O Wurf!5/2Versuch!G1,!JahnenODechent,!10531,!1319/12 ao78127:: 26.03.12 10531G1 black
334767 100 B6.D2O(FetA)tm F 0 54595 01.01.12 11,!12 18 FetA!O/O Wurf!6/1Versuch!G1,!JahnenODechent,!10531,!1319/12 ao78127:: 26.03.12 10531G1 black
334768 101 B6.D2O(FetA)tm F 1 54595 01.01.12 11,!12 18 FetA!O/O Wurf!6/1Versuch!G1,!JahnenODechent,!10531,!1319/12 ao78127:: 26.03.12 10531G1 black
334769 102 B6.D2O(FetA)tm F 2 54595 01.01.12 11,!12 18 FetA!O/O Wurf!6/1Versuch!G1,!JahnenODechent,!10531,!1319/12 ao78127:: 26.03.12 10531G1 black
334770 103 B6.D2O(FetA)tm F 3 54595 01.01.12 11,!12 18 FetA!O/O Wurf!6/1Versuch!G1,!JahnenODechent,!10531,!1319/12 ao78127:: 26.03.12 10531G1 brown
334771 104 B6.D2O(FetA)tm F 4 54595 01.01.12 11,!12 18 FetA!O/O Wurf!6/1Versuch!G1,!JahnenODechent,!10531,!1319/12 ao78127:: 26.03.12 10531G1 brown
334772 105 B6.D2O(FetA)tm F 5 54595 01.01.12 11,!12 18 FetA!O/O Wurf!6/1Versuch!G1,!JahnenODechent,!10531,!1319/12 ao78127:: 26.03.12 10531G1 grey
334773 106 B6.D2O(FetA)tm M 6 54595 01.01.12 11,!12 18 FetA!O/O Wurf!6/1Versuch!G1,!JahnenODechent,!10531,!1319/12 ao78127:: 26.03.12 10531G1 black
334774 107 B6.D2O(FetA)tm M 7 54595 01.01.12 11,!12 18 FetA!O/O Wurf!6/1Versuch!G1,!JahnenODechent,!10531,!1319/12 ao78127:: 26.03.12 10531G1 black
336715 108 B6.D2O(FetA)tm F 8 54953 20.01.12 9,!10 17 FetA!O/O Wurf!3/2Versuch!G1,!JahnenODechent,!10531,!1548/12 ao78982:: 12.04.12 10531G1 brown
336716 109 B6.D2O(FetA)tm F 9 54953 20.01.12 9,!10 17 FetA!O/O Wurf!3/2Versuch!G1,!JahnenODechent,!10531,!1548/12 ao78982:: 12.04.12 10531G1 black
336717 110 B6.D2O(FetA)tm F 10 54953 20.01.12 9,!10 17 FetA!O/O Wurf!3/2Versuch!G1,!JahnenODechent,!10531,!1548/12 ao78982:: 12.04.12 10531G1 grey
336718 111 B6.D2O(FetA)tm F 11 54953 20.01.12 9,!10 17 FetA!O/O Wurf!3/2Versuch!G1,!JahnenODechent,!10531,!1548/12 ao78982:: 12.04.12 10531G1 black
336719 112 B6.D2O(FetA)tm F 12 54953 20.01.12 9,!10 17 FetA!O/O Wurf!3/2Versuch!G1,!JahnenODechent,!10531,!1548/12 ao78982:: 12.04.12 10531G1 grey
336720 113 B6.D2O(FetA)tm M 13 54953 20.01.12 9,!10 17 FetA!O/O Wurf!3/2Versuch!G1,!JahnenODechent,!10531,!1548/12 ao78982:: 12.04.12 10531G1 brown
336721 114 B6.D2O(FetA)tm M 14 54953 20.01.12 9,!10 17 FetA!O/O Wurf!3/2Versuch!G1,!JahnenODechent,!10531,!1548/12 ao78982:: 12.04.12 10531G1 black
336722 115 B6.D2O(FetA)tm M 15 54953 20.01.12 9,!10 17 FetA!O/O Wurf!3/2Versuch!G1,!JahnenODechent,!10531,!1548/12 ao78982:: 12.04.12 10531G1 black
336723 116 B6.D2O(FetA)tm M 16 54953 20.01.12 9,!10 17 FetA!O/O Wurf!3/2Versuch!G1,!JahnenODechent,!10531,!1548/12 ao78982:: 12.04.12 10531G1 black
336724 117 B6.D2O(FetA)tm F 17 54954 20.01.12 13,!14 21 FetA!O/O Wurf!4/2Versuch!G1,!JahnenODechent,!10531,!1548/12 ao78982:: 12.04.12 10531G1 grey
336725 118 B6.D2O(FetA)tm F 18 54954 20.01.12 13,!14 21 FetA!O/O Wurf!4/2Versuch!G1,!JahnenODechent,!10531,!1548/12 ao78982:: 12.04.12 10531G1 brown
336726 119 B6.D2O(FetA)tm F 19 54954 20.01.12 13,!14 21 FetA!O/O Wurf!4/2Versuch!G1,!JahnenODechent,!10531,!1548/12 ao78982:: 12.04.12 10531G1 black
336727 120 B6.D2O(FetA)tm F 20 54954 20.01.12 13,!14 21 FetA!O/O Wurf!4/2Versuch!G1,!JahnenODechent,!10531,!1548/12 ao78982:: 12.04.12 10531G1 brown
336728 121 B6.D2O(FetA)tm F 21 54954 20.01.12 13,!14 21 FetA!O/O Wurf!4/2Versuch!G1,!JahnenODechent,!10531,!1548/12 ao78982:: 12.04.12 10531G1 grey
336729 122 B6.D2O(FetA)tm M 22 54954 20.01.12 13,!14 21 FetA!O/O Wurf!4/2Versuch!G1,!JahnenODechent,!10531,!1548/12 ao78982:: 12.04.12 10531G1 grey
336730 123 B6.D2O(FetA)tm M 23 54954 20.01.12 13,!14 21 FetA!O/O Wurf!4/2Versuch!G1,!JahnenODechent,!10531,!1548/12 ao78982:: 12.04.12 10531G1 grey
336731 124 B6.D2O(FetA)tm F 24 54955 11.01.12 11,!12 18 FetA!O/O Wurf!6/2Versuch!G1;10531G1;1468/12;Kinkeldey ao78747:: 05.04.12 10531G1 brown
336732 125 B6.D2O(FetA)tm F 25 54955 11.01.12 11,!12 18 FetA!O/O Wurf!6/2Versuch!G1;10531G1;1468/12;Kinkeldey ao78747:: 05.04.12 10531G1 black
336733 126 B6.D2O(FetA)tm F 26 54955 11.01.12 11,!12 18 FetA!O/O Wurf!6/2Versuch!G1;10531G1;1468/12;Kinkeldey ao78747:: 05.04.12 10531G1 brown
336734 127 B6.D2O(FetA)tm F 27 54955 11.01.12 11,!12 18 FetA!O/O Wurf!6/2Versuch!G1;10531G1;1468/12;Kinkeldey ao78747:: 05.04.12 10531G1 brown
336735 128 B6.D2O(FetA)tm M 28 54955 11.01.12 11,!12 18 FetA!O/O Wurf!6/2Versuch!G1;10531G1;1468/12;Kinkeldey ao78747:: 05.04.12 10531G1 black
336736 129 B6.D2O(FetA)tm M 29 54955 11.01.12 11,!12 18 FetA!O/O Wurf!6/2Versuch!G1;10531G1;1468/12;Kinkeldey ao78747:: 05.04.12 10531G1 brown
336737 130 B6.D2O(FetA)tm M 30 54955 11.01.12 11,!12 18 FetA!O/O Wurf!6/2Versuch!G1;10531G1;1468/12;Kinkeldey ao78747:: 05.04.12 10531G1 black
336738 131 B6.D2O(FetA)tm M 31 54955 11.01.12 11,!12 18 FetA!O/O Wurf!6/2Versuch!G1;10531G1;1468/12;Kinkeldey ao78747:: 05.04.12 10531G1 grey
336739 132 B6.D2O(FetA)tm M 32 54955 11.01.12 11,!12 18 FetA!O/O Wurf!6/2Versuch!G1;10531G1;1468/12;Kinkeldey ao78747:: 05.04.12 10531G1 black
336740 133 B6.D2O(FetA)tm M 33 54955 11.01.12 11,!12 18 FetA!O/O Wurf!6/2Versuch!G1;10531G1;1468/12;Kinkeldey ao78747:: 05.04.12 10531G1 black
338646 134 B6.D2O(FetA)tm F 34 55261 24.01.12 13,!14 21 FetA!O/O Wurf!4/3Versuch!G1,!JahnenODechent,!10531,!1548/12 ao78982:: 12.04.12 10531G1 brown
338647 135 B6.D2O(FetA)tm F 35 55261 24.01.12 13,!14 21 FetA!O/O Wurf!4/3Versuch!G1,!JahnenODechent,!10531,!1548/12 ao78982:: 12.04.12 10531G1 black
338648 136 B6.D2O(FetA)tm F 36 55261 24.01.12 13,!14 21 FetA!O/O Wurf!4/3Versuch!G1,!JahnenODechent,!10531,!1548/12 ao78982:: 12.04.12 10531G1 black
338649 137 B6.D2O(FetA)tm F 37 55261 24.01.12 13,!14 21 FetA!O/O Wurf!4/3Versuch!G1,!JahnenODechent,!10531,!1548/12 ao78982:: 12.04.12 10531G1 brown
338650 138 B6.D2O(FetA)tm M 38 55261 24.01.12 13,!14 21 FetA!O/O Wurf!4/3Versuch!G1,!JahnenODechent,!10531,!1548/12 ao78982:: 12.04.12 10531G1 black
338651 139 B6.D2O(FetA)tm M 39 55261 24.01.12 13,!14 21 FetA!O/O Wurf!4/3Versuch!G1,!JahnenODechent,!10531,!1548/12 ao78982:: 12.04.12 10531G1 black
338652 140 B6.D2O(FetA)tm M 40 55261 24.01.12 13,!14 21 FetA!O/O Wurf!4/3Versuch!G1,!JahnenODechent,!10531,!1548/12 ao78982:: 12.04.12 10531G1 grey
338653 141 B6.D2O(FetA)tm M 41 55261 24.01.12 13,!14 21 FetA!O/O Wurf!4/3Versuch!G1,!JahnenODechent,!10531,!1548/12 ao78982:: 12.04.12 10531G1 grey
338654 142 B6.D2O(FetA)tm M 42 55261 24.01.12 13,!14 21 FetA!O/O Wurf!4/3Versuch!G1,!JahnenODechent,!10531,!1548/12 ao78982:: 12.04.12 10531G1 black
338655 143 B6.D2O(FetA)tm M 43 55261 24.01.12 13,!14 21 FetA!O/O Wurf!4/3Versuch!G1,!JahnenODechent,!10531,!1548/12 ao78982:: 12.04.12 10531G1 brown
340267 144 B6.D2O(FetA)tm F 44 55526 06.02.12 7,!8 16 FetA!O/O Wurf!5/3;Versuch!G1;10531;Kinkeldey ao80548:: 08.05.12 10531G1 black
340268 145 B6.D2O(FetA)tm F 45 55526 06.02.12 7,!8 16 FetA!O/O Wurf!5/3;Versuch!G1;10531;Kinkeldey ao80548:: 08.05.12 10531G1 black
340269 146 B6.D2O(FetA)tm F 46 55526 06.02.12 7,!8 16 FetA!O/O Wurf!5/3;Versuch!G1;10531;Kinkeldey ao80548:: 08.05.12 10531G1 grey
340270 147 B6.D2O(FetA)tm F 47 55526 06.02.12 7,!8 16 FetA!O/O Wurf!5/3;Versuch!G1;10531;Kinkeldey ao80548:: 08.05.12 10531G1 grey
340271 148 B6.D2O(FetA)tm M 48 55526 06.02.12 7,!8 16 FetA!O/O Wurf!5/3;Versuch!G1;10531;Kinkeldey ao80548:: 08.05.12 10531G1 black
340272 149 B6.D2O(FetA)tm M 49 55526 06.02.12 7,!8 16 FetA!O/O Wurf!5/3;Versuch!G1;10531;Kinkeldey ao80548:: 08.05.12 10531G1 black
340273 150 B6.D2O(FetA)tm M 50 55526 06.02.12 7,!8 16 FetA!O/O Wurf!5/3;Versuch!G1;10531;Kinkeldey ao80548:: 08.05.12 10531G1 brown
340274 151 B6.D2O(FetA)tm M 51 55526 06.02.12 7,!8 16 FetA!O/O Wurf!5/3;Versuch!G1;10531;Kinkeldey ao80548:: 08.05.12 10531G1 brown
340275 152 B6.D2O(FetA)tm M 52 55526 06.02.12 7,!8 16 FetA!O/O Wurf!5/3;Versuch!G1;10531;Kinkeldey ao80548:: 08.05.12 10531G1 grey
341678 153 B6.D2O(FetA)tm F 53 55766 14.02.12 9,!10 17 FetA!O/O Wurf!3/3;Versuch!G1;10531;Kinkeldey ao80548:: 08.05.12 10531G1 black
341679 154 B6.D2O(FetA)tm F 54 55766 14.02.12 9,!10 17 FetA!O/O Wurf!3/3;Versuch!G1;10531;Kinkeldey ao80548:: 08.05.12 10531G1 grey
341680 155 B6.D2O(FetA)tm F 55 55766 14.02.12 9,!10 17 FetA!O/O Wurf!3/3;Versuch!G1;10531;Kinkeldey ao80548:: 08.05.12 10531G1 black
341681 156 B6.D2O(FetA)tm F 56 55766 14.02.12 9,!10 17 FetA!O/O Wurf!3/3;Versuch!G1;10531;Kinkeldey ao80548:: 08.05.12 10531G1 brown
341682 157 B6.D2O(FetA)tm F 57 55766 14.02.12 9,!10 17 FetA!O/O Wurf!3/3;Versuch!G1;10531;Kinkeldey ao80548:: 08.05.12 10531G1 brown
341683 158 B6.D2O(FetA)tm F 58 55766 14.02.12 9,!10 17 FetA!O/O Wurf!3/3;Versuch!G1;10531;Kinkeldey ao80548:: 08.05.12 10531G1 black
341684 159 B6.D2O(FetA)tm F 59 55766 14.02.12 9,!10 17 FetA!O/O Wurf!3/3;Versuch!G1;10531;Kinkeldey ao80548:: 08.05.12 10531G1 grey
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Supplemental table 6. Mouse D2,Ahsg-/- X B6,Ahsg-/- intercross. 12-week-old fetuin-A deficient 
mice of the F2 generation of a D2,Ahsg-/- X B6,Ahsg-/- intercross were scored regarding calcification 
severity. Additional data includes animal ID, strain, sex, earmark, litter number, birthdate, parents, 
fetuin-A genotype, animal order number, death date and fur color.
 
341685 160 B6.D2O(FetA)tm M 60 55766 14.02.12 9,!10 17 FetA!O/O Wurf!3/3;Versuch!G1;10531;Kinkeldey ao80548:: 08.05.12 10531G1 brown
341686 161 B6.D2O(FetA)tm M 61 55766 14.02.12 9,!10 17 FetA!O/O Wurf!3/3;Versuch!G1;10531;Kinkeldey ao80548:: 08.05.12 10531G1 brown
341687 162 B6.D2O(FetA)tm M 62 55766 14.02.12 9,!10 17 FetA!O/O Wurf!3/3;Versuch!G1;10531;Kinkeldey ao80548:: 08.05.12 10531G1 black
341688 163 B6.D2O(FetA)tm M 63 55766 14.02.12 9,!10 17 FetA!O/O Wurf!3/3;Versuch!G1;10531;Kinkeldey ao80548:: 08.05.12 10531G1 black
341689 164 B6.D2O(FetA)tm M 64 55766 14.02.12 9,!10 17 FetA!O/O Wurf!3/3;Versuch!G1;10531;Kinkeldey ao80548:: 08.05.12 10531G1 black
341690 165 B6.D2O(FetA)tm M 65 55766 14.02.12 9,!10 17 FetA!O/O Wurf!3/3;Versuch!G1;10531;Kinkeldey ao80548:: 08.05.12 10531G1 black
341691 166 B6.D2O(FetA)tm M 66 55766 14.02.12 9,!10 17 FetA!O/O Wurf!3/3;Versuch!G1;10531;Kinkeldey ao80548:: 08.05.12 10531G1 black
341692 167 B6.D2O(FetA)tm M 67 55766 14.02.12 9,!10 17 FetA!O/O Wurf!3/3;Versuch!G1;10531;Kinkeldey ao80548:: 08.05.12 10531G1 brown
341693 168 B6.D2O(FetA)tm M 68 55766 14.02.12 9,!10 17 FetA!O/O Wurf!3/3;Versuch!G1;10531;Kinkeldey ao80548:: 08.05.12 10531G1 black
341858 169 B6.D2O(FetA)tm F 69 55796 09.02.12 11,!12 18 FetA!O/O Wurf!6/3;Versuch!G1;10531;Kinkeldey ao80548:: 08.05.12 10531G1 black
341859 170 B6.D2O(FetA)tm F 70 55796 09.02.12 11,!12 18 FetA!O/O Wurf!6/3;Versuch!G1;10531;Kinkeldey ao80548:: 08.05.12 10531G1 black
341860 171 B6.D2O(FetA)tm F 71 55796 09.02.12 11,!12 18 FetA!O/O Wurf!6/3;Versuch!G1;10531;Kinkeldey ao80548:: 08.05.12 10531G1 black
341861 172 B6.D2O(FetA)tm F 72 55796 09.02.12 11,!12 18 FetA!O/O Wurf!6/3;Versuch!G1;10531;Kinkeldey ao80548:: 08.05.12 10531G1 black
341862 173 B6.D2O(FetA)tm F 73 55796 09.02.12 11,!12 18 FetA!O/O Wurf!6/3;Versuch!G1;10531;Kinkeldey ao80548:: 08.05.12 10531G1 black
341863 174 B6.D2O(FetA)tm M 74 55796 09.02.12 11,!12 18 FetA!O/O Wurf!6/3;Versuch!G1;10531;Kinkeldey ao80548:: 08.05.12 10531G1 black
341864 175 B6.D2O(FetA)tm M 75 55796 09.02.12 11,!12 18 FetA!O/O Wurf!6/3;Versuch!G1;10531;Kinkeldey ao80548:: 08.05.12 10531G1 black
341865 176 B6.D2O(FetA)tm M 76 55796 09.02.12 11,!12 18 FetA!O/O Wurf!6/3;Versuch!G1;10531;Kinkeldey ao80548:: 08.05.12 10531G1 black
341866 177 B6.D2O(FetA)tm M 77 55796 09.02.12 11,!12 18 FetA!O/O Wurf!6/3;Versuch!G1;10531;Kinkeldey ao80548:: 08.05.12 10531G1 black
341867 178 B6.D2O(FetA)tm M 78 55796 09.02.12 11,!12 18 FetA!O/O Wurf!6/3;Versuch!G1;10531;Kinkeldey ao80548:: 08.05.12 10531G1 grey
341868 179 B6.D2O(FetA)tm M 79 55796 09.02.12 11,!12 18 FetA!O/O Wurf!6/3;Versuch!G1;10531;Kinkeldey ao80548:: 08.05.12 10531G1 black
341869 180 B6.D2O(FetA)tm M 80 55796 09.02.12 11,!12 18 FetA!O/O Wurf!6/3;Versuch!G1;10531;Kinkeldey ao80548:: 08.05.12 10531G1 brown
341870 181 B6.D2O(FetA)tm M 81 55796 09.02.12 11,!12 18 FetA!O/O Wurf!6/3;Versuch!G1;10531;Kinkeldey ao80548:: 08.05.12 10531G1 black
341871 182 B6.D2O(FetA)tm M 82 55796 09.02.12 11,!12 18 FetA!O/O Wurf!6/3;Versuch!G1;10531;Kinkeldey ao80548:: 08.05.12 10531G1 black
341872 183 B6.D2O(FetA)tm M 83 55796 09.02.12 11,!12 18 FetA!O/O Wurf!6/3;Versuch!G1;10531;Kinkeldey ao80548:: 08.05.12 10531G1 black
341873 184 B6.D2O(FetA)tm M 84 55796 09.02.12 11,!12 18 FetA!O/O Wurf!6/3;Versuch!G1;10531;Kinkeldey ao80548:: 08.05.12 10531G1 black
341874 185 B6.D2O(FetA)tm M 85 55796 09.02.12 11,!12 18 FetA!O/O Wurf!6/3;Versuch!G1;10531;Kinkeldey ao80548:: 08.05.12 10531G1 brown
341875 186 B6.D2O(FetA)tm M 86 55796 09.02.12 11,!12 18 FetA!O/O Wurf!6/3;Versuch!G1;10531;Kinkeldey ao80548:: 08.05.12 10531G1 grey
341876 187 B6.D2O(FetA)tm M 87 55796 09.02.12 11,!12 18 FetA!O/O Wurf!6/3;Versuch!G1;10531;Kinkeldey ao80548:: 08.05.12 10531G1 black
343344 188 B6.D2O(FetA)tm F 88 56060 20.02.12 13,!14 21 FetA!O/O Wurf!4/4Versuch!G1,!JahnenODechent,!10531,!2054/12 ao80996:: 15.05.12 10531G1 grey
343345 189 B6.D2O(FetA)tm F 89 56060 20.02.12 13,!14 21 FetA!O/O Wurf!4/4Versuch!G1,!JahnenODechent,!10531,!2054/12 ao80996:: 15.05.12 10531G1 black
343346 190 B6.D2O(FetA)tm F 90 56060 20.02.12 13,!14 21 FetA!O/O Wurf!4/4Versuch!G1,!JahnenODechent,!10531,!2054/12 ao80996:: 15.05.12 10531G1 black
343347 191 B6.D2O(FetA)tm F 91 56060 20.02.12 13,!14 21 FetA!O/O Wurf!4/4Versuch!G1,!JahnenODechent,!10531,!2054/12 ao80996:: 15.05.12 10531G1 black
343348 192 B6.D2O(FetA)tm M 92 56060 20.02.12 13,!14 21 FetA!O/O Wurf!4/4Versuch!G1,!JahnenODechent,!10531,!2054/12 ao80996:: 15.05.12 10531G1 brown
343349 193 B6.D2O(FetA)tm M 93 56060 20.02.12 13,!14 21 FetA!O/O Wurf!4/4Versuch!G1,!JahnenODechent,!10531,!2054/12 ao80996:: 15.05.12 10531G1 grey
343350 194 B6.D2O(FetA)tm M 94 56060 20.02.12 13,!14 21 FetA!O/O Wurf!4/4Versuch!G1,!JahnenODechent,!10531,!2054/12 ao80996:: 15.05.12 10531G1 black
343351 195 B6.D2O(FetA)tm M 95 56060 20.02.12 13,!14 21 FetA!O/O Wurf!4/4Versuch!G1,!JahnenODechent,!10531,!2054/12 ao80996:: 15.05.12 10531G1 brown
343352 196 B6.D2O(FetA)tm F 96 56061 22.02.12 7,!8 16 FetA!O/O Wurf!5/4Versuch!G1,!JahnenODechent,!10531,!2054/12 ao80996:: 15.05.12 10531G1 black
343353 197 B6.D2O(FetA)tm F 97 56061 22.02.12 7,!8 16 FetA!O/O Wurf!5/4Versuch!G1,!JahnenODechent,!10531,!2054/12 ao80996:: 15.05.12 10531G1 black
343354 198 B6.D2O(FetA)tm F 98 56061 22.02.12 7,!8 16 FetA!O/O Wurf!5/4Versuch!G1,!JahnenODechent,!10531,!2054/12 ao80996:: 15.05.12 10531G1 black
343355 199 B6.D2O(FetA)tm F 99 56061 22.02.12 7,!8 16 FetA!O/O Wurf!5/4Versuch!G1,!JahnenODechent,!10531,!2054/12 ao80996:: 15.05.12 10531G1 black
343356 200 B6.D2O(FetA)tm F 0 56061 22.02.12 7,!8 16 FetA!O/O Wurf!5/4Versuch!G1,!JahnenODechent,!10531,!2054/12 ao80996:: 15.05.12 10531G1 black
344807 201 B6.D2O(FetA)tm F 1 56291 29.02.12 7,!8 16 FetA!O/O Wurf!5/5Versuch!G1,!JahnenODechent,!10531,!2301/12 ao81828:: 04.06.12 10531G1 black
344808 202 B6.D2O(FetA)tm F 2 56291 29.02.12 7,!8 16 FetA!O/O Wurf!5/5Versuch!G1,!JahnenODechent,!10531,!2301/12 ao81828:: 04.06.12 10531G1 black
344809 203 B6.D2O(FetA)tm F 3 56291 29.02.12 7,!8 16 FetA!O/O Wurf!5/5Versuch!G1,!JahnenODechent,!10531,!2301/12 ao81828:: 04.06.12 10531G1 black
344810 204 B6.D2O(FetA)tm M 4 56291 29.02.12 7,!8 16 FetA!O/O Wurf!5/5Versuch!G1,!JahnenODechent,!10531,!2301/12 ao81828:: 04.06.12 10531G1 black
344811 205 B6.D2O(FetA)tm M 5 56291 29.02.12 7,!8 16 FetA!O/O Wurf!5/5Versuch!G1,!JahnenODechent,!10531,!2301/12 ao81828:: 04.06.12 10531G1 black
344812 206 B6.D2O(FetA)tm M 6 56291 29.02.12 7,!8 16 FetA!O/O Wurf!5/5Versuch!G1,!JahnenODechent,!10531,!2301/12 ao81828:: 04.06.12 10531G1 black
344813 207 B6.D2O(FetA)tm M 7 56291 29.02.12 7,!8 16 FetA!O/O Wurf!5/5Versuch!G1,!JahnenODechent,!10531,!2301/12 ao81828:: 04.06.12 10531G1 black
344814 208 B6.D2O(FetA)tm M 8 56291 29.02.12 7,!8 16 FetA!O/O Wurf!5/5Versuch!G1,!JahnenODechent,!10531,!2301/12 ao81828:: 04.06.12 10531G1 black
344815 209 B6.D2O(FetA)tm M 9 56291 29.02.12 7,!8 16 FetA!O/O Wurf!5/5Versuch!G1,!JahnenODechent,!10531,!2301/12 ao81828:: 04.06.12 10531G1 black
344816 210 B6.D2O(FetA)tm M 10 56291 29.02.12 7,!8 16 FetA!O/O Wurf!5/5Versuch!G1,!JahnenODechent,!10531,!2301/12 ao81828:: 04.06.12 10531G1 black
346165 212 B6.D2O(FetA)tm F 12 56517 05.03.12 9,!10 17 FetA!O/O Wurf!3/4Versuch!G1,!JahnenODechent,!10531,!2301/12 ao81828:: 04.06.12 10531G1 grey
346166 213 B6.D2O(FetA)tm F 13 56517 05.03.12 9,!10 17 FetA!O/O Wurf!3/4Versuch!G1,!JahnenODechent,!10531,!2301/12 ao81828:: 04.06.12 10531G1 black
346167 214 B6.D2O(FetA)tm F 14 56517 05.03.12 9,!10 17 FetA!O/O Wurf!3/4Versuch!G1,!JahnenODechent,!10531,!2301/12 ao81828:: 04.06.12 10531G1 brown
346168 215 B6.D2O(FetA)tm F 15 56517 05.03.12 9,!10 17 FetA!O/O Wurf!3/4Versuch!G1,!JahnenODechent,!10531,!2301/12 ao81828:: 04.06.12 10531G1 black
346169 216 B6.D2O(FetA)tm M 16 56517 05.03.12 9,!10 17 FetA!O/O Wurf!3/4Versuch!G1,!JahnenODechent,!10531,!2301/12 ao81828:: 04.06.12 10531G1 black
346405 217 B6.D2O(FetA)tm F 17 56553 08.03.12 13,!14 21 FetA!O/O Wurf!4/5Versuch!G1,!JahnenODechent,!10531,!2301/12 ao81828:: 04.06.12 10531G1 grey
346406 218 B6.D2O(FetA)tm F 18 56553 08.03.12 13,!14 21 FetA!O/O Wurf!4/5Versuch!G1,!JahnenODechent,!10531,!2301/12 ao81828:: 04.06.12 10531G1 grey
346407 219 B6.D2O(FetA)tm F 19 56553 08.03.12 13,!14 21 FetA!O/O Wurf!4/5Versuch!G1,!JahnenODechent,!10531,!2301/12 ao81828:: 04.06.12 10531G1 black
346408 220 B6.D2O(FetA)tm F 20 56553 08.03.12 13,!14 21 FetA!O/O Wurf!4/5Versuch!G1,!JahnenODechent,!10531,!2301/12 ao81828:: 04.06.12 10531G1 black
346409 221 B6.D2O(FetA)tm F 21 56553 08.03.12 13,!14 21 FetA!O/O Wurf!4/5Versuch!G1,!JahnenODechent,!10531,!2301/12 ao81828:: 04.06.12 10531G1 grey
346410 222 B6.D2O(FetA)tm F 22 56553 08.03.12 13,!14 21 FetA!O/O Wurf!4/5Versuch!G1,!JahnenODechent,!10531,!2301/12 ao81828:: 04.06.12 10531G1 brown
346411 223 B6.D2O(FetA)tm M 23 56553 08.03.12 13,!14 21 FetA!O/O Wurf!4/5Versuch!G1,!JahnenODechent,!10531,!2301/12 ao81828:: 04.06.12 10531G1 grey
346412 224 B6.D2O(FetA)tm M 24 56553 08.03.12 13,!14 21 FetA!O/O Wurf!4/5Versuch!G1,!JahnenODechent,!10531,!2301/12 ao81828:: 04.06.12 10531G1 black
346413 225 B6.D2O(FetA)tm M 25 56553 08.03.12 13,!14 21 FetA!O/O Wurf!4/5Versuch!G1,!JahnenODechent,!10531,!2301/12 ao81828:: 04.06.12 10531G1 brown
348834 226 B6.D2O(FetA)tm F 26 56965 20.03.12 11,!12 18 FetA!O/O Wurf!6/5Versuch!G1,!JahnenODechent,!10531,!2411/12 ao82392:: 14.06.12 10531G1 black
348835 227 B6.D2O(FetA)tm F 27 56965 20.03.12 11,!12 18 FetA!O/O Wurf!6/5Versuch!G1,!JahnenODechent,!10531,!2411/12 ao82392:: 14.06.12 10531G1 brown
348836 228 B6.D2O(FetA)tm F 28 56965 20.03.12 11,!12 18 FetA!O/O Wurf!6/5Versuch!G1,!JahnenODechent,!10531,!2411/12 ao82392:: 14.06.12 10531G1 black
348837 229 B6.D2O(FetA)tm F 29 56965 20.03.12 11,!12 18 FetA!O/O Wurf!6/5Versuch!G1,!JahnenODechent,!10531,!2411/12 ao82392:: 14.06.12 10531G1 black
348838 230 B6.D2O(FetA)tm F 30 56965 20.03.12 11,!12 18 FetA!O/O Wurf!6/5Versuch!G1,!JahnenODechent,!10531,!2411/12 ao82392:: 14.06.12 10531G1 black
348839 231 B6.D2O(FetA)tm F 31 56965 20.03.12 11,!12 18 FetA!O/O Wurf!6/5Versuch!G1,!JahnenODechent,!10531,!2411/12 ao82392:: 14.06.12 10531G1 black
348840 232 B6.D2O(FetA)tm F 32 56965 20.03.12 11,!12 18 FetA!O/O Wurf!6/5Versuch!G1,!JahnenODechent,!10531,!2411/12 ao82392:: 14.06.12 10531G1 black
348841 233 B6.D2O(FetA)tm F 33 56965 20.03.12 11,!12 18 FetA!O/O Wurf!6/5Versuch!G1,!JahnenODechent,!10531,!2411/12 ao82392:: 14.06.12 10531G1 brown
348842 234 B6.D2O(FetA)tm F 34 56965 20.03.12 11,!12 18 FetA!O/O Wurf!6/5Versuch!G1,!JahnenODechent,!10531,!2411/12 ao82392:: 14.06.12 10531G1 grey
348843 235 B6.D2O(FetA)tm F 35 56965 20.03.12 11,!12 18 FetA!O/O Wurf!6/5Versuch!G1,!JahnenODechent,!10531,!2411/12 ao82392:: 14.06.12 10531G1 black
348844 236 B6.D2O(FetA)tm M 36 56965 20.03.12 11,!12 18 FetA!O/O Wurf!6/5Versuch!G1,!JahnenODechent,!10531,!2411/12 ao82392:: 14.06.12 10531G1 black
348845 237 B6.D2O(FetA)tm M 37 56965 20.03.12 11,!12 18 FetA!O/O Wurf!6/5Versuch!G1,!JahnenODechent,!10531,!2411/12 ao82392:: 14.06.12 10531G1 black
348846 238 B6.D2O(FetA)tm M 38 56965 20.03.12 11,!12 18 FetA!O/O Wurf!6/5Versuch!G1,!JahnenODechent,!10531,!2411/12 ao82392:: 14.06.12 10531G1 black
348847 239 B6.D2O(FetA)tm M 39 56965 20.03.12 11,!12 18 FetA!O/O Wurf!6/5Versuch!G1,!JahnenODechent,!10531,!2411/12 ao82392:: 14.06.12 10531G1 black
348848 240 B6.D2O(FetA)tm M 40 56965 20.03.12 11,!12 18 FetA!O/O Wurf!6/5Versuch!G1,!JahnenODechent,!10531,!2411/12 ao82392:: 14.06.12 10531G1 brown
348849 241 B6.D2O(FetA)tm M 41 56965 20.03.12 11,!12 18 FetA!O/O Wurf!6/5Versuch!G1,!JahnenODechent,!10531,!2411/12 ao82392:: 14.06.12 10531G1 black
348850 242 B6.D2O(FetA)tm M 42 56965 20.03.12 11,!12 18 FetA!O/O Wurf!6/5Versuch!G1,!JahnenODechent,!10531,!2411/12 ao82392:: 14.06.12 10531G1 black
350176 243 B6.D2O(FetA)tm F 43 57176 28.03.12 13,!14 21 FetA!O/O Wurf!4/6Versuch!G1,!JahnenODechent,!10531,!2411/12 ao82392:: 14.06.12 10531G1 brown
350177 244 B6.D2O(FetA)tm F 44 57176 28.03.12 13,!14 21 FetA!O/O Wurf!4/6Versuch!G1,!JahnenODechent,!10531,!2411/12 ao82392:: 14.06.12 10531G1 black
350178 245 B6.D2O(FetA)tm F 45 57176 28.03.12 13,!14 21 FetA!O/O Wurf!4/6Versuch!G1,!JahnenODechent,!10531,!2411/12 ao82392:: 14.06.12 10531G1 black
350179 246 B6.D2O(FetA)tm F 46 57176 28.03.12 13,!14 21 FetA!O/O Wurf!4/6Versuch!G1,!JahnenODechent,!10531,!2411/12 ao82392:: 14.06.12 10531G1 black
350180 247 B6.D2O(FetA)tm F 47 57176 28.03.12 13,!14 21 FetA!O/O Wurf!4/6Versuch!G1,!JahnenODechent,!10531,!2411/12 ao82392:: 14.06.12 10531G1 grey
350181 248 B6.D2O(FetA)tm M 48 57176 28.03.12 13,!14 21 FetA!O/O Wurf!4/6Versuch!G1,!JahnenODechent,!10531,!2411/12 ao82392:: 14.06.12 10531G1 black
350182 249 B6.D2O(FetA)tm M 49 57176 28.03.12 13,!14 21 FetA!O/O Wurf!4/6Versuch!G1,!JahnenODechent,!10531,!2411/12 ao82392:: 14.06.12 10531G1 brown
350183 250 B6.D2O(FetA)tm F 50 57177 27.03.12 7,!8 16 FetA!O/O Wurf!5/7Versuch!G1,!JahnenODechent,!10531,!2411/12 ao82392:: 14.06.12 10531G1 brown
350184 251 B6.D2O(FetA)tm F 51 57177 27.03.12 7,!8 16 FetA!O/O Wurf!5/7Versuch!G1,!JahnenODechent,!10531,!2411/12 ao82392:: 14.06.12 10531G1 grey
350185 252 B6.D2O(FetA)tm F 52 57177 27.03.12 7,!8 16 FetA!O/O Wurf!5/7Versuch!G1,!JahnenODechent,!10531,!2411/12 ao82392:: 14.06.12 10531G1 brown
350186 253 B6.D2O(FetA)tm F 53 57177 27.03.12 7,!8 16 FetA!O/O Wurf!5/7Versuch!G1,!JahnenODechent,!10531,!2411/12 ao82392:: 14.06.12 10531G1 brown
350187 254 B6.D2O(FetA)tm F 54 57177 27.03.12 7,!8 16 FetA!O/O Wurf!5/7Versuch!G1,!JahnenODechent,!10531,!2411/12 ao82392:: 14.06.12 10531G1 black
350188 255 B6.D2O(FetA)tm M 55 57177 27.03.12 7,!8 16 FetA!O/O Wurf!5/7Versuch!G1,!JahnenODechent,!10531,!2411/12 ao82392:: 14.06.12 10531G1 black
350189 256 B6.D2O(FetA)tm M 56 57177 27.03.12 7,!8 16 FetA!O/O Wurf!5/7Versuch!G1,!JahnenODechent,!10531,!2411/12 ao82392:: 14.06.12 10531G1 black
350190 257 B6.D2O(FetA)tm M 57 57177 27.03.12 7,!8 16 FetA!O/O Wurf!5/7Versuch!G1,!JahnenODechent,!10531,!2411/12 ao82392:: 14.06.12 10531G1 grey
350191 258 B6.D2O(FetA)tm M 58 57177 27.03.12 7,!8 16 FetA!O/O Wurf!5/7Versuch!G1,!JahnenODechent,!10531,!2411/12 ao82392:: 14.06.12 10531G1 black
350192 259 B6.D2O(FetA)tm M 59 57177 27.03.12 7,!8 16 FetA!O/O Wurf!5/7Versuch!G1,!JahnenODechent,!10531,!2411/12 ao82392:: 14.06.12 10531G1 grey
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